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GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
Overview
Genetic alterations leading to inactivation of the transcription factor IKZF1 (IKAROS) are 
present in about 15% off all patients with B-cell precursor leukemia (BCP-ALL). We and 
others have shown that genetic aberrations affecting IKZF1 represent a highly relevant 
clinical marker for poor outcome in BCP-ALL. However, how loss of IKZF1 function 
contributes to an unfavorable outcome remains poorly understood. In this thesis, we 
therefore investigated the link between loss of IKZF1 function and resistance towards 
commonly used chemotherapeutic agents in BCP-ALL, such as synthetic glucocorticoids 
and pyrimidine analogs. Next to this, additional genetic events may either enhance or 
negate the effects of IKZF1 deletions on outcome. Therefore, we examined which other 
co-occurring genetic events affect therapy response and outcome in IKZF1-deleted BCP-
ALL.
1 | Hematopoiesis
1.1 | Blood cell formation and hierarchy
The formation of blood cells in the bone marrow is known as hematopoiesis, which is 
derived from the two ancient greek words αἷμα haíma “blood” and ποíησις poíēsis “to 
make”. The major site of blood cell production changes during human development. In 
the developing embryo, the fetal liver is the main location for blood cell development. 
Prior to  birth, the major site of blood cell development shifts to the  bone marrow 
compartment [1]. During hematopoiesis, all blood cell lineages are derived from a small 
pool of self-renewing hematopoietic stem cells (HSCs) (Figure 1). This HSC pool is capable 
to reconstitute the entire blood system of an organism by expanding and differentiating 
to more restricted multipotent progenitors (MPPs), which branch into either common 
myeloid progenitor (CMP) or common lymphoid progenitor (CLP) cell populations [2]. 
These two branches further subdivide, in which CMPs differentiate into granulocyte-
monocyte progenitors (GMPs) and megakaryocyte-eryhtroid progenitors (MEPs), thereby 
giving rise to erythrocytes, and platelets, whereas CLPs ultimately form the lymphoid part 
of the immune system, represented by NK cells, T cells and B cells [3]. 
1.2 | B-cell development
B-cells represent an important part of the adaptive immune system. Their main function 
is to provide the humoral component of the immune response against pathogens by 
producing antibodies, capable of recognizing and binding specific foreign antigens. 
Next to this, B-cells can also function as antigen presenting cells (APCs) [4] and produce 
cytokines such as lymphotoxin, interleukin 6 (IL-6), interferon-γ, tumor necrosis factor 
(TNF), IL-10 and IL-35 [5]. Originating from the bone marrow, immature B cells undergo 
their first maturation steps in the bone marrow niche, before they further migrate to 
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germinal centers in peripheral lymphoid organs to ultimately mature and take part in the 
immune defense [6]. During the differentiation process, proper development of B cells is 
strictly regulated at distinct developmental stages and checkpoints orchestrated by B cell 
transcription factors such as EBF1, PAX5, PU1, E2A and IKAROS gene family members [7-
9] (Figure 2). These transcription factors control VDJ recombination and the subsequent 
formation of the B cell receptor (BCR) [10]. Only after a functional BCR is present on the 
surface of a B cell, it will leave the bone marrow and migrate to peripheral lymphoid organs. 
 
Figure 1 Schematic overview of haematopoiesis. Simplified model of blood cell lineage 
commitment from HSC differentiation to multipotent progenitors (MMP), followed by further 
branching into common myeloid precursors (CMP) and common lymphoid precursors (CLP). 
The CMP generate granulocyte/macrophage precursors (GMP) that yield granulocytes (Grano), 
monocyte/macrophages (Mono/macro) and osteoclasts (Osteo), as well as megakaryocyte/
erythroid precursors (MEP) that yield megakaryocytes (Mega), platelets and erythroid cells 
(Ery). The CLP generate T cell precursors that produce three types of T helper cells (Th1,2&17), 
regulatory T cells (Tregs) and cytotoxic T cells (Tc), B cell precursors that produce memory and 
plasma cells, as well as Natural Killer (NK) cells. Adapted from  [11]. Recent advances in deciphering 
the hematopoietic dynamics are more and more challenging this rigid developmental dogma and 
indicate more fluidity of the blood development [12]. To simplify this complex topic, we only refer 
to a simplified model of hematopoiesis in this figure.
 
The Ikaros family of zinc-finger proteins, whose names are inspired by Greek mythological 
characters, consist of IKZF1 (Ikaros), IKZF2 (Helios), IKZF3 (Aiolos), IKZF4 (Eos) and IKZF5 
(Pegasus) [13-16]. The members of the Ikaros family play a crucial role during lymphoid 
differentiation and are highly conserved between mice and humans [17-19]. Ikaros family 
members contain several conserved functional domains including two C-terminal zinc-
finger domains, required for homo- and/or heterodimerization with other Ikaros family 
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members and an N-terminal DNA binding domain [20]. IKZF1 (Ikaros), which is located on 
chromosome 7p12.2, is the founding member of the Ikaros family, and a key determinant of 
early lymphoid lineage specification during hematopoiesis [21-23]. IKZF1 is required for the 
transition from HSCs to CLPs [14], but also at later stages of lymphoid (B cell) development 
[24].  Importantly, IKZF1 plays a critical role in the pathogenesis of leukemia and deletions 
in the IKZF1 gene are associated with adverse prognosis in BCP-ALL (See 2.3)
Further downstream, E2A and EBF1 are essential for the generation of pro-B-cells. E2A 
promotes the development of LMPPs, CLPs, ETPs and controls all B-cell differentiation 
stages [25,26]. Simultaneously, E2A represses myeloid/erythroid lineage commitment 
and induces EBF1 expression [27,28]. EBF1 functions downstream of E2A during B-cell 
maturation and is essential for the expression of B-lineage committing genes, such as 
FOXO1 and PAX5  [26]. Later, EBF1 maintains the identity of follicular and germinal center 
B-cells [28-30]. At later stages, PAX5 and PU.1 are necessary to maintain proper B cell 
identity by repressing non-B-cell lineage genes, while activating B-cell lineage genes [31-35].
 
 
 
 
Figure 2 Transcription factor expression during B lymphopoiesis. The progression of cells from 
hematopoietic stem cells through the different stages of B lymphopoiesis is shown in this simplified 
model. Shaded bars represent the levels of gene expression of transcription factors that are 
important in B cell development during the course of differentiation. HSCs (hematopoietic stem 
cells), MPPs (multipotent progenitors), LMPPs (lymphoid-primed MPPs), ELPs (early lymphoid 
progenitors), CLPs (common lymphoid progenitors), ETPs (early T lineage progenitors). Darker 
shading indicates increased gene expression. Important branch points during B lymphopoiesis are 
shown with arrows indicating alternative developmental pathways. Adapted from [36]. 
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2 | Leukemogenesis
2.1 | Introduction  
Over the course of a day, human hematopoiesis is responsible for the proper 
development of approximately 1012 blood cells [37]. A strict regulation of differentiation 
and proliferation of all these blood cells is crucial to ensure proper development of the 
hematopoietic system. This balanced process is perturbed in leukemia, which is defined 
by the unsuppressed production of large numbers of immature white blood cells that fail 
to differentiate into mature functional lymphoid cells [38]. This malignant expansion of 
immature B-cells, so called blasts, in the bone marrow leads to a subsequent infiltration 
of the peripheral blood. As a consequence of this uncontrolled expansion, normal blood 
cell development is suppressed resulting in a defective immune system, anemia and/or 
thrombocythemia.
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children according 
to the World Health Organization classification, with an estimated 4930 new cases in 
2016 in the US [39]. In the Netherlands, on average 130 children are diagnosed with ALL 
every year [40]. Approximately 15-20% of the patients succumb to the disease mainly due 
to relapse and associated therapy resistance [38,41]. Leukemias can be classified based on 
their lineage of origin, lymphoid or myeloid [41]. Amongst the lymphoid malignancies, 
approximately 85% of all patients develop B-cell leukemia, whereas the remaining 15% are 
T-cell lineage leukemias [42]. 
2.2 | Prognostic factors in pediatric leukemia 
Several prognostic factors are related to the overall chance of survival of a patient 
with lymphoblastic leukemia treated with current, multi-agent chemotherapy: 
Immunophenotyping of the disease (B or T cell leukemia) [43], age at initial diagnosis [44] 
and response on treatment (e.g., defined by day 8 prednisone response [45] and minimal 
residual disease (MRD) status [46-48] after Induction and/or consolidation treatment) 
are important parameters for risk stratification of ALL patients [49]. However, increased 
insight into the genetic make-up of leukemia has also contributed to improved prediction 
of disease outcome during the last decades.
Cancer is as a disease characterized by an accumulation of genetic aberrations. In 
comparison to other cancers, pediatric leukemias display a low number of somatic 
mutations [50]. In addition to specific karyotypes, both gene expression signatures and 
certain genetic alterations play a role in ALL prognosis. Especially in the last decade, 
complementary genome-wide screening approaches made it possible to identify genetic 
drivers contributing to leukemia development. [51,52]. Many of these aberrations affect 
crucial cellular processes, such as lymphoid development, cell cycle progression, 
epigenetic changes and cellular metabolism [51-53].
15
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Figure 3 Frequency of cytogenetic subtypes of pediatric ALL. T-cell acute lymphoblastic 
leukemia (T-ALL) is indicated in red, B cell acute lymphoblastic leukemia (B-ALL) in blue and both 
BCR-ABL1 and BCR-ABL1- like ALLs are indicated in green. Adapted from [54].
In BCP-ALL, B-lineage transcription factors (See 1.2) are frequently deregulated and 
affected by either chromosomal translocations, gene deletions or point mutations [54].   
Several genetic rearrangements, each with a different prognostic impact, have been 
identified in BCP-ALL (Figure 3). For example, chromosomal translocations involving the 
ETV6 and the RUNX1-gene found in almost 22% of all BCP-ALL cases [55-57] (TEL-AML1 
fusions) correlate with good overall survival of leukemia patients [58], whereas BCR-ABL1 
and MLL-rearrangements predict poor treatment outcome [59]. The fusion of BCR to the 
ABL1 locus (t9;22)(q34;11) leads to a constitutive active ABL1 tyrosine kinase, thereby 
strongly enhancing proliferation of leukemic cells [60]. Therefore, BCR-ABL1 is considered 
to be an initiating driver lesion in leukemia. Next to translocations, also alterations of 
chromosome numbers are related with disease outcome: Hyperdiploidy is a genetic event 
observed in approximately 30% of all pediatric BCP-ALL patients and is defined by the 
presence of more than 50 chromosomes per leukemic cell [61]. Microdeletions in ETV6, 
CDKN2A and PAX5, as well as point mutations of FLT3, NRAS, KRAS and PTPN11 have been 
identified in this subgroup [61]. Hyperdiploidy is correlated with a favorable prognosis, 
whereas hypodiploids with fewer than 45 chromosomes predict a poor outcome [59]. 
16
CHAPTER 1
Recently, a novel genetic group associated with poor survival has been identified in BCP-
ALL [62,63]. The so-called BCR-ABL1-like subtype represent leukemias with a genetic 
expression profile similar to BCR-ABL1 positives cases, but without a detectable BCR-
ABL1 rearrangement. Identified simultaneously by independent groups, these leukemias 
are characterized by activation of various kinase and cytokine pathways combined with 
a high frequency of aberrations in B-cell differentiation genes such as EBF1, PAX5 and 
IKZF1 [62,63].
2.3 | IKZF1 in leukemia 
When studying the biological function of affected genes in BCP-ALL, it becomes apparent 
that many deletions in BCP-ALL can be found in genes encoding lymphoid transcription 
factors [51,52]. The important role of IKAROS family members as key determinants of 
lymphoid development evidently implies their involvement in the development and 
onset of hematopoietic malignancies. Genomic profiling of ALL patients indeed revealed 
that deletions of Ikaros transcription factor family members are frequently detectable 
alterations in leukemia [51,52]. Surprisingly, despite the importance of all IKAROS family 
members in lymphoid development and differentiation, only IKZF1, IKZF2 and IKZF3 
deletions have been shown to be present in different types of leukemia up to now. Loss 
of IKZF2 has been found in adult T-cell ALL and low hypodiploid BCP-ALL [64,65]. However, 
the role of IKZF2 in pediatric leukemia is barely studied. IKZF3 gene deletions or point 
mutations have been detected in about 2% of all BCP-ALL cases, especially in near-haploid 
ALL [52], which also harbor alterations targeting receptor tyrosine kinase- (RTK-) and Ras 
signaling [65]. Despite their role in T-cell development [19], both IKZF4 and IKZF5 have 
not been reported to contribute to leukemogenesis or to have any prognostic value in a 
clinical setting. 
Deletions and mutations affecting IKZF1 have been found in about 10–15% of BCP-ALL and 
4% of T-ALL cases [51,52] and IKZF1 aberrations are highly enriched in BCR-ABL1 positive 
leukemia [66] and BCR-ABL1-like cases [62,63]. Importantly, a number of studies from our 
laboratory and others have shown that deletions and inactivating mutations targeting the 
lymphoid transcription factor gene IKZF1 represents a strong risk factor for poor outcome 
and the development of relapse in BCP-ALL [63,67,68]. The majority of IKZF1 deletions 
impact the whole gene resulting in haplodeficiency, or delete the DNA-binding domain 
residing in exon 4-6 or 4-7, leading to expression of dominant-negative isoforms of IKZF1. 
This so called IK6-isoform of IKZF1 impairs the function of IKZF proteins in a dominant-
negative manner and results in a loss of the tumor suppressor function of IKZF1 [69]. 
Moreover, IKZF1 deletions are associated with several high-risk features, for example high 
white blood cell count (WBC), age and persistent MRD [63,70,71]. Aberrations of IKZF1 can 
be detected in the majority of cytogenetic subgroups in BCP-ALL: IKZF1 deletions (i) are 
present with a low frequency of ETV6-RUNX1 t(12;21)(p13;q22) positive cases (3-6%) 
[72,73] (ii) are overrepresented in BCR-ABL1 positive cases (75%) [66] and (iii) can be found 
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highly enriched in the so-called “B-others” subgroup (39%) [62]. Notably, IKZF1 deletions in 
both B-others as well as BCR-ABL-positive cases are highly associated with poor outcome 
[74,75].  In addition, IKZF1 is reported to be frequently mutated in high hyperdiploid BCP-
ALLs (20%) [61,74]. In summary, IKZF1 gene deletions represent an independent prognostic 
factor that predicts inferior treatment outcome in different cohorts of childhood and adult 
BCP-ALL [63,68,76-78]. 
2.4 | The importance of genetic context in IKZF1-deleted leukemia 
Although IKZF1 aberrations contribute to leukemia onset, it is evident that loss of IKZF1 
alone is not sufficient to induce leukemogenesis [79,80]. This leads to the assumption that 
IKZF1 aberrations are secondary events in leukemia formation, acting in combination with 
initiating events such as BCR-ABL1 translocations [81] or a BCR-ABL1-like genetic context 
such as activated JAK-STAT signaling [82]. Co-occurrence of deregulated CRLF2 and JAK2 
mutations can also be detected in IKZF1-deleted BCP-ALL cases and may also increase 
the risk of relapse [74,83]. However, not all IKZF1-deleted leukemias relapse, arguing that 
other cooperative genetic events can alter the survival outcome of IKZF1-deleted ALL. 
For example, deletions of the ERG gene have been reported to counteract the rather 
poor prognosis of IKZF1-deleted leukemia [84]. Besides IKZF1, many other recurrent 
genetic aberrations have been observed in BCP-ALL, which include deletions affecting 
BTG1, CDKN2A/B, EBF1, ETV6, PAX5, RAG1, RB1 and TCF3 [51,52]. From this, it seems that 
alterations in B cell development genes, leading to a block in B cell differentiation, are 
almost obligatory steps in the development of ALL (Also see 2.2). 
Amongst these B cell developmental genes, a frequently affected gene in BCP-ALL is the 
transcriptional co-regulator B cell translocation gene 1 (BTG1), which occurs in about 9% 
of all pediatric BCP/ALL patients [51,52]. BTG1 was originally identified as a translocation 
partner of the c-MYC gene in chronic lymphocytic leukemia and is part of a family of 
antiproliferative genes, including BTG2, BTG3, TOB and TOB2 [85]. BTG1 on its own has 
no proven enzymatic activity, but several studies suggest that BTG1 functions as an 
adaptor molecule or as a cofactor involved in transcriptional regulation. It  was shown  to 
interact with homeobox transcription factor 9 [86], the transcriptional regulator CAF1 [87] 
and with the arginine methyltransferase PRMT1 [88,89]. Next to this, we have established 
BTG1 as crucial regulator of glucocorticoid receptor autoinduction in acute lymphoblastic 
leukemia [90]. 
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3 | Therapy resistance in BCP-ALL
3.1 | Treatment of children with leukemia
The administration of chemotherapy in the treatment of children with acute lymphoblastic 
leukemia consists of induction of remission (induction phase), intensification (consolidation) 
and maintenance phase. The goal of remission induction is to effectively eliminate the bulk 
of leukemic cells, driving the disease into remission. However, despite the fact that initial 
induction of remission indicates a good prognosis of the overall disease outcome, the 
initial achievement of remission does not mean the patient is cured [91]. The persistence of 
residual leukemic cells (often called ´Minimal´ residual disease (MRD)) is one of the main 
causes of relapse in ALL and quantification of MRD is an important indicator for a successful 
early response to therapy [92-94]. 
The current ALL-11 protocol of the Dutch childhood oncology group consists of a 
combination of different classes of (chemo-)therapeutic agents to effectively eradicate 
all residual leukemic cells [95]. Amongst them are synthetic glucocorticoids (prednisone, 
dexamethasone) [96], DNA damaging agents (for example daunorubicin) [96], cell 
cycle arrest therapies (vincristine) and amino acid depleting drugs (asparaginase) [97]. 
Furthermore, patients can receive methotrexate, AraC and 6-mercaptopurine (6-MP) or 
6-thioguanine (6-TG) [98,99]. The average length of therapy for the ALL-11 medium risk 
group  is 2 to 3 years, in which children with IKZF1-deleted leukemia receive one additional 
year of 6-MP and methotrexate due to a higher risk of relapse [95]. It is important to note 
that the aforementioned improved survival of children with ALL is almost exclusively due 
to better risk stratification, supportive care and strong improvements of both the dosage 
and the scheduling of chemotherapies rather than the development of novel drugs.  
3.2 | Mechanisms of cellular drug resistance 
Although most patients with ALL initially respond to therapy by achieving complete 
remission (CR), responses are not always lasting [100]. Even with the current standard of 
treatment for ALL, close to 15% of young leukemia patients ultimately succumb to the 
disease [101]. Despite the fact that chemotherapy effectively reduces the tumor burden, in 
case of relapse, cancer cells that are no longer sensitive to the therapy are able to expand 
[102]. As a consequence, relapsed leukemic blasts are often more resistant to therapy in 
comparison to leukemic blasts at diagnosis [103], making the treatment of relapsed ALL 
challenging [104].   
The genetic composition of leukemia can change from diagnosis to relapse and the 
contribution of minor genetic subpopulations to chemotherapy resistance and thereby 
relapse formation is still highly discussed in ALL [105]. Next to this, small undetectable 
remaining populations of leukemic cells can avoid therapeutic killing during initial 
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treatment by adopting a dormant, and thereby non-active state [106]. These dormant, 
probably pre-leukemic stem cells were found to cause recurrence of relapse, sometimes 
even years after remission [106].
Several mechanisms for chemotherapy resistance in leukemia have been proposed and 
can broadly be divided into extrinsic and intrinsic mechanisms of resistance: Intrinsic 
resistance drug mechanisms  involve specific properties of the leukemic cell, which are 
usually dictated by the genetic context of the leukemia [107]. For instance, activation and 
efflux of a chemotherapeutic agent, inhibition of apoptotic pathways, activation of DNA 
repair mechanisms and proliferation pathways as well as epigenetics are all contributing 
to intrinsic drug resistance [108]. In addition, extrinsic mechanisms contributing to drug 
resistance can be provided by the cellular microenvironment of the bone marrow, the so-
called leukemic niche, in which interactions with stromal cells can enhance survival of 
leukemic cells during therapy [109]. Moreover, leukemic cells invading the central nervous 
system (CNS) can similarly escape therapy induced apoptosis by interaction with the CNS 
microenvironment [110,111] and because of  poor penetration of many chemotherapeutic 
agents into the CNS [112]. All these factors can act either independently or in combination 
and can be mediated by a broad variety of signaling pathways.
During my thesis work, we focussed on glucocorticoids and pyrimidine analogs, which 
is why I will focus on these two classes of chemotherapeutic agents in the following 
segments. 
3.3.1 | Glucocorticoids as cornerstone drugs in ALL treatment 
Glucocorticoids (GCs) were among the first drugs used in the treatment of childhood 
acute lymphoblastic leukemia and have been the cornerstone of ALL treatment for 
more than 60 years. In 1948, synthetic versions of steroid hormones isolated from 
animal adrenal glands where shown for the first time to be effective in treating patients 
with rheumatoid arthritis [113]. Only two years later, the discovery of adrenal cortex 
hormones and their biological effects by Philip S.Hench, Edward Kendall and Tadeus 
Reichstein was awarded with the Nobel Prize in Physiology or Medicine. Since then, 
GCs have been introduced for the treatment of inflammation, autoimmune reactions 
and hematological cancers. Glucocorticoids are stress signaling hormones that regulate 
a broad variety of physiological processes [114]. The physiological and pharmacological 
effects  of glucocorticoids are mediated by the glucocorticoid receptor (GR), also termed 
NR3C1, a member of the nuclear receptor super family of ligand-dependend transcription 
factors [115]. In its unoccupied and therefore inactive state, the GR resides in the cellular 
cytoplasm as part of a large multi-protein complex including chaperone proteins such as 
the head/shock proteins HSP90 and HSP70, SRC kinases, p23 and immunophilins [116,117] 
(Figure 4). 
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Figure 4 Simplified scheme of classical Glucorticoid Receptor (GR) activation. The GR remains 
in an inactive confirmation as a part of a large protein complex together with Head Shock proteins, 
p2, SRC kinases and others. After binding of GCs to the GR, the GR undergoes a conformational 
change and is able to translocate to the Nucleus, where it binds to DNA and either activates or 
inhibits GR-target genes.
 
Whereas the GR remains functionally silenced as long as it is bound in this complex, 
it holds a high affinity for GCs (Figure 4). Upon binding of GCs to its C-terminal ligand 
binding domain, the GR undergoes a conformational change, which allows translocation 
into the nucleus and bind other transcriptional regulators, such as activating protein (AP1) 
or nuclear factor kB (NFkB), thereby inhibiting their activity [118,119]. Alternatively, the 
GR is recruited to glucocorticoids response elements (GRES) in the nucleus [120], where it 
either activates or inhibits transcription, thereby regulating several  downstream pathways 
involved in proliferation, survival pathways, NFkB signaling and glucose metabolism. In 
addition, several posttranslational modifications can affect GR signaling: The most studied 
GR modification is phosphorylation [121-123]. Various kinases such as Casein Kinase 
II, GSK3, AKT and MAPKs were shown to modulate GR signaling by phosphorylation of 
specific serine residues [124-126]. This leads to changes in the transcriptional activity of 
the GR, in which the phosphorylation of different serine residues can either drastically 
enhance or decrease the expression of GC-responsive target genes [127,128]. Next to 
phosphorylation, also sumoylation [129] and ubiquination [130,131] have been reported to 
affect transactivation and subnuclear trafficking of the GR. 
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3.3.2 | Resistance mechanisms against glucocorticoids
Studies performed by the Berlin-Frankfurt-Münster (BFM) group showed that the initial 
response to prednisone after seven days of single-agent treatment was strongly predictive 
of the overall survival outcome of patients [132]. Moreover, other studies indicated that 
ex vivo GC treatment of leukemic blasts was also effective in predicting disease outcome 
[103,133,134]. Therefore, both in vitro as well as in vivo resistance to glucocorticoids can be 
considered an adverse prognostic factor in ALL [45,134,135] and the resistance to synthetic 
GCs remains a substantial problem in the treatment of ALL patients. 
 
Figure 5 Mechanisms contributing to GC resistance in BCP-ALL
A number of studies have revealed potential mechanisms of GC resistance in ALL. For 
instance,  it was shown that low expression levels and mutations of the NR3C1 gene [136], 
epigenetic silencing of the pro-apoptotic gene BIM [137], downregulation of the anti-
apoptotic BCL2, and increased activity of the Ser/Thr kinase AKT [138] can contribute to 
GC resistance (Figure 5).
Other studies have identified novel regulators of GR-dependent gene transcription that 
may impact GC therapy responses, including noncoding RNA GAS5 [139] GMEB1 and 
GMEB2 [140], BTG1 [90], histone methyltransferase G9a/KMT1C [141], TBL1XR1 [142] and 
metastasis-related methyltransferase 1 (MERM1)/WBSCR22 [143]. Finally, not all GR 
isoforms have the ability to induce apoptosis, suggesting that mechanisms that regulate 
isoform selection may also play a role [144]. Recent studies also indicate that PAX5 and 
IKZF1 can function as metabolic gatekeepers of a leukemic cell, thereby potentially 
changing therapy responses of a cancer cell [145]. 
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3.4.1 | Pyrimidine analogs in the treatment of children with leukemia 
Nucleoside analogs are commonly used in the treatment of leukemia, as the incorporation 
of these so-called antimetabolites into the DNA during DNA repair and replication 
induces apoptosis of cells. Amongst the different analogs, the cytidine analog Cytarabine 
(cytosine arabinoside (AraC)) is reported to be effective in the treatment of acute myeloid 
leukemia, both in adults and pediatric patients, already since the 1960s [146]. Notably, AraC 
is also implemented  in ALL treatment protocols next to methrotrexate and thiopurines 
such as 6-MP or 6-TG [95]. After its transmembrane transport into the cytoplasm, AraC 
transits from AraC monophosphate (AraCMP) to AraC diphosphate (AraCDP) before it 
finally forms AraC triphosphate (AraCTP). This reaction is depending on the sequential 
phosphorylation by several kinases, amongst them deoxycytidine kinase (dCK). In 
contrast, the formation of AraCTP is opposed by the dephosphorylation of AraCMP into 
AraC by pyrimidine nucleotidase I (PN-I), the deamination of AraC into its inactive form, 
Ara-uridine (AraU), by cytidine deaminase (CDA) and the deamination of AraCMP into 
AraUMP by deoxycytidylate deaminase (dCMPD). In addition, AraCTP competes with 
deoxycytidine triphosphate (dCTP) for incorporation into DNA [147] (Figure 6).
 
 
 
Figure 6 Symplified model of the cellular metabolism of AraC. Abbreviations: Cytosine 
arabinoside (AraC), human equilibrative nucleoside transporter, (hENT1) AraC monophosphate 
(AraCMP) , AraC diphosphate (AraCDP), AraC triphosphate (AraCTP). Cytidine deaminase (CDA), 
deoxycytidine kinase (dCK), pyrimidine nucleotidase I (PN-I deoxycytidylate deaminase (dCMPD), 
deoxycytidine triphosphate (dCTP). Adapted from  [148].
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3.4.2 | Resistance mechanisms against cytarabine
Despite intensive chemotherapy, 20% of pediatric patients with ALL do not achieve a 
complete remission or relapse after intensified chemotherapy [149]. AraC is an effective 
drug in the chemotherapeutic treatment of patients with acute myeloid leukemia [150,151] 
and acute lymphoblastic leukemia [152,153]. Still, the resistance to AraC therapy remains a 
substantial issue in the treatment of patients with leukemia [147]. 
Several mechanisms of AraC therapy resistance have been described in leukemia, in which 
all mechanisms decrease the availability of active AraCTP in the cell (Figure 7). First, 
reduced activity of the Human equilibrative nucleoside transporter (hENT1) has been 
linked to low cytoplasmic concentration of AraC [148]. hENT1 functions as transporter 
for several nucleoside analogs, such as AraC, gemcitabine, fludarabine and cladribine 
and transports up to 80% of total AraC into leukemic cells [154,155]. Also reduced 
levels of deoxycytidine kinase (DCK) render cells resistant towards AraC, as the initial 
phosphorylation step from AraC to AraCMP is decreased [156]. Seemingly, lower DCK levels 
are more relevant for AML, as several studies have shown that DCK levels in ALL patients 
did not correlate with AraC sensitivity [154,155]. On the other hand, increased levels of 
enzymes involved in AraC metabolism can be involved in nucleoside analogue resistance: 
It has been shown that high levels/activation of the 5’ nucleotidase (NT5C2), next to 
its relevance in AML [157], is also associated with both worse outcomes and cytarabine 
(AraC) resistance in ALL [158], particular in T-ALL [159,160]. In addition, increased levels 
of nucleotidase NT5C2 lead to resistance to thiopurines such as 6MP and 6-Thioguanine 
(6TG) [159,160]. Next to this, also an increased intracellular dCTP pool has been shown to 
compete with AraC for its incorporation into DNA, thereby effectively outcompeting AraC 
[161]. As another mechanisms, cytidine deaminase (CDA) is the main inactivating enzyme 
in the AraC metabolic pathway and is capable to irreversibly deaminate AraC to AraU. 
High CDA expression levels are associated with AraC resistance [162] and also correlate 
with increased relapse occurrence in AML [163,164]. Importantly, increased activity of CDA 
has been shown to protect leukemic cells from AraC induced apoptosis [165,166].  
Figure 7 Factors contributing to AraC resistance in leukemia. Abbreviations: Cytosine 
arabinoside (AraC), human equilibrative nucleoside transporter, (hENT1) Cytidine deaminase 
(CDA), deoxycytidine kinase (DCK), deoxycytidine triphosphate (dCTP), 5’-Nucleotidase (NT5C2).
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Unfortunately, the direct cause of differential chemotherapy responses often remains 
elusive and there is an urgent need to link genetic events and chemotherapy resistance 
at a mechanistic level as we still do not understand why specific genetic subgroups 
respond poorly to therapy in BCP-ALL. To this end, it is necessary to (i) identify novel 
genetic markers predicting chemotherapy responses and (ii) understand the molecular 
mechanisms underlying chemotherapy resistance to develop personalized treatment 
protocols and to open the door for targeted therapy. 
4 | Outline of the thesis
Despite the fact that IKZF1 deletions were identified as a poor prognostic factor, a direct 
role for IKZF1 aberrations in chemotherapy resistance was not yet been established at 
the start of my thesis. Therefore, this thesis aimed to unravel the contribution of the 
tumor suppressor gene IKZF1 to therapy resistance in BCP-ALL: Chapter 2 provides an 
overview of the many faces of the IKZF1 gene by summarizing the impact of IKZF1 on 
normal and malignant lymphopoiesis  and describes signaling pathways affected by loss 
of IKZF1. In Chapter 3, we used various model systems to examine the effects of IKZF1 
aberrations on chemotherapy resistance to common chemotherapeutic agents such as 
GCs, asparaginase and DNA-damaging agents in BCP-ALL. In Chapter 4, we identified a 
potential mechanism responsible for glucocortiocid resistance in IKZF1-deleted BCP-ALL. 
In Chapter 5, we have studied if and how other genetic events impact the effects of IKZF1 
on outcome in BCP-ALL patients. We further describe how these co-occurring genetic 
events contribute to leukemogenesis and therapy resistance in murine models of BCP-
ALL. In Chapter 6, we investigated whether loss of IKZF1 influences resistance to other 
classes of chemotherapeutic agents. Nucleoside analogs, as one of the major classes of 
antimetabolites used in the treatment of children with leukemia, were of special interest 
in our studies as IKZF1 has been described to influence the metabolic state of a cancer cell. 
The work presented in this study is summarized and discussed in Chapter 7 together with 
perspectives for future studies. Finally, Chapter 8 summarizes the work presented in this 
thesis in Dutch.  
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Abstract
Transcription factor IKZF1 (IKAROS) acts as a critical regulator of lymphoid differentiation 
and is frequently deleted or mutated in B cell precursor acute lymphoblastic leukemia (BCP-
ALL). IKZF1 gene defects are associated with inferior treatment outcome in both childhood 
and adult BCP-ALL and occur in more than 70% of BCR-ABL1 positive and BCR-ABL1-like 
ALL cases. Over the past few years, much has been learned about the tumor suppressive 
function of IKZF1 during leukemia development and the molecular pathways that relate 
to its impact on treatment outcome. In this review, we provide a concise overview on the 
role of IKZF1 during normal lymphopoiesis and the pathways that contribute to leukemia 
pathogenesis as a consequence of altered IKZF1 function. Furthermore, we will discuss 
different mechanisms by which IKZF1 alterations impose therapy resistance to leukemic 
cells, including enhanced cell adhesion and modulation of glucocorticoid response.
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Introduction
B cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most common malignancy 
in children and involves uncontrolled expansion of B-lymphoid progenitors in the bone 
marrow. The disease is frequently initiated by a chromosomal translocation but becomes 
manifest only when leukemic progenitors in the bone marrow have accumulated a number 
of additional gene deletions and mutations that drive disease progression. With current 
treatment protocols long term survival approaches 90% [1], however relapses still pose a 
significant clinical challenge due to chemotherapy resistance of the recurrent disease[1]. 
Both in pediatric and adult BCP-ALL, specific genetic subtypes with distinct prognostic 
outcomes can be identified [2]. Some of these subtypes, such as hyperdiploid ALL and 
ETV6-RUNX1 rearranged ALL are associated with a favorable outcome, while other 
genetic hallmarks, such as MLL gene rearrangements, hypodiploidy, intrachromosomal 
translocation of chromosome 21 (iAMP21), or the presence of the t(9;22) BCR-ABL1 
translocation predict poor outcome. Moreover, the presence of a gene expression profile 
similar to BCR-ABL1 positive ALL, which frequently involves genetic alterations that 
deregulate cytokine receptor and/or tyrosine kinase signaling, is similarly associated 
with poor outcome2. In addition to these gross chromosomal rearrangements, deletions 
or mutations affecting B cell transcription factor IKZF1, are a strong and independent 
predictor of poor outcome in BCP-ALL [3,4]. Next to its role as a critical regulator of B cell 
development and a leukemia tumor suppressor, there is mounting evidence that IKZF1 
loss also affects signaling pathways that modulate therapy response.  
Here, we provide an overview of the complex role of transcription factor IKZF1 during 
normal lymphopoiesis and consequences of IKZF1 loss for BCP-ALL pathogenesis. Finally, 
we will discuss some of the molecular mechanisms by which IKZF1 gene alterations may 
contribute to therapy resistance.     
Transcription regulation by IKAROS zinc-finger protein 1
The IKAROS family of transcription factors consists of five different IKAROS zinc-finger 
proteins (IKZF1-IKZF5) that are able to bind DNA directly at the core motif A/GGGAA through 
their N-terminal zinc-finger domain [5,6]. Furthermore, all IKAROS family members harbor 
two additional C-terminal zinc-fingers required for homo- and heterodimerization between 
the different IKZF proteins (Figure 1A). Formation of homo- or heterodimers between 
IKAROS zinc-finger proteins with a functional DNA binding domain strongly enhances their 
DNA affinity and transcriptional activity. However, a common feature of IKZF1 and related 
family members is the presence of shorter variants due to alternative splicing. These variants 
often lack DNA binding activity but retain the ability to interact with full-length IKZF1-IKZF5, 
thereby creating dominant-negative isoforms. A well-known splice variant of both the mouse 
and human IKZF1 gene is the IK6 isoform, which lacks exons 4 to 7 that encode the four 
N-terminal zinc-fingers representing the DNA binding domain (Figure 1B).   
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Figure 1 Overview of the human family of IKAROS zinc-finger (IKZF) transcription factors and 
IKZF1 isoforms. (A) Schematic representation of the five IKZF proteins (IKZF1-IKZF5), including 
the N-terminal zinc-fingers that define the DNA-binding domain and the two C-terminal zinc-
fingers representing the dimerization domain. The colored boxes indicate the individual regions 
within the protein that are encoded by distinct exons. (B) The common IKZF1 splice variants (IK1-
IK8) are shown, including the shorter isoforms that are generated by alternative splicing. The 
splice variants lacking exons 4 and 5 (IK6-IK8) represent dominant-negative isoforms of IKZF1.
 
IKZF1 mainly regulates gene expression through association with the nucleosome 
remodeling and deacetylase (NuRD) complex [7-10], which includes histone deacetylases 
HDAC1, HDAC2 and the ATP-dependent chromatin remodeling proteins CHD3 and 
CHD4. The NuRD complex is involved in both transcriptional repression as well as 
gene activation by IKZF1 [11, 12]. Gene silencing by IKZF1 is also facilitated through 
interaction with Polycomb repressive complex 2 (PRC2), which promotes histone H3 
lysine 27 trimethylation (H3K27me3) to maintain genes in an inactive state [13,14]. Other 
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transcriptional co-factors that can associate with IKZF1 and mediate gene regulation 
include CtBP, CtIP and SWI/SNF-related complex[15-17]. On the other hand, IKZF1 may 
itself participate in transcription initiation through direct interaction with the general 
transcription factors TFIIB and TBP [16]. IKZF1 also controls transcription elongation via 
association with protein phosphatase 1α (PP1α) and cyclin-dependent kinase 9 (CDK9), 
the enzymatic component of the positive transcription elongation factor b (P-TEFb) [18-20]. 
IKZF1-mediated transfer of PP1α to CDK9 promotes P-TEFb activation and recruitment 
to gene regulatory regions, thereby facilitating transcription elongation of IKZF1-target 
genes in hematopoietic cells [18]. 
Distinct post-translational modifications are able to modify the function of IKZF1. 
Phosphorylation of IKZF1 at multiple serine and threonine residues by casein kinase 
II (CK2) impairs its function as a transcription factor [20-22]. Conversely, CK2 inhibition 
enhances the transcriptional repressor function of IKZF1 [23]. On the other hand, dual-
specificity kinases BTK and SYK both phosphorylate IKZF1 on specific serine residues 
in close proximity of the DNA binding domain, to augment its nuclear localization and 
DNA binding activity [24,25]. Sumoylation of IKZF1 on lysine residues occurs within the 
nucleus and seems to interfere with transcriptional repression [26,27]. Previously, it was 
shown that IKZF1 is also subject to ubiquitination [20], but now there is a renewed interest 
in this pathway, since both IKZF1 and IKZF3 are targets of the immunomodulatory drugs 
(IMiDs) thalidomide, lenalidomide, pomalidomide and CC-122 [28]. These IMiDs promote 
proteosomal degradation of IKZF1 and IKZF3 by redirecting the substrate specificity of 
the CRL4CRBN ubiquitin ligase complex [29,30]. IMiDs show therapeutic effects in a broad 
range of hematological malignancies by their ability to target the malignant cells and 
modulate the immune system and its microenvironment.       
IKZF1 is essential for normal lymphopoiesis
Studies performed in both constitutive and conditional Ikzf1 knockout mouse models have 
demonstrated that IKZF1 function is not only required at different stages of lymphopoiesis 
[12,31,32], but also for normal myeloid, megakaryocyte and erythroid differentiation [33-
36]. Ikzf1-deficient mice (Ikzf1null/null) lack all B cells, natural killer (NK) cells, plasmacytoid 
dendritic cells and fetal T cells [31,37] (Figure 2). Nonetheless, post-natal Ikzf1-null mice 
harbor early T lineage progenitors (ETPs) within the thymus and export mature T cells to 
the periphery [38]. Mice homozygous mutant for a hypomorphic allele of Ikzf1 (Ikzf1L/L) 
show reduced B cell progenitors in the bone marrow compartment, but still generate 
normal counts of mature B2 cells [39]. These splenic B cells display alterations in isotype 
selection during immunoglobulin class switch recombination and a hyper-proliferation 
phenotype upon antigenic stimulation [40,41]. Although spontaneous progression to B 
cell acute lymphoblastic leukemia is not observed in Ikzf1L/L  mice, haplodeficient Ikzf1L/+ 
animals demonstrate an accelerated onset of B cell leukemia in combination with a 
BCR-ABL1 transgene [42]. Moreover, all Ikzf1L/L mice develop thymic lymphoma within 
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a period of 10 months through activation of the Notch pathway [43]. Ikzf1 mutant mice 
expressing dominant-negative isoforms of IKZF1 (Ikzf1DN/DN and Ikzf1Plstc/Plstc) demonstrate 
a widespread failure of hematopoiesis [44, 45], highlighting the importance of IKAROS 
transcription factors in hemato-lymphoid differentiation. Notably, heterozygous Ikzf1 
mutant mice develop T cell malignancies with very high penetrance and short latency in 
case of the dominant-negative isoforms [46, 47], while this phenotype is less obvious in 
Ikzf1+/- mice [48].     
Detailed gene expression profiling has revealed that IKZF1 is essential for the generation 
of common lymphoid progenitors (CLPs) by priming lymphoid lineage-specific signatures 
in hematopoietic stem cells and lymphoid-primed multipotent progenitors (LMPPs) 
[49]. At different stages of T-lineage differentiation and development, IKZF1 is engaged 
by setting thresholds for (pre-)T cell receptor-controlled checkpoints as well as T cell 
activation downstream of IL-2 receptor signaling [50,51]. In B cell progenitors, Ikzf1 is 
required to induce Rag1 and Rag2 expression, and mediates chromatin accessibility 
during immunoglobulin gene rearrangement and allelic exclusion at the Igk locus [12,32,52]. 
During pre-B cell differentiation, IKZF1 regulates the transcription of genes implicated in 
pre-B cell receptor signaling, cell survival, stromal cell adhesion and B cell commitment, 
such as Pax5, Foxo1 and Ebf1 [12,32,53]. Many of those regulatory activities during B-lineage 
differentiation are navigated by super-enhancer networks controlled by IKZF1 and other B 
cell master transcription factors [54]. Besides expression regulation of B-lymphoid genes, 
IKZF1 is actively involved in repression of a lineage-inappropriate transcriptional program 
normally prevalent in epithelial and mesenchymal precursors [54]. 
To further delineate the function of the individual zinc-fingers within the DNA-binding 
domain of IKZF1 in B-lymphopoiesis, Ikzf1 mouse mutants have been generated with 
targeted deletion of exon 4, which encodes zinc-finger 1 (Ikzf1ΔF1/ΔF1), or exon 6 encoding 
zinc-finger 4 (Ikzf1ΔF4/ΔF4) [37]. Germline deletion of either exon 4 or 6 results in decreased 
B cell precursors with a stronger developmental block in Ikzf1ΔF1/ΔF1 mice, especially at 
the pre-B cell stage37. In contrast, the fraction of large pre-B cells is strongly increased in 
Ikzf1ΔF4/ΔF4 mice as compared to wild-type control animals. Interestingly, deletion of zinc-
finger 4, but not zinc-finger 1, accelerates the onset of BCR-ABL1-mediated B cell leukemia 
[37,55]. Conditional deletion of exon 5 (Ikzf1E5Δ/Δ), which encodes zinc-fingers 2 and 3, at 
the CLP-stage also results in an expansion of large pre-B cells within the bone marrow 
compartment, which is followed by a subsequent block in the transition to small pre-B 
cells56. These findings indicate that N-terminal zinc-fingers 2, 3 and 4 of IKZF1 limiT cell 
proliferation and survival at the time of active pre-B cell receptor signaling, while zinc-
fingers 1, 2 and 3 are absolutely required for the transition to the pre-B cell stage. 
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Figure 2 Summary of the observed phenotypes in the different constitutive Ikzf1 knockout 
mouse models. The knockout allele shows a schematic representation at which position the 
deletion or mutation is present in the mouse Ikzf1 gene. Abbreviations used: DN, dominant 
negative; Plstc, ENU-induced dominant-negative point mutation, called Plastic; Neo, Neomycin 
gene; Geo, fusion between LacZ and Neomycin gene; ZF, zinc-finger; HSC, hematopoietic stem 
cell; NK, natural killer; pDCs, plasmacytoid dendritic cells; LT-HSC, long term hematopoietic stem 
cell; GMPs, granulocyte-macrophage precursors; mo, months.
IKZF1 gene lesions drive leukemia development and relapse
In the past decade, complementary genome-wide approaches have been employed to 
identify the genetic drivers implicated in the pathogenesis of ALL. Those studies revealed 
that the IKZF1 gene, which is located on chromosome band 7p12.2, is recurrently affected 
by different types of genetic alterations in BCP-ALL. Analysis of copy number alterations 
(CNAs) has demonstrated that IKZF1 gene deletions are present in about 15% of childhood 
BCP-ALL cases and 40%-50% of adult patients with BCP-ALL [57-60]. These deletions 
frequently involve the whole gene (DEL1-8) that results in loss of expression of wild-type 
IKZF1, as well as focal deletions that alter the function of IKZF1, like the dominant-negative 
isoform IK6 (DEL4-7). Other common variants include deletions affecting exons 2-3, exons 
2-7 and exons 4-8 [61]. In most cases these are monoallelic IKZF1 deletions where one 
functional copy of IKZF1 is retained, although biallelic deletions are also observed in a 
fraction of BCP-ALL cases [62, 63]. In addition, IKZF1 function is compromised by insertions, 
frameshift and missense mutations, which represent ~7% of IKZF1 alterations in BCP-ALL 
[63]. Furthermore, rare in-frame gene fusions involving IKZF1 have been identified by RNA 
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sequencing in BCP-ALL, including IKZF1-NUTM1, IKZF1-SETD5 and the reciprocal SETD5-
IKZF1 [64]. However, it remains to be established whether these IKZF1 gene fusions are 
pathogenic and contribute to leukemia development.   
An interesting feature is the strongly increased prevalence of IKZF1 deletions and 
mutations in high-risk BCP-ALL cases with an activated tyrosine kinase profile, particularly 
BCR-ABL1 positive ALL (~85%) [65], and BCR-ABL1-like ALL (~70%), which is characterized 
by a range of genetic alterations driving cytokine receptor and kinase signaling3, [66-
68]. Similarly, IKZF1 deletions and mutations are highly abundant in chronic myeloid 
leukemia (CML) that has progressed to lymphoid blast crises, but IKZF1 alterations are 
virtually absent in chronic-phase and myeloid blast crises CML [65,69,70]. IKZF1 deletions 
are also rarely detected in ETV6-RUNX1 positive BCP-ALL (3%), TCF3-rearranged (~3%) 
and MLL-rearranged (~5%) B-ALL [58,71,72]. The distribution of IKZF1 deletions among the 
remaining subtypes, including hyperdiploid and B-other, ranges from 15%- 20% [72].
IKZF1 acts as a critical tumor suppressor in mouse T-lymphoid malignancies [43,46,47], 
but IKZF1 gene lesions are not very prevalent in T-ALL. CNAs and mutations affecting the 
IKZF1 gene can be detected in ~4% of T-ALL [58,65,71,73]. Notably, IKZF1 alterations occur 
in ~13% of early T cell precursor (ETP) ALL, a high-risk T-ALL subtype characterized by 
recurrent mutations activating tyrosine kinases (FLT3, JAK1, JAK3) and cytokine signaling 
(IL7R) [74]. IKZF1 alterations have also been reported in myeloproliferative neoplasms 
[75], and both pediatric and adult acute myeloid leukemia harbor IKZF1 deletions that 
affect its function [76,77]. Thus, the tumor suppressive activity of IKZF1 is not uniquely 
restricted towards the lymphoid lineage and extends to a broader range of hematological 
malignancies.
Besides its critical role in leukemia pathogenesis, IKZF1 alterations are also associated 
with adverse prognosis in BCP-ALL [3,4,78], even within the high-risk group BCR-ABL1 
positive ALL[79, 80]. Notably, the occurrence and prognostic impact of IKZF1 alterations 
is not restricted to high-risk cases, but is also observed in non-high risk B-ALL subtypes 
[72], including high hyperploidy81. Indeed, IKZF1 deletion represents one of the strongest 
independent predictor of poor treatment outcome in childhood BCP-ALL [71, 72, 82]. Similar 
data have been reported in adult BCP-ALL, where loss-of-function gene deletions of IKZF1 
predict poor treatment outcome in BCR-ABL1 negative cases [83-86]. Interestingly, the 
presence of other co-occurring gene lesions may either enhance or negate the prognostic 
value of IKZF1 deletions. For instance, focal deletions affecting both transcriptional 
regulator BTG1 and IKZF1 represent a high-risk group with a worse outcome than 
IKZF1 alterations alone48. On the other hand, the BCP-ALL subtype characterized by 
deregulation of transcription factors ERG and DUX4 has a favorable outcome, despite the 
strong presence of IKZF1 deletions in approximately 40% of these patients [64,87-90]. An 
explanation for this latter observation remains elusive. 
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Genetic alterations that cooperate with IKZF1 deletions 
in BCP-ALL
There is accumulating evidence that recurrent chromosomal aberrations present in BCP-
ALL, such as BCR-ABL1 translocations or CRLF2 rearrangements, act as driver lesions and 
represent early events in leukemia development. Genome-wide analysis has established 
that several other genetic alterations cooperate before B cell leukemia becomes manifest. 
Especially, gene lesions that inactivate the lymphoid transcription factor IKZF1 are 
frequently observed in BCR-ABL1 positive and CRLF2-rearranged BCP-ALL [65,69,91,92]. 
The latter group is associated with concomitant JAK1 and JAK2 activating mutations91. 
Similarly, IKZF1 alterations are highly prevalent in tyrosine kinase-activating lesions 
that define BCR-ABL1-like ALL [67,68]. These include rearrangements involving ABL1/
ABL2, CSF1R, EPOR, JAK2 and PDGFRB, or sequence mutations affecting FLT3, IL7R or 
SH2B3. Indeed, loss of IKZF1 may permit more effectively STAT5 target gene regulation 
downstream of these pathways93. Collectively, these findings argue that loss of IKZF1 
function strongly cooperates with activated tyrosine kinase signaling pathways linked to 
enhanced progenitor B cell proliferation and immortalization (Figure 3). 
The predilection for IKZF1 gene alterations in BCR-ABL1-mediated lymphoid versus 
myeloid malignancies has been further corroborated in mouse studies. In a bone marrow 
transplantation model using lineage-negative hematopoietic progenitor cells, it was 
shown that expression of IK6 skews BCR-ABL1-mediated leukemia from an exclusive 
myeloproliferative disease towards a combined myeloid and B-lymphoid disease 
[63]. Introducing p19Arf-deficiency further strengthens this trend towards uniformly 
induced B-ALL. This is in agreement with the finding that BCR-ABL1 positive BCP-ALL is 
characterized by the co-occurrence of IKZF1 and CDKN2A gene deletions [65]. 
Another group of genetic changes that frequently co-occur with IKZF1 alterations in 
BCP-ALL include gene deletions affecting lymphoid transcription factors, such as EBF1 
and PAX5, and the transcriptional co-factor BTG1 [48,58] (Figure 3). BTG1 belongs to the 
BTG/TOB antiproliferative (APRO) protein family [94], which control gene transcription 
by their ability to interact with specific transcription factors, like nuclear receptors and 
homeobox proteins [95,96], the CCR4-NOT transcriptional regulatory complex [97], or 
through recruitment of protein arginine methyl transferase PRMT1 [98]. In addition, 
BTG1 through interaction with the CCR4-NOT, may also regulate mRNA deadenylation 
and consequently mRNA decay [99, 100]. Mice deficient for Btg1 show a partial block in 
B cell development, which is even more evident in Btg1-/-;Btg2-/- mice [101]. These studies 
have demonstrated that BTG1, together with BTG2, is required to suppress a T-lineage 
inappropriate expression program in progenitor B cells. Thus, mono-allelic gene deletions 
of IKZF1 in combination with EBF1, PAX5 or BTG1 may contribute to a more prominent 
block in B cell development and increased proliferative expansion of precursor B cells. 
Indeed, intercrossing haplodeficient Ikzf1 animals with heterozygous Ebf1 or Pax5 
knockout mice promotes the onset of acute lymphoblastic leukemia, giving rise to both 
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B-ALL and T-ALL [102]. On the other hand, Btg1-deficiency specifically accelerates the 
development of T-ALL in Ikzf1+/- mice, which suggests that B-lineage restricted mouse 
models will be required to establish their synergistic action in B-ALL pathogenesis.       
 
Figure 3 Pathways cooperating with IKZF1 alterations in leukemia pathogenesis. Pathways 
involving cytokine receptor signaling and B cell differentiation by lymphoid transcriptional 
regulators in normal progenitor B cells are schematically indicated on the left. Alterations of 
these pathways co-occur frequently with IKZF1 deletions and mutations in B cell progenitor acute 
lymphoblastic leukemia (BCP-ALL) as indicated on the right. These include, activating mutations 
in FLT3, IL7R, JAK2 (*), upregulation of CRLF2 (↑), C-terminal truncations or upregulation of EPOR 
(^), chromosomal translocations generating fusion proteins with PDGFR or CSF1R (-), and BCR-
ABL1, which collectively results in activated cytokine receptor and tyrosine kinase signaling 
leading to STAT activation. In addition, IKZF1 alterations co-occur with gene deletions affecting 
the activity of B-lymphoid transcriptional regulators EBF1, PAX5 and BTG1, which results in 
a block of B cell differentiation. Abbreviations used: FLT3, FMS Related Tyrosine Kinase 3; IL7R, 
Interleukin 7 Receptor; CRLF2, Cytokine Receptor Like Factor 2; C-KIT, Mast/stem cell growth 
factor receptor Kit; JAK, Janus kinase; STAT, signal transducer and activator of transcription; BTG1, 
B cell Translocation Gene 1; EBF1, Early B cell Factor 1; PAX5, Paired Box 5; IKZF1, IKAROS Family 
Zinc Finger 1; CSF1R, Colony Stimulating Factor 1 Receptor;  EPOR, Erythropoietin Receptor; 
PDGFR, Platelet Derived Growth Factor Receptor.
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Effector pathways downstream of IKZF1 involved in 
leukemia pathogenesis
Since lymphoid transcription factors are commonly deleted in BCP-ALL, the tumor 
suppressive functions of IKZF1 and other B cell master regulators, like EBF1 and PAX5, 
have been mostly linked to the suppression of their B cell differentiation programs in these 
leukemic cells. However, this would not fully explain the predilection of IKZF1 alterations 
in BCR-ABL1 positive and BCR-ABL1-like leukemia, suggesting that IKZF1 regulates also 
other molecular pathways. Furthermore, loss of IKZF1 function probably affects different 
target genes in human leukemic cells as compared to mouse progenitor B cells, which 
could even be distinct from those deregulated by expression of dominant negative 
isoforms, like IK6. Nonetheless, mouse studies performed over the past 5 years have been 
very instrumental in deciphering the transcriptional networks downstream of IKZF1. 
Thus, gene expression profiling in different Ikzf1 knockout mouse models combined with 
genome-wide chromatin immunoprecipitation studies has uncovered IKZF1-specific 
targets that are not only linked to lymphoid lineage commitment and B cell differentiation, 
but also to leukemia development. 
A large group of those Ikzf1-target genes can be classified as signal transducers, some of 
which drive early lymphoid differentiation, such as c-Kit, Flt3 and Il7r  [12,32,37,53]. Adult 
ALL samples harboring IKZF1 deletions display increased expression of IL7R together 
with reduced expression of SH2B3, which represents a defined subset of high-risk B-ALL 
[103].  Other genes differentially expressed in Ikzf1-mutant mice are important for pre-B 
cell receptor (BCR) signaling, and several of these IKZF1 targets appear to be deregulated 
in BCR-ABL1 positive B-ALL, including IGLL1, SYK, and SLP65 [104,105]. Indeed, defective 
pre-BCR function is a hallmark of BCR-ABL1 positive ALL, and loss of IKZF1 function 
enhances SRC phosphorylation at the expense of the SYK/SLP65 pathway activation, 
which is required for pre-B cell differentiation [104]. Besides transcriptional regulation of 
signal transducers, Ikzf1 controls the expression of cell surface receptors, such as CD34 
and CD43, and these molecules confer leukemic growth advantage to IKZF1-mutated 
BCR-ABL1 positive B-ALL cells [55]. 
Another group of identified IKZF1 target genes in mouse progenitor B cells seems to 
converge on a cellular network coupling cell surface protein expression with intracellular 
Wnt and Rho signaling as well as catenin-driven gene regulation inside the nucleus [55,106]. 
A critical target gene within this subgroup includes Ctnnd1 encoding p120-catenin. This is 
a multifunctional protein that regulates cadherin stability at the cell membrane, activation 
of Rho family of GTPases in the cytoplasm and Wnt/β-catenin target genes within the 
nucleus by interacting with Kaiso [107]. Activation of CTNND1 expression is observed 
in IKZF1-deleted patient samples [108], and inactivation of p120-catenin reduces the 
proliferative capacity of BCR-ABL1 positive leukemic cells [55,106]. A related downstream 
effector pathway of IKZF1 that plays an eminent role during mouse B cell development is 
integrin-dependent survival signaling, which involves activation of focal adhesion kinase 
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(FAK) [12,56]. In mouse models of BCR-ABL1 positive B-ALL, perturbation of Ikzf1, including 
loss-of-function deletions and expression of IK6, leads to activation of an adhesive 
phenotype, which correlates with overexpression of FAK [63,109]. Focal adhesion pathway 
upregulation is also observed in BCR-ABL1 positive BCP-ALL, especially in the context of 
IK6 expression [109]. Moreover, FAK inhibition potentiates the responsiveness to the ABL 
inhibitor dasatinib in a xenograft model system and improves survival [109].   
Recently, it has been proposed that the B-lymphoid transcriptional program regulated by 
IKZF1, as well as PAX5, acts as a metabolic barrier against malignant transformation of B 
cell precursor cells [110]. Inducible reconstitution of functional IKZF1 in patient-derived 
IKZF1-deleted B-ALL cells results in activation of the LKB1-AMPK energy-stress-sensor 
pathway, and decreased protein levels of the insulin receptor, the glucose transporters 
GLUT1, GLUT3 and GLUT6, as well as the effectors of glucose metabolism, such as HK2, 
HK3, and G6PD. On the other hand, the expression of glucose-transport inhibitors, like 
TXNIP and CNR2, are strongly induced by IKZF1. Consequently, these IKZF1-reconstituted 
B-ALL cells transit into a state of chronic energy deficit. Thus, this ‘metabolic gatekeeper’ 
function of IKZF1 may force silent pre-leukemic clones that carry potentially oncogenic 
lesions to remain in a latent state.     
Besides imposing a change on pre-BCR signaling, cell adhesion and metabolic state, 
IKZF1 alterations in combination with BCR-ABL1 expression also result in acquisition of 
stem cell-like features and enhanced self-renewal of progenitor B cells [63,105] (Figure 4). 
Activation of THY1 expression has been linked to enhanced self-renewal [63], and Ikzf1 
has been shown to regulate expression of multiple genes involved in cell cycle regulation, 
including Cdkn1a, Cdkn2a, and Cdk6 [53,55]. In mouse progenitor B cells and human B-ALL, 
BCL6 and MYC have been identified as IKZF1 targets [32,111-113], which both probably 
contribute to enhanced cell proliferation of IKZF1-deleted B-ALL. However, it remains to 
be established whether targeting of these pathways has therapeutic potential in high-risk 
B-ALL patients.   
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Figure 4 Effector pathways downstream of IKZF1 involved in leukemia pathogenesis. Loss of 
IKZF1 function due to IKZF1 gene deletions and mutations affects multiple pathways, including 
pre-B cell receptor signaling, cell adhesion and proliferation, metabolic pathways and signal 
transducers and cell surface receptors. IKZF1 affects the expression of defined key molecules within 
each of these pathways, as indicated in the boxes. Green boxes define targets that are upregulated 
upon loss of IKZF1 function, while red boxes represent repressed targets. Abbreviations used: SRC, 
Sarcoma proto-oncogene tyrosine kinase; SYK, Spleen tyrosine kinase; IGLL1, Immunoglobulin 
lambda like polypeptide 1; SLP65, B cell linker; RHO, RHO family of GTPases ; CTNND1, Catenin 
delta 1/p120 catenin; FAK, Focal adhesion kinase; ITGA5, Integrin subunit alpha 5; THY1, Thymus 
cell antigen 1; CDK6, Cyclin dependent kinase 6; CDKN1A,  Cyclin dependent kinase inhibitor 
1A; BCL6, B cell lymphoma 6; CDKN2A, Cyclin dependent kinase inhibitor 2A; c-MYC, Cellular 
myelocytomatosis oncogene; GLUT1/3/6, Glucose transporter 1/3/6; INSR, Insuline Receptor; 
HK2, Hexokinase 2; HK3, Hexokinase 3; AMPK, AMP-activated protein kinase; LKB1, Liver kinase 
B1; G6PD, Glucose-6-phosphate dehydrogenase; TXNIP, Thioredoxin Interacting Protein; NR3C1, 
Nuclear Receptor Subfamily 3, Group C, Member 1 (Glucocorticoid Receptor); CNR2, Cannabinoid 
Receptor 2; FLT3, FMS Related Tyrosine Kinase 3; CD34, Hematopoietic progenitor cell antigen; 
c-KIT,  KIT receptor tyrosine kinase; CD43, Sialophorin; IL7R, Interleukin 7 Receptor.
IKZF1 alterations mediate therapy resistance  
The presence of IKZF1 gene lesions in BCR-ABL1 positive B-ALL result in inferior treatment 
outcome and mouse xenograft models suggest that IKZF1 loss contributes to resistance 
to tyrosine kinase inhibitor (TKI)-based therapy [63,80]. Reactivation of cell adhesion 
pathways by perturbation of IKZF1 function leads to elevation of key adhesion molecules, 
such as integrins (ITGA5), CD90 and FAK, as well as increased phosphorylation of FAK 
itself, which permits relocalization of leukemic cells to the bone marrow niche. Indeed, 
FAK inhibition re-sensitizes BCR-ABL1 leukemic cells to TKI therapy [109]. Similar results 
are observed after treatment with retinoids, specifically retinoid X receptor agonists, 
which induce expression of wild-type IKZF1, but not IK6, thereby abrogating expression 
of stem cell and adhesion molecules [63]. Although these studies have provided important 
clues about how IKZF1 deletions alter treatment response especially in the context of 
BCR-ABL1 positive ALL, alternative mechanisms of therapy resistance may exist besides 
protection through cell interactions within the bone marrow microenvironment.        
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Synthetic glucocorticoids (GCs), such as prednisolone, constitute essential drugs in 
the treatment of ALL patients and GC resistance remains a substantial problem in the 
treatment of BCP-ALL. There is accumulating evidence that IKZF1 deletions mediate 
prednisolone resistance in vivo [114,115], but different mechanisms have been proposed. 
IKZF1 actively represses genes of the phosphatidylinositol-3 kinase (PI3K) pathway, 
including PIK3CD and PIK3C2B [23]. Disruption of IKZF1 function, and subsequent 
activation of PI3K/AKT/mTOR pathway can promote GC resistance [116,117]. IKZF1 
controls expression of several genes involved in glucose and energy supply [110]. This 
metabolic program may alter the threshold for responses to glucocorticoids in BCP-
ALL. Specifically, the glucocorticoid receptor NR3C1 was reported as a target of IKZF1 
in pre-B ALL cells, and downregulation of NR3C1 protein levels could be observed upon 
expression of IK6 [110]. However, studies performed in mouse Ikzf1+/- B cells and human 
BCP-ALL cell lines with short hairpin-mediated IKZF1 knockdown have demonstrated 
that loss of IKZF1 function induces GC resistance independent of altered NR3C1 mRNA 
and protein expression [114]. Indeed, IKZF1 itself appears to regulate NR3C1-dependent 
gene transcription [114]. Transcriptional regulator BTG1 has been identified as a modifier 
of IKZF1-mediated GC therapy resistance and combined loss of BTG1 and IKZF1 leads to 
even a stronger inhibition of GC-induced cell death48. Finally, IKZF1 target gene EMP1 
[106], which itself represents a poor prognostic factor in pediatric ALL, was shown to 
regulate the response to prednisolone, but on the other hand also affects normal leukemic 
cell viability and proliferation [118]. Collectively, these findings demonstrate that IKZF1 
through modulation of different signaling pathways and acting directly on GC target genes 
alters treatment response, thereby mediating therapy resistance in BCP-ALL (Figure 5).     
Figure 5 IKZF1 alterations mediate therapy resistance. Overview of IKZF1-affected pathways 
contributing to tyrosine kinase inhibitor (TKI) resistance and glucocorticoid (GC) resistance. 
Enhanced cell adhesion due to loss of IKZF1 function has been shown to contribute to both TKI and 
GC resistance. Deregulation of metabolic pathways, such as LKB1/AMPK signaling and glucose 
metabolism, attenuated glucocorticoid receptor (GR) target gene regulation and upregulation of 
epithelial membrane protein 1 (EMP1) have been implicated in mediating GC resistance of IKZF1-
deleted BCP-ALL. Green boxes indicate activated targets or pathways, while red boxes define 
attenuated pathways. Targets within the metabolic pathway can either promote or inhibit GC 
resistance.  
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Conclusions and perspectives
From this review it becomes clear that loss of IKZF1 function impacts a broad variety of 
biological pathways which all may contribute to leukemia development. Moreover, the 
recently established roles for IKZF1 in cell adhesion, metabolism and glucocorticoid-
dependent target gene regulation seem to be important determinants of therapy 
resistance. Preclinical studies are helping with the identification of molecular pathways 
that can be exploited for targeted therapy of IKZF1-deleted BCP-ALL.  
Over the past decade, a large series of studies conducted in both childhood and adult ALL 
have provided clear evidence that IKZF1 alterations predict adverse outcome in BCP-ALL, 
both in BCR-ABL1 positive and negative B-ALL. However, more recently the role of IKZF1 
deletions as an independent prognostic marker has been challenged [119], and also the 
specific contributions of whole gene versus intragenic dominant-negative IKZF1 deletions 
[86]. One potential explanation for such disparities may relate to differences in, scheduling 
and dosing of specific therapeutic agents between different treatment protocols. 
Therefore, it will be important to study these protocol-dependent differences in order to 
define what is currently the most efficient treatment for IKZF1-deleted ALL. For the near 
future, more systematic screens aimed at determining specific vulnerabilities of IKZF1-
deleted ALL may lead to the identification of targeted therapies that can re-sensitize this 
high-risk ALL subgroup to curative treatment.
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Abstract 
Synthetic glucocorticoids are essential anticancer drugs in the treatment of acute 
lymphoblastic leukemia (ALL). Despite improved therapy outcome in ALL, resistance 
to glucocorticoids remains a major problem in the curative treatment of ALL. Genetic 
alterations inactivating the transcription factor IKZF1 represent a novel prognostic 
marker associated with a higher incidence of relapse in patients with B cell precursor ALL 
(BCP-ALL). In this study, we assessed whether IKZF1 had a direct impact on the sensitivity 
towards glucocorticoids. Mouse Ikzf1+/- B cells were more resistant towards glucocorticoid-
induced apoptosis, which correlated with attenuation of the transcriptional response 
to glucocorticoids. To the converse, IKZF1 overexpression enhanced glucocorticoid 
receptor-dependent gene transcription in luciferase reporter assay. The glucocorticoid 
resistance phenotype was also observed in human BCP-ALL cell lines displaying loss 
of IKZF1 function. In primary BCP-ALL patient samples, IKZF1 alterations conferred 
resistance towards prednisolone and dexamethasone as determined by MTT assay, but 
not other single chemotherapeutic agents. In addition, the frequency of IKZF1 deletions 
was significantly higher in patients with a poor prednisolone response in vivo. All together, 
we conclude that tumor suppressor IKZF1 is a key determinant of the cellular response to 
glucocorticoids in normal and leukemic B cells, and IKZF1 alterations mediate resistance 
to glucocorticoids in BCP-ALL.  
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Introduction
Acute lymphoblastic leukemia (ALL) is characterized by the presence of acquired genetic 
alterations, including chromosomal translocations, gene deletions and mutations, 
which drive leukemia initiation and maintenance of the leukemic clone [1,2]. With recent 
advances in genomic profiling and whole-genome sequencing, the genomic landscape of 
ALL has been intensively characterized. Several of these genetic alterations were shown 
to be more prevalent in relapsed leukemia samples and appear to play a direct role in 
regulating chemotherapy responses, such as mutations in the genes CREBBP and NT5C2 
[3-6]. In B cell precursor ALL (BCP-ALL), gene deletions and inactivating point mutations 
affecting the IKZF1 (IKAROS) gene occur at increased frequencies in high-risk patients 
harboring a BCR-ABL1 translocation [7], JAK2 mutation/CRLF2 rearrangement, and 
those classified with a Philadelphia- or BCR-ABL1-like gene expression signature [10-13]. 
Moreover, IKZF1 deletions represent an independent prognostic factor that predicts 
inferior treatment outcome in different cohorts of childhood and adult BCP-ALL [10,14-17]. 
However, it has not been established whether loss of IKZF1 function directly impacts the 
response to chemotherapy.  Synthetic glucocorticoids (GCs), such as dexamethasone 
and prednisolone, are essential drugs in the multi-agent chemotherapy regimens used 
to treat patients with lymphoid malignancies, including BCP-ALL. It has been established 
that both in vitro resistance and the initial clinical day 8 response to GCs predict an 
unfavorable outcome in pediatric ALL [18-20]. GCs act through the glucocorticoid receptor 
(GR), which is encoded by the NR3C1 gene. Upon binding to the inactive cytoplasmic 
form of GR, the activated ligand-GR complex translocates to the nucleus and binds to 
specific DNA sequences known as glucocorticoid response elements (GREs). This results 
in transcriptional activation of target genes through recruitment of co-activators, like 
SRC2 [21], or inhibition of gene expression via GR tethering to other transcription factors, 
GR recruitment of the co-repressor GRIP1, or through binding to negative GREs [22,23]. 
However, despite intensive research, it remains poorly understood which biological 
mechanisms contribute to GC resistance phenotype clinically relevant for BCP-ALL.
In this paper, we report that loss of IKZF1 function in normal as well as leukemic B cells 
confers resistance to GC-induced apoptosis by modulating GR-dependent target gene 
regulation. 
Materials and methods
Ikzf1 knockout animals
In this study, the Ikzf1Neo knockout mouse line was used 24, which was kindly provided by 
M. Busslinger (Research Institute of Molecular Pathology, Vienna, Austria). The Ikzf1Neo 
strain was maintained as a heterozygous knockout line (Ikzf1+/-) on an inbred C57BL/6J 
genetic background, and all animals were housed under specific pathogen-free conditions. 
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All animal experiments were approved by the Animal Experimental Committee of the 
Radboud university medical center and performed in accordance with institutional and 
national guidelines. For detailed experimental descriptions, see Supplementary methods.
Experimental procedures Ikzf1 knockout animals
Wild-type and Ikzf1+/- mice were sacrificed at the age of 8 to 14 weeks and spleen, tibiae 
and femurs were removed. The leg bones were flushed to isolate bone marrow (BM) cells 
and single cell suspensions of splenocytes were obtained using a 70 µM cell strainer. 
Erythrocytes in the isolates were removed by lysis in Red blood cell lysis buffer (Sigma-
Aldrich, Zwijndrecht, Netherlands). After washing the cells, CD19+ Bone marrow (BM) cells 
were obtained by positive selection on CD19 microbeads according to the manufacturer’s 
protocol (Miltenyi, Bergisch Gladbach, Germany).  BM cells were cultured for 48 hours in 
IMEM medium (Life Technologies, Bleiswijk, Netherlands) supplemented with 25% fetal 
bovine serum optimized for mouse pre-B lymphoid cells (Stem Cell Technology, Grenoble, 
France), 0.03% Primaton (Sigma-Aldrich, Zwijndrecht, Netherlands), 1% penicillin/
streptomycin (Invitrogen, Merelbeke, Belgium), 50 µM Beta-Mercaptoethanol and 20 
ng/mL murine IL-7 (R&D, Oxon, UK). Single cell splenocytes were cultured for 48 hours 
in RPMI 1640 medium (Life technologies, Carlsbad, CA) supplemented with 10% heat-
inactivated fetal calf serum (FCS), 1% penicillin/streptomycin (Invitrogen), and 50 µM 
β-Mercaptoethanol in the presence of 5 µg/mL lipopolysaccharide (LPS). Stimulated CD19+ 
BM cells and viable splenic B-lymphocytes obtained after ficoll gradient were subsequently 
cultured in a 96-well plate at a density of 1x 105 cells/well under similar conditions as 
the initial expansion phase. B cells were treated with increasing concentrations of 
prednisolone or dexamethasone (both Centrafarm, Etten-Leur, the Netherlands). After 48 
hours, relative cell viability was assessed using the CellTiter 96® AQueous One Solution 
Cell Proliferation (MTS) Assay (Promega, Madison, WI). Absorbance was acquired using a 
plate reader (Infinite F50; TECAN, Männedorf, Switzerland).  Phenotypic characterization 
of the B-lymphocytes derived from WT and Ikzf1+/- mice after 48h exposure to 5 µg/mL LPS 
was obtained by B220 and CD19 (both BD Pharmingen, San Jose, CA) staining and analyzed 
by FACS using the LSRII flow cytometer (BD Biosciences, San Jose, CA). For AnnexinV 
analyses splenic B-lymphocytes derived from 8-14 weeks old WT and Ikzf1+/- mice were 
treated for 48h with prednisolone or dexamethasone and stained with the AnnexinV-PE/7-
AAD Viability Kit (BD Biosciences) according to manufacturer’s instructions and analyzed 
by FACS. AnnexinV positive cell fractions were determined by FlowJo software Version 
5.03 (Treestar, Ashland, OR). For analysis of PARP cleavage, cleaved PARP fractions were 
divided by uncleaved PARP fractions to determine the relative PARP cleavage ratio.
Protein lysates and immunoblotting
Whole cell extracts were prepared in NP-40 lysisbuffer (200mM NaCl, 0.5% NP-40, 
20mM Tris.Cl pH8.0, 5mM EDTA, 1mM Na3VO4, 100mM NaF) supplemented with 1mM 
PMSF and Complete protease inhibitors (Roche Life Sciences, Almere, Netherlands), and 
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cleared by centrifugation. Protein concentration was determined with Biorad assay and 
equal amount of protein lysates were resolved by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene difluoride (PVDF) 
membrane. The membranes were probed with primary antibodies against PARP (# 9542), 
GR (#12041), pSer211-GR (#4161) (Cell Signaling Technology, Leiden, the Netherlands), 
GAPDH (H-12, Santa Cruz Biotechonology, Santa Cruz, CA), IKZF1 (R&D Systems Oxon, 
UK), followed by horseradish peroxidase (HRP) conjugated secondary antibody. Proteins 
were visualized with ECL reagent (GE Healthcare) and expression was detected with 
Fluorchem (Cell biosciences, Santa Clara, USA). Quantification was performed with 
AlphaView software version 3.3.10 (Cell biosciences, Santa Clara, USA).
Microarray-based gene expression analyses
Total RNA was extracted from 3x106 splenic B cells from WT (n=3) and Ikzf1+/- mice (n=3) 
according to the manufacturer’s protocol (Qiagen RNAeasy kit, Venlo, the Netherlands). 
The RNA of each group was pooled and biotinylated complementary RNA was prepared 
using the Illumina TotalPrep RNA Amplification kit (Ambion, Austin, TX) according to 
manufacturer’s specifications with an input of 200ng total RNA. Samples were hybridized 
onto the Illumina MouseRef-8 v2 at ServiceXS B.V (Leiden, The Netherlands). Samples 
were normalized to Robust Multi-array Average (RMA) and analyzed with ArrayStar 
software (DNAStar, Madison, WI).  We then used the Ingenuity software package to 
conduct upstream regulator analyses of the genes that were differentially expressed 
between untreated and prednisolone-treated WT and Ikzf1+/- B cells with an absolute value 
expression cut-off of 3.5 and a fold change (FC) ≥ 2. Illumina bead array expression data 
are available at the NCBI Gene Expression Omnibus database (GSE65554).
Real-time quantitative polymerase chain reaction
Total RNA was extracted using the RNeasy mini-kit (Qiagen). Subsequently, cDNA was 
synthesized of 500ng RNA template using the iScriptTM cDNA synthesis kit (Bio-Rad, 
Hercules, CA). mRNA expression levels were determined by use of Power SYBR® Green 
PCR master mix using gene-specific primers (sequences are listed in Supplementary Table 
1) and the CFX96 TouchTM Real-Time PCR detection system (Bio-Rad, Hercules, CA, USA). 
HPRT mRNA expression was used as a reference to obtain the relative fold expression of 
target genes using the comparative cycle threshold 2(-ΔΔCt) method.
Luciferase reporter assay
A minimal mouse mammary tumor virus (MMTV)-Luc promoter construct was generated 
by cloning a 405-bp region containing four glucocorticoid response elements (GREs) of 
the long terminal repeat (LTR) region of MMTV into the NheI-XhoI restriction sites of the 
pGL3-basic plasmid vector (Promega, Madison, WI, USA). HEK293 cells were cultured in 
DMEM medium with 10% FCS and 1% Pen/Strep in 24-well plates and transfected with 
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MMTV-Luc promoter reporter construct, plasmid human influenza hemagglutinin (pHA)-
N1-GRalpha expression vector, pcDNA-StrepII-FLAG-Ty1-IKZF1 or pcDNA-StrepII-FLAG-
Ty1-IK6 expression plasmids using polyethylenimine (Pei) reagent. A cytomegalovirus 
immediate early promoter (CMV)-Renilla expression plasmid was included to control for 
transfection efficiency. After transfection, cells were treated with 3 µM prednisolone for 
20 hours before cells were harvested with Passive Lysis Buffer (Promega Madison, WI). 
Luciferase activity was determined by using the dual luciferase reporter assay system 
following the manufacturer’s instructions (Promega Madison, WI). 
Lentiviral shRNA-mediated gene knockdown and lenalidomide treatment
RS4;11 and NALM6 leukemia cell lines were cultured in RPMI160 medium (Life 
Technologies, Bleiswijk, Netherlands) supplemented with 10% fetal calf serum and 1% 
penicillin/streptomycin (Invitrogen, Merelbeke, Belgium). For lentiviral transduction, 
HEK293FT cells were transfected with one lentiviral pLKO.1-puro vector (see 
Supplementary Table 1 for shRNA sequences) together with pVSV-G and psPAX2 using 
Lipofectamine 2000 (Invitrogen). Leukemia cell lines were transduced in the presence 
of 1 µg/mL polybrene and 24 hours after transduction selected with 1µg/mL puromycin. 
For lenalidomide-induced IKZF1 protein degradation, RS4;11 were pretreated with 1µg/
ml lenalidomide (Selleckchem, Houston, TX, USA) for 24 hours. Subsequently, cells were 
in continuous presence of 1µg/mL lenalidomide during incubation with prednisolone or 
dexamethasone for MTS assays and AnnexinV/7AAD assays (48 hours) or RNA isolation 
(16 hours).
Patient leukemia samples and MTT assay
The MTT data were obtained from 187 diagnosis samples of the Dutch Childhood 
Oncology Group (DCOG) trial ALL-9. The day 8 prednisolone response was obtained from 
646 patients of ALL-10 and ALL-11 trials. In accordance with the Declaration of Helsinki, 
written informed consent was obtained from parents and guardians, to use excess 
diagnostic material for research purposes. Viable leukemic cells were obtained from 
fresh bone marrow or peripheral blood samples using a ficoll gradient. The mononuclear 
cells were cultured in 96-well plate at a density of 1.6 x 105 cells/well in complete 
culture medium, which consisted of RPMI 1640 medium supplemented with 20% heat-
inactivated FCS, 2 mM Glutamine, 200 g/mL Gentamycine, 5 µg/mL Insuline, 5 µg/mL 
Transferrine, and 5 ng/mL Sodium selenite. The following chemotherapeutic drugs were 
added to the cells in duplicate in 6 different concentrations:  L-Asparaginase /Paronal 
(Takeda Pharmaceuticals, Zurich, Switzerland), range 0.0032-10 U/mL; dexamethasone 
(Brocacef, Maarssen, the Netherlands), range 0.0005-15 µM; vincristine/Oncovin (Eli Lilly, 
Indianapolis, In), range 0.06-60 µM; prednisolone (Brocacef, Maarssen, the Netherlands), 
range 0.02-700 µM. After 4 days, 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium 
bromide (MTT) was added to the cells. After 6 hours incubation at 37 ºC, isopropanol-HCl 
was added and samples were measured in microplate reader at 562 nM wavelength. To 
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detect IKZF1 deletions and mutations, genomic DNA was isolated from leukemic blasts 
present in bone marrow or peripheral blood with the QIAamp DNA Mini Kit (Qiagen) 
according to the manufacturer’s instructions. IKZF1 gene deletions were identified using 
the SALSA P335 ALL Multiplex Ligation-dependent Probe Amplification (MLPA) assay 
(MRC-Holland, Amsterdam, the Netherlands). IKZF1 deletions were confirmed with the 
previously described P202 MLPA probe set. The presence of inactivating point mutations 
in IKZF1 was determined using PCR amplification and subsequent Sanger sequencing of 
exons 4, 5, 6 and 8.
Statistical analyses
The statistical analyses for the cell viability assays and quantitative real-time polymerase 
chain reaction (qRT-PCR) were performed using PRISM6 (GraphPad Software, La Jolla, 
CA), and for the MTT data of the patient samples, the SPSS program (IBM, Amsterdam, 
Netherlands) was used. For the MTS assays, two-sided ANOVA was performed to assess 
differences between the best-fit curves. For the AnnexinV, PARP cleavage and qRT-PCR, a 
student’s t test was performed. For the patient data (MTT assay), the statistical significance 
in the IKZF1-Mut group versus IKZF1-WT group was calculated using the Mann-Whitney 
U test. All statistical tests were two-sided and P values of less than 0.05 were considered 
statistically significant.
Results
Glucocorticoid resistance phenotype in Ikzf1-haplodeficient B cells 
To address whether loss of the transcription factor IKZF1 has an impact on the level of 
GC-induced apoptosis in lymphoid cells, we analyzed the phenotype of mouse B cells 
lacking one functional allele of Ikzf1. Lipopolysaccharide (LPS)-activated splenic B cells 
obtained from Ikzf1+/- mice showed enhanced cell survival after treatment with GCs 
compared to wild-type (WT) cells as measured with MTS assay (Figure 1a), which was not 
related to differences in B cell differentiation (Supplementary Figure S1). The inhibitory 
concentration targeting 50% of the cells (IC50) after prednisolone treatment was about 
90-fold higher in Ikzf1+/- B cells compared to wild type control cells (P<0.001) (Figure 1a, 
left panel). An even stronger effect was observed for dexamethasone, with a 275-fold 
higher IC50 for Ikzf1+/- B cells (P<0.001) (Figure 1a, right panel). A similar phenotype was 
observed in bone marrow-derived CD19+ progenitor B cells, where Ikzf1-haplodeficiency 
also conferred resistance to GC-induced apoptosis (Supplementary Figure S2). The 
resistance against GC-induced apoptosis in splenic B cells was confirmed by AnnexinV 
staining, where the fraction of AnnexinV-positive cells was significantly lower in 
Ikzf1+/- B-lymphocytes treated with prednisolone or dexamethasone, compared to WT 
B-lymphocytes (P<0.001 for both drugs) (Figure 1b, Supplementary Figure S3). In addition, 
another marker of apoptosis, PARP protein cleavage, revealed that Ikzf1+/- B cells displayed 
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lower levels of cleaved PARP after prednisolone treatment in comparison to WT control 
cells (Supplementary Figure S4). Together these data demonstrate that IKZF1 is a critical 
determinant of GC-induced apoptosis in B cells.
Attenuated glucocorticoid-responsive target gene regulation in Ikzf1-
haplodeficient B cells
To explore the mechanism underlying the glucocorticoid resistance phenotype, we 
performed microarray gene expression analyses on wild-type and Ikzf1+/- B-lymphocytes. 
Ingenuity upstream regulator analyses revealed a dexamethasone-related signature in 
both untreated and prednisolone-treated B cells (Supplementary Figure S5, Supplementary 
Table 2), indicating that GC-regulated target genes were differentially expressed in Ikzf1+/- 
B cells. Indeed, the level of gene induction of 769 prednisolone-activated genes in Ikzf1+/-
B-lymphocytes was significantly lower compared to the WT cells (P<0.001; Figure 1c, left 
panel). Similarly, the 774 prednisolone-repressed genes showed a significantly impaired 
response in Ikzf1+/- B-lymphocytes compared to controls (P<0.001; Figure 1c, right panel). 
Comparison with the global gene expression signature derived from IKZF1-deleted BCP-
ALL patient samples showed a minimal overlap (Supplementary Figure S6). 
To further investigate the expression of individual GC-responsive genes, quantitative 
reverse-transcription polymerase chain reaction (qRT-PCR) was performed for seven 
genes known to be activated by GCs. The transcriptional response of Tsc22d3, Dusp1, Irs2 
and Zfp36l2 was significantly attenuated by Ikzf1 haplodeficiency (Figure 1d), whereas 
three other GC-activated genes (Sgk1, Ddit4, and Fkbp5) were not differentially regulated 
in response to prednisolone (Supplementary Figure S7). All four GC-repressed target 
genes examined (Il1a, Il1b, Sdpr, Il6) displayed a lower basal level of expression in Ikzf1+/-
B-lymphocytes, of which only one (Il6) displayed an attenuated response to prednisolone. 
(Figure 1d). Together, our results show that in Ikzf1+/- B cells a major subset of GC-
responsive target genes display lower steady-state expression levels and significantly 
impaired gene regulation by prednisolone.   
Figure 1 Glucocorticoid-resistance phenotype in Ikzf1+/- B cells. (a) Wild-type (WT) and Ikzf1+/-
splenic B cells pre-stimulated by lipopolysaccharide (LPS) were treated for 48 hours with increasing 
concentrations of prednisolone (left panel) or dexamethasone (right panel) and analyzed by MTS 
assay (n=9). All values were normalized to untreated B cells. Error bars represent ± standard error 
of the mean (SEM). P values were calculated based on the differences of the best-fit curve. (b) 
AnnexinV/7-AAD staining was performed on WT and Ikzf1+/- B cells after 48 hours prednisolone 
(n=6) or dexamethasone (n=5) treatment and analyzed by flow cytometry. Data are means and 
SEM. (c) Boxplots indicate the median level of 769 prednisolone-activated target genes (left 
panel) or 774 prednisolone-repressed target genes (right panel) in wild-type B cells as compared 
to the level of target gene regulation in Ikzf1+/-- B cells. (d) Transcript levels of glucocorticoid (GC)-
target genes that were either activated (left panel) or repressed (right panel) by prednisolone 
treatment as measured by quantitative reverse transcription polymerase chain reaction in B cells 
from WT (n=4) and Ikzf1+/- mice (n= 4). All expression levels were normalized to Hprt expression 
and compared to the levels in the untreated (control) WT B cells. Data are means and SEM. 
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Figure 2 Expression and phosphorylation of glucocorticoid receptor in IIkzf1+/- B cells in response 
to glucocorticoid treatment. (a) Expression levels for Nr3c1 were analyzed in wild-type (WT) and 
Ikzf1+/- B cells (both n=3) by quantitative reverse transcription polymerase chain reaction after 16 
hours of 2µM prednisolone treatment and normalized to Hprt expression. Data are means and 
SEM. (b) Immunoblot shows levels of phospho-Ser220 and total levels of glucocorticoid receptor 
(GR) in mouse B cells of two independent WT (WT1, WT2) and Ikzf1+/- (Ikzf1+/--1 and Ikzf1+/--2) 
animals in the absence or presence of 16 hours 2µM prednisolone treatment. GAPDH antibody 
staining serves as a loading control. 
Glucocorticoid-dependent signaling in Ikzf1-haplodeficient B cells
Different aspects of GC signaling could be responsible for the altered state of GC-mediated 
gene regulation in Ikzf1+/- B cells, including indirect effects on the expression or activity 
of the glucocorticoid receptor (GR). To investigate this possibility, we first determined 
whether basal mRNA expression and auto-induction of the GR gene Nr3c1 itself was 
affected by Ikzf1 levels, which was not the case (Figure 2a). Next, the level of GC-induced 
phosphorylation of GR was investigated. It has been well established that in response 
to GCs, cyclin-dependent kinases (CDKs), glycogen synthase kinase 3 (GSK-3), and 
mitogen activated protein kinases (MAPKs) can phosphorylate GR at multiple sites [25-27], 
including serine residue 220 of mouse GR. Western blot analysis showed similar levels of 
prednisolone-induced phosphorylation on serine 220 (pSer220) in B-lymphocytes of two 
independent WT and Ikzf1+/-  mice (Figure 2b). Together, these data indicate that IKZF1 has 
no significant impact on the expression and activation of GR in primary B-lymphocytes 
treated with prednisolone.  
Effect of IKZF1 on glucocorticoid receptor-dependent transcription
Next, we assessed more direct effects of IKZF1 on GR-dependent gene transcription. To 
this end, a GC-responsive luciferase reporter construct was used, harboring a minimal 
MMTV promoter fragment with four glucocorticoid responsive elements (GREs). Both 
full length IKZF1 and the dominant negative deletion variant IK6, which can be detected 
in BCP-ALL patients with intragenic IKZF1 deletions [28], were tested. HEK293 cells 
transfected with IKZF1 and GR expression plasmids displayed an IKZF1 concentration-
dependent activation of GR-induced gene transcription in the presence of prednisolone 
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(Figure 3a). This additional increase of luciferase activity by IKZF1 was not observed in the 
absence of transfected GR plasmid (Figure 3a). Moreover, transfection of similar levels 
of IK6 had no effect on GR-mediated transcriptional activation (Figure 3a). Western blot 
analyses confirmed that IKZF1 had no impact on GR protein levels (Figure 3b), suggesting 
that IKZF1 activates GR-dependent transcription. 
 
Figure 3 IKZF1 overexpression enhances glucocorticoid receptor-dependent gene activation. 
(a) Luciferase reporter assay was performed in HEK293 cells by co-transfection of a MMTV-Luc 
reporter construct harboring four glucocorticoid responsive elements together with expression 
plasmids for HA-tagged glucocorticoid receptor (GR), full length IKZF1 or mutant IK6 lacking 
amino acids 54-283, including the four N-terminal zinc-fingers encoding the DNA binding domain, 
and CMV-Renilla. Normalized luciferase activity for each sample was related to MMTV-Luc vector 
alone.  Results represent the mean and standard deviation from two independent experiments 
performed in duplicate. (b) Western blot analysis shows expression levels of IKZF1, IK6 and GR as 
used for the MMTV-Luc reporter assay using IKZF1 (for IKZF1 and IK6 detection) and HA (for GR 
detection) antibodies
 
Silencing of IKZF1 expression induces glucocorticoid resistance in 
leukemia cell lines
We next determined whether loss of IKZF1 function would also alter the response to GCs 
in the BCP-ALL cell lines RS4;11 and NALM6, using lentiviral-mediated short hairpin RNA 
(shRNA) approach. IKZF1-shRNA expression resulted in a ~50% reduction in IKZF1 mRNA 
and protein expression compared to non-targeting (NT)-shRNA (Figure 4a-b). MTS assays 
revealed that IKZF1-silencing inhibited GC-induced apoptosis in RS4;11 cells (Figure 4c), 
where the IC50 for prednisolone was ~10-fold higher in the IKZF1-shRNA cells compared to 
NT-shRNA cells (P<0.001). For dexamethasone, the IC50 was ~30 fold higher in the IKZF1-
shRNA transduced RS4;11 cells compared to NT-shRNA cells (P<0.001). Similar results 
were obtained in NALM6 cells, where the IC50 for prednisolone and dexamethasone 
was significantly higher in comparison to NT-shRNA cells (P<0.001) (Figure 4d). The GC 
resistance phenotype was confirmed with AnnexinV staining in both cell lines, showing 
enhanced survival for IKZF1-shRNA transduced cells in response to GCs (Figure 4c-d, 
right panels). The GC-resistance phenotype was shown to correlate with attenuated 
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regulation of prednisolone-responsive target genes ZFP36L2, DFNA5 and IL1B in both 
RS4;11 and NALM6 cells transduced with IKZF1-shRNA (Figure 4e). In a second approach, 
the thalidomide analog lenalidomide was used to selectively degrade IKZF1 protein 
in RS4;11 cells [29,30]. Treatment for 24 hours with 1-2µM lenalidomide significantly 
reduced IKZF1 protein levels in RS4;11 cells (Figure 5a). Lenalidomide-treated RS4;11 
cells also displayed a protection against GC-induced apoptosis as measured by MTS assay 
(Figure 5b) and AnnexinV staining (Figure 5c). This Lenalidomide-induced GC resistance 
phenotype observed in RS4;11 could also be confirmed in ALL-PO (Supplementary Figure 
S8). Similar to the shRNA approach, lenaldiomide-treated RS4;11 cells demonstrated 
altered regulation of GC-responsive genes (Figure 5d), including attenuation of the GC-
induced target genes SGK1, DFNA5 and FBXW7, as well as decreased basal levels of the 
GC-repressed target genes PRICKLE1 and IL1B. Together, these data indicate that loss of 
IKZF1 function confers resistance towards glucocorticoids in human BCP-ALL cell lines by 
affecting the glucocorticoid transcriptional response. 
 
Figure 4 Effect of IKZF1 silencing on glucocorticoid resistance phenotype in leukemia cell lines. (a-
b) Expression analysis of IKZF1 in BCP-ALL cell lines RS4;11 and NALM6 lentiviral transduced with 
NT- and IKZF1-shRNA. (a) Quantitative reverse transcription polymerase chain reaction (qRT-
PCR) was used to assess the efficiency of IKZF1 silencing in RS4;11 and NALM6 cell lines. Relative 
expression levels of IKZF1 knockdown were compared to non-targeting (NT) shRNA. (b) Western 
blot analysis of IKZF1 protein levels in NT-shRNA and IKZF1-shRNA expressing cell lines. GAPDH 
was used as loading control. (c-d) MTS assay (left panels) or AnnexinV staining (right panels) were 
performed on RS4;11 (c) and NALM6 (d) cells expressing NT-shRNA or IKZF1-shRNA  48 hours 
after treatment with increasing concentrations of prednisolone or dexamethasone. All values 
were normalized to NT-shRNA for MTS analysis. Error bars represent ± standard error of the mean 
(SEM) from three independent experiments. For MTS assays, P values were calculated based on the 
differences of the best-fit curve. For AnnexinV/7AAD assays, data represent the means from three 
independent experiments, and error bars represent SEM. (e) Relative expression of commonly 
shared glucocorticoid (GC)-responsive target genes ZFP36L2, DFNA5 and IL1B in RS4;11 and 
NALM6 cells expressing IKZF1-shRNA. GC-target gene expression was measured after 16 hours 
2μM prednisolone treatment as determined by qRT-PCR and normalized to HPRT expression. All 
expression levels are compared to untreated (UT) NT-shRNA cells. Error bars represent SEM from 
at least three independent experiments.
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Figure 5 Lenalidomide-mediated IKZF1 protein degradation confers glucocorticoid resistance 
in RS4;11 cells. (a) Lenalidomide-induced IKZF1 protein degradation was validated by Western 
blot analysis after 24 hours incubation with 1µM or 2µM lenalidomide. GAPDH was used as 
loading control. (b-c) RS4;11 pre-treated for 24 hours with 1µM lenalidomide were incubated with 
increasing concentrations of prednisolone (left panel) or dexamethasone (right panel) and relative 
cell survival was determined by MTS assay (b) or AnnexinV/7-AAD staining (c). For MTS assays, 
all values were normalized to untreated control cells. Error bars represent ± standard error of the 
mean (SEM) from three independent experiments. For MTS assays, P values were calculated based 
on the differences of the best-fit curve. For AnnexinV/7AAD assays, data represent the means 
from three independent experiments, and error bars represent SEM. (d) Relative expression 
of glucocorticoid (GC)-responsive target genes SGK1, DFNA5, FBXW7, PRICKLE1 and IL1B in 
RS4;11 cells displaying loss of IKZF1 function through either lenalidomide-induced IKZF1 protein 
degradation (upper panel) or IKZF1-shRNA expression (lower panel). Expression was measured 
after 16 hours of 2 μM prednisolone treatment by qRT-PCR and normalized to HPRT expression. All 
expression levels are compared to untreated (UT) parental or NT-shRNA cells. Error bars represent 
SEM from at least three independent experiments.
 
IKZF1 alterations mediate glucocorticoid resistance in childhood BCP-ALL 
patients
To assess whether primary pediatric BCP-ALL patient samples with IKZF1 alterations 
displayed GC resistance, we first examined the outcome of MTT assays performed on 
187 diagnosis patient samples collected as part of the ALL-9 trial of the Dutch Childhood 
Oncology Group (DCOG) [31,32]. Data were available for 152 BCP-ALL patients without 
an IKZF1 alteration (IKZF1-WT) and 35 patients with either an IKZF1 deletion (n=33) or 
mutation (n=2).  For each primary leukemic sample, the median lethal concentration (LC50) 
was determined 96 hours after treatment with one specific type of chemotherapeutic 
drug, which included prednisolone, dexamethasone, L-asparaginase and vincristine 
(Supplementary Table 3 and 4). We observed that primary BCP-ALL samples with an IKZF1 
alteration (IKZF1-Mut) had a 10-fold higher LC50 for prednisolone (P=0.004) and a 20-
fold higher LC50 for dexamethasone (P=0.0001) relative to IKZF1-WT samples (Figure 6). 
In contrast, LC50 values for L-asparaginase and vincristine were not significantly different 
between the two patient groups. Next, we examined the early in vivo day 8 prednisolone 
response in 646 pediatric patients from DCOG trials ALL-10 and ALL-11, which has been 
shown to act as an important prognostic parameter in childhood ALL. Strikingly, we found 
that the frequency of IKZF1 deletions was significantly higher in patients with a poor 
prednisolone response compared to good prednisolone responders (15% versus 7%; 
P=0.015; Figure 6). In conclusion, our data demonstrate that pediatric BCP-ALL patients 
with monoallelic IKZF1 alterations display resistance to GCs.
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Figure 6 IKZF1 gene alterations impact glucocorticoid therapy response in BCP-ALL patients. 
Primary leukemia samples obtained at the time of diagnosis from pediatric BCP-ALL patients 
of the Dutch childhood oncology (DCOG) trial ALL-9 were treated with a range of different 
concentrations of prednisolone (0.02-700 µM), dexamethasone (0.0003-15 µM), L-asparaginase 
(0.003-10 IU/mL), and vincristine (0.01-60 µM). After 96 hours the samples were measured by 
MTT assay (right upper table). The median lethal concentration (LC50) and 95% confidence 
interval (CI) was determined for the patient samples without (n=152) or with an IKZF1 gene 
deletion or mutation (n=35). For statistical analyses of the MTT data the Mann-Whitney U 
test was performed. In addition, the effect of IKZF1-deletion status on the in vivo prednisolone 
response was determined in BCP-ALL patients from the DCOG trials ALL-10 and ALL-11 (right 
lower panel). The presence (IKZF1-Del) or absence of IKZF1 deletions (IKZF1-WT) was determined 
in prednisolone good responders (n=594) and prednsiolone poor responders (n=52). Prednisolone 
poor responders were defined as patients with ≥ 1000 leukemic blasts/µl blood at day 8 after the 
initial prednisolone treatment regimen. P value was calculated by Chi-square test.
Discussion
In this study, we have identified the tumor suppressor IKZF1 as an important regulator 
of the apoptotic response to synthetic glucocorticoids (GCs), which are cornerstone 
drugs in the treatment of lymphoid malignancies. Specifically, we demonstrate that 
haplodeficiency for Ikzf1 in normal B cells, silencing of IKZF1 expression in BCP-ALL cell 
lines, as well as the presence of inactivating IKZF1 alterations in BCP-ALL lead to GC 
resistance. In BCP-ALL, IKZF1 deletions and missense mutations correlate with inferior 
treatment outcome and are present in about 35% of relapsed ALL cases [10,14,33]. Our 
findings suggest that leukemic clones harboring IKZF1 alterations show enhanced survival 
in response to GC treatment, which likely contributes to an increased risk of relapse.
GC resistance constitutes a serious clinical problem in the treatment of ALL, since relapsed 
leukemic cells display intrinsic resistance against prednisolone and dexamethasone [18]. 
Investigation of GC resistance mechanisms has shown that low expression levels and 
mutations of the NR3C1 gene [34], epigenetic silencing of the pro-apoptotic gene BIM 
[35] , high CASP1 and NALP3 expression [36] and increased AKT activation [37] contribute 
to GC resistance. Other studies have identified novel regulators of GR-dependent gene 
Prednisolone
(Day 8 response)
In vivo
Ex vivo
MTT assay
at diagnosis
Glucocorticoid chemotherapy response in
IKZF1-WT vs IKZF1-Mut BCP-ALL patients
Day 8 Prednisolone
Response (N=646)
IKZF1-WT 
(N=551)
IKZF1-Mut
(N=95)
Chi-square
(P-value)
Good responders (92%) 515 (93%) 82 (85%)
0.015
Poor responders (8%)  36 (7%) 13 (15%)
Chemotherapeutic drug
(MTT assay)
IKZF1-WT 
(N=152)
LC50 (95% CI)
IKZF1-Mut
(N=35)
LC50 (95% CI)
Mann-Witney U
(P-value)
Prednisolone (µM) 0.88 (0.72-1.14) 9.1 (1.22-77.3) 0.004
Dexamethasone (µM) 0.08 (0.03-0.12) 1.7 (0.21-15.0) 0.0001
L-Asparaginase (U/mL) 0.23 (0.06-0.38) 0.25 (0.05-1.1) 0.292
Vincristine (µM) 0.83 (0.76-3.5) 1.62 (0.76-3.5) 0.290
FIGURE 6 
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transcription that may impact GC therapy responses [38-42]. However, to date only the 
transcriptional co-factor CBP (encoded by CREBBP) and TBL1XR1 were shown to be 
genetically altered and enriched in relapsed BCP-ALL [3,7,43], accounting for only a small 
fraction of the relapsed cases. Thus, in spite of the improved knowledge on the molecular 
mechanisms through which GCs act, the exact genetic pathways that contribute to GC 
therapy resistance in the majority of relapsed BCP-ALL cases remain to be elucidated.
Here, we identified IKZF1 as a novel regulator of GC-induced transcriptional responses 
and a critical determinant of the sensitivity towards GC-mediated cell death in normal 
and leukemic B cells. Ikzf1+/- B cells displayed reduced sensitivity towards GC-induced 
apoptosis, which correlated with attenuated regulation of GC-responsive target genes. 
However, it was evident that not all genes were affected in an equal manner and there 
was a clear difference between individual GR-target genes. Furthermore, all GC-repressed 
genes examined were already affected in their basal expression levels upon Ikzf1 
haplodeficiency. In addition, reduction of IKZF1 levels in human BCP-ALL cell lines NALM6 
and RS4;11 resulted in an attenuated expression of GC-responsive target genes. We 
propose that IKZF1 affects GR-dependent gene transcription, at least in part through GRE 
sites, based on the observation that IKZF1 target sites partially overlap with GR binding 
sites [44]. Whether stimulation of GR-dependent gene transcription by IKZF1 involves 
recruitment of positive transcriptional co-factors or quenching of negative regulators of 
GR-dependent gene transcription remains to be determined. Furthermore, we cannot 
exclude that IKZF1 affects chromatin accessibility of GR in normal and leukemic B cells. 
Our studies show that IKZF1 silencing in NALM6 and RS4;11 results in a GC resistance 
phenotype. Others have demonstrated that IKZF1 knockdown in the BCP-ALL cell 
lines REH and UOCB1 had no impact on the sensitivity towards prednisolone-induced 
apoptosis [45]. However, we found that REH and UOCB1 cell lines are intrinsically resistant 
towards GCs (Supplementary Figure S9) and are therefore not suitable to study IKZF1-
mediated GC resistance. Furthermore, our analyses of the BCP-ALL patient samples 
revealed that not all patient samples with IKZF1 deletions show a similar protection 
against GC-induced apoptosis. These findings suggest that either threshold levels of 
IKZF1 expression, the type of IKZF1 aberrations, or specific genetic factors may contribute 
to the resistance phenotype in leukemic cells. Indeed, gene deletions involving BTG1 
and TBL1XR1, or inactivating point mutations in CREBBP represent candidate genetic 
factors that could enhance the GC therapy resistance in IKZF1-deleted BCP-ALL [3,39], 
41. Unfortunately, our cohort of patient samples was too small to analyze the effect of 
such co-occurring alterations within the IKZF1-deleted patient group. Furthermore, other 
genetic factors may suppress the therapy resistance phenotype, as for instance ERG 
deletions weaken the prognostic value of IKZF1 lesions [46,47]. It is also important to note 
that for leukemia patients receiving chemotherapy treatment, different in vivo factors 
could affect the GC therapy resistance phenotype due to IKZF1 alterations, including the 
bone marrow microenvironment. Interestingly, consistent with the in vitro data of MTT 
assays on primary BCP-ALL patient samples, analysis of the initial prednisolone response 
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at day 8 revealed a significant enrichment for IKZF1 deletions in the poor prednisolone 
responders. This suggests a novel role for IKZF1 alterations in predicting GC therapy 
response by mediating GC-resistance. However, further studies are required to obtain a 
comprehensive understanding of the complex interplay between loss of IKZF1 function 
and the specific genetic pathways that modulate GC therapy responses.   
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qPCR Targets Forward (5’->3’) Reverse (3’->5’)
Mouse
Dusp1 TACAAGAGCATCCCTGTGGAGGAC TGAGGTAAGCAAGGCAGATGGTGG
Tsc22d3 GGCCCTAGACAACAAGATTG TCAAGCAGCTCACGAATCTG
Zfp36l2 ACTCTTGCAATTTCGACCATTACA CGTCCCTACCGCCTTCTTGTCCAG
Fkbp5 GCGAAGGAGCACAACGAGCGGGAC GTTGTTTGCCAGCGGCTCCTTCTA
Sgk1 ACTGGGATGATCTCATCAATAAGA TGTCAGGGGACCTGCCGATGGAGC
Ddit4 ACTGCGAGTCCCTGGACAGCAGCA GGCTCTCCTGCAGCAGCTGCATCA
Irs2 AGGCACTGGAGCTTTGCCCTCTGC AACATGGCGGCGATGGGGCTGGTA
Il1a GAGAGGGAGTCAACTCATTGG AGAGATGGTCAATGGCAGAAC
Il1b CACTACAGGCTCCGAGATGAACAA CTTTGAGGCCCAAGGCCACAGGTA
Il6 CTAATTCATATCTTCAACCAAGAG GCCACTCCTTCTGTGACTCCAGCT
Sdpr TGCAGTCCATAACCCATGATC ACAAACTTCTGCCTGACGAG
Nr3c1 AACTGGAATAGGTGCCAAGG CCAGGGCTTGAATATCCATT
Hprt GGGGGCTATAAGTTCTTTGCTGACC TCCAACACTTCGAGAGGTCCTTTTCAC
qPCR Targets Forward (5’->3’) Reverse (3’->5’)
Human
SGK1 ACCTTCTGTGGCACGCCGGA CTGTGTTTCGGCTATAAAAAGGC
ZFP36L2 CACACTTCTGTCCGCCTTCTA GCATGTTGTTCAGGTTGAGGT
DFNA5 AACTCCAGATCATTCCCACAC CTGCACAATCCCAAACCTTTC
FBXW7 GCTACTGGAGAATTTTGGCTG TGGACTGTGTATGAAACCTGG
PRICKLE1 ACTGGGAAGAGGAACAATTAAGC AGACAAAACAGGATGGGTGC
FKBP5 GGCCATGTGCTACCTGAAGC ACAAGCCTTTCTCATTGGCACTGTC
DDIT4 AGGAAGACACGGCTTACCTG CATCAGGTTGGCACACAAGT
TSC22D3 CCAGCGTGGTGGCCATAGAC GGATCTGCTCCTTCAGGATCTCCA
IL1B ACTGCACGCTCCGGGACTCACAGC ACTGCACGCTCCGGGACTCACAGC
HPRT GGTCCTTTTCACCAGCAAGCT TGACACTGGCAAAACAATGCA
shRNA Targets sense antisense
Human
IKZF1 GAAGAATGTGCGGAGGATTT AAATCCTCCGCACATTCTTC
Non-targeting (NT) CGTACGCGGAATACTTCGA TCGAAGTATTCCGCGTACG
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Supplementary Table 4 Summary BCP-ALL patient characteristics included in MTT assay.
Presence or absence of IKZF1 deletions and mutations (IKZF1-Mut) was based on MLPA and targeted 
sequencing. *Because of missing values, numbers do not always add up to 187 BCP-ALL cases.
Supplementary Figures
 
Figure S1 Phenotypic characterization of wild-type and Ikzf1+/- splenic B cells. Single cell 
splenocytes were stimulated with lipopolysaccharide (LPS) for 48 hours and cells were stained 
before and after LPS treatment with cell surface markers CD19 and B220 and analyzed by flow 
cytometry. Fraction CD19+B220+ cells is not significantly different between wild-type (left two 
panels) and Ikzf1+/- (right two panels) splenic B cells.
B220
CD19
- LPS - LPS+ LPS + LPS
Ikzf1    splenocytes Wild-type splenocytes +/-
Supple entary Figure S1
Number of 
samples*
IKZF1-WT
(N=152)
IKZF1-Mut 
(N=35)
P-value
Chi-square
Sex
Male 115 (61%)  92 (61%) 23 (66%) 0.57
Female 72 (39%)  60 (39%) 12 (34%)
Relapse
Relapse 56 (30%)  34 (22%) 22 (63%) <0.001
No Relapse 131(70%)  118 (78%) 13 (37%)
ETV6-RUNX1
Translocation 42 (26%)  40 (30%) 2  (6%) 0.007
No translocation 122 (74%)  93 (70%) 29 (94%)
BCR-ABL1
Translocation 8 (4%)  2 (1%) 6 (18%) <0.001
No translocation 170 (96%)  143 (99%) 27 (82%)
Hyperdiploid
N>51 chr 42 (25%) 37 (27%) 5 (18%) 0.32
N<51 chr 124 (75%)  101 (73%) 23 (82%)
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Figure S2 Survival response of CD19+ Ikzf1+/- progenitor B cells upon glucocorticoid treatment. 
Wild-type and Ikzf1+/- mice (n=6) were treated for 48 hours with increasing concentrations of 
prednisolone (left panel) or dexamethasone (right panel) and analyzed by MTS assay. All values 
were normalized to untreated B cells. Error bars represent ± standard error of the mean (SEM). P 
values (two-sided ANOVA) were calculated based on the differences of the best-fit curve and are 
shown in each panel. 
Figure S3 AnnexinV staining of Ikzf1+/- B cells treated with glucocorticoids. Wild-type (WT) and 
Ikzf1+/- splenic B cells pre-treated by lipopolysaccharide (LPS) were cultured for 48 hours with 
2µM prednisolone and analyzed by AnnexinV (PE-conjugated)/ 7-AAD staining. Plots show 
representative data from FACS analyses measuring 10.000 events, excluding cellular debris, from 
samples untreated (UT) or treated with 2µM prednisolone (PRED) for 48hours.
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Figure S4 Analysis of glucocorticoid resistance phenotype in Ikzf1+/- B cells by PARP cleavage. 
(a) Western blot analysis to detect protein levels of cleaved PARP as marker for apoptosis in wild-
type (WT) and Ikzf1+/- B cells after 16 hours treatment with 2µM prednisolone. GAPDH was used 
as loading control. (b) Quantification of cleaved versus uncleaved PARP ratio for WT and Ikzf1+/- B 
cells after 16 hours treatment with 2 µM prednisolone. Data are means, and error bars represent 
SEM of three independent experiments.
Figure S5 Identification of glucocorticoid-responsive target genes in Ikzf1+/-B cells. Microarray 
expression analyses was performed on RNA isolated from wild type (WT) and Ikzf1+/- splenic B 
cells in the absence (untreated, UT) or presence of a 16 hours prednisolone treatment. Ingenuity 
pathway analyses on differentially expressed genes between wild-type (WT) and Ikzf1+/- 
B-lymphocytes identified upstream regulatory pathways that were commonly affected in both 
control and prednisolone treated samples.
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Figure S6 Comparison gene expression signature between mouse B cells and human leukemic 
blasts displaying loss of IKZF1 function. (a) Schematic representation of the overlap between 
genes that were differentially up-regulated in the mouse B cell dataset comparing wild-type with 
Ikzf1+/- B cells (Marke et al; this manuscript), and genes that were up-regulated in the human 
dataset comparing BCP-ALL blasts of patients without or with and IKZF1 deletion (Vitanza et al; 
2014). (b)  Schematic representation of the overlap between genes that were differentially down-
regulated in the mouse B cell dataset comparing wild-type with Ikzf1+/- B cells (Marke et al; this 
manuscript), and genes that were down-regulated in the human dataset comparing BCP-ALL 
blasts of patients without or with and IKZF1 deletion (Vitanza et al; 2014).  
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Figure S7 Expression levels of glucocorticoid-responsive target genes in mouse B cells not 
affected by Ikzf1-haplodeficiency. B cells pretreated with lipopolysaccharide (LPS) were cultured 
for 16 hours with 2μM prednisolone and subsequently RNA was isolated. Transcript levels of 
glucocorticoid (GC)-induced target genes Sgk1, Ddit4 and Fkbp5 were measured by quantitative 
reverse transcription polymerase chain reaction in B cells from wild-type (WT) and Ikzf1+/-mice. All 
expression levels were normalized to Hprt expression and compared to the levels in the untreated 
(control) WT B cells. Data are means, and error bars represent SEM from four independent 
experiments performed in duplicate.
 
 
Figure S8 Silencing of IKZF1 by lenalidomide inhibits glucocorticoid-induced apoptosis in ALL-
PO cell line. (a) Effect of lenalidomide treatment on IKZF1 protein levels in ALL-PO cells. GAPDH 
was used as loading control. (b) AnnexinV/7-AAD staining on ALL-PO cells that were pretreated 
for 16 hours with or without lenalidomide (control) and subsequently incubated for 48 hours 
with either prednisolone (PRED) or dexamethasone (DEX) and compared to untreated (UT) cells. 
(c) Relative cell survival of ALL-PO cells pretreated for 16 hours with lenalidomide and incubated 
with increasing concentrations prednisolone and dexamethasone.
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Figure S9 Effect of IKZF1 knockdown on glucocorticoid-resistant and glucocorticoid-sensitive 
BCP-ALL cell lines. (a) Relative cell survival was determined in the BCP-ALL cell lines UOCB1, 
REH, RS4;11, NALM6 and ALL-PO after 48 hours treatment with increasing concentrations of 
prednisolone or dexamethasone using MTS assay. (b-c) Efficiency of IKZF1 knockdown using 
lentiviral expression of non-targeting (NT) shRNA or IKZF1-shRNA in cell lines UOCB1 and 
ALL-PO, as determined by quantitative reverse transcription PCR (b) or Western blot analysis 
using GAPDH as loading control (c). (d-e) Relative cell survival of UOCB1 (d) and ALL-PO (e) 
cell lines expressing either NT-shRNA or IKZF1-shRNA in response to increasing concentrations 
prednisolone or dexamethasone.
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Abstract
Resistance to glucocorticoid therapy remains an important clinical problem in the 
treatment of B cell precursor acute lymphoblastic leukemia (BCP-ALL). We have recently 
shown that loss of IKZF1 function promotes resistance to glucocorticoid-induced 
apoptosis, compromising the therapeutic efficacy of glucocorticoids (GCs). In T-ALL, 
inactivation of PTEN has been linked to glucocorticoid resistance, but in BCP-ALL such 
a role for PTEN has not been reported.  Here, we identify the PTEN/AKT axis as the main 
driver of GC resistance in IKZF1-deleted leukemic cells (IKZF1KO). Loss of IKZF1 resulted 
in decreased PTEN mRNA and protein expression in mouse B cells as well as in BCP-ALL 
leukemic cell lines and involves upregulation of the transcription factor HES1. Silencing 
of PTEN expression in Nalm6 pre-B ALL cells phenocopied the GC resistance phenotype 
observed in IKZF1KO cells. Targeted deletion of IKZF1, or shRNA-mediated knockdown 
of PTEN, resulted in activation of the AKT pathway, and increased AKT-dependent 
phosphorylation of the glucocorticoid receptor (GR). Moreover, pharmacological inhibition 
of AKT re-sensitized IKZF1KO cells to GCs and restored GC-target gene regulation, both in 
BCP-ALL cell line models and in patient-derived xenografts. Collectively, our data show 
that there are unexpected parallels between mechanisms driving GC therapy resistance in 
T- versus BCP-ALL and that therapeutic targeting of AKT in IKZF1-deleted ALL can restore 
response to GCs.
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Introduction
During the initial treatment of patients with B cell precursor acute lymphoblastic 
leukemia (BCP-ALL), the early response to glucocorticoids (GCs) single-agent treatment 
is a strong predictor of outcome [1]. In addition, challenging leukemic blasts ex vivo with 
GCs can be used to predict therapy response in vivo [2,3]. Therefore, resistance to GCs 
can be considered as an adverse prognostic factor in BCP-ALL [4]. Indeed, GC resistance 
remains a significant problem in the treatment of BCP-ALL, since relapsed leukemic cells 
display intrinsic resistance towards prednisolone and dexamethasone [3]. Studies on 
mechanisms of GC resistance in ALL have shown that low expression levels and mutations 
of the glucocorticoid receptor (GR) [5], epigenetic silencing of the pro-apoptotic gene 
BIM [6], high CASP1 and NALP3 expression [7] and increased AKT activation [8] contribute 
to GC resistance. Other studies have identified novel regulators of GR-dependent gene 
transcription that may impact GC therapy responses [9-13]. Our lab has recently shown that 
loss of tumor suppressor IKZF1 confers resistance to GCs in both mouse and human model 
systems as well as primary BCP-ALL patient samples [14]. IKZF1 aberrations are frequently 
observed in BCP-ALL and represent an independent poor prognostic factor in BCP-ALL 
[15-18]. However, the exact molecular pathways that contribute to GC therapy resistance 
IKZF1-deleted BCP-ALL cases have not yet been resolved. The tumor suppressor PTEN is 
the main negative regulator of the PI3K/AKT pathway and PTEN disfunction is a common 
event in approximately 10% of all pediatric T-ALLs [19]. NOTCH1 activating mutations, 
which are common events in T-ALL [19], can downregulate PTEN via the transcription factor 
HES1 [20]. Loss of PTEN function leads to hyperactivation of the AKT pathway, which has 
been linked to GC resistance in T-ALL [8]. However, much less is known about the role of 
PTEN in BCP-ALL, as PTEN mutations are not observed in BCP-ALL.
Here we show that GC therapy resistance in IKZF1-deleted ALL leads to loss of PTEN 
expression, which appears to involve upregulation of the transcription factor HES1. 
Of note, HES1 was previously identified as a target of IKZF1-mediated transcriptional 
repression in erythroid and T cells [21,22] Furthermore, we show that IKZF1-mediated GC 
resistance can be effectively reversed by inhibition of AKT both in cellline models and 
primary patient samples. 
Methods
Primary patient samples 
Bone marrow patient samples were obtained from the Dutch Childhood Oncology group 
(DCOG). In accordance with the Declaration of Helsinki, written informed consent was 
obtained from parents or legal guardians, and institutional review boards approved the 
use of excess diagnostic material for research purposes. 
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Cell culture 
HEK293-FT cells and BCP-ALL cell lines, RS4;11 and Nalm6, were cultured in DMEM 
GlutaMAX medium (Life Technologies) or RPMI 1640 GlutaMAX medium (Life 
Technologies), respectively. Culture media were supplemented with 10% heat inactivated 
fetal calf serum (HI-FCS) and 1% Penicillin/Streptomycin (P/S) (Invitrogen). Cells were 
maintained in a humidified incubator at 37 °C with 5% CO2.  
Lentiviral production and transduction 
Viral particles were produced by transient transfection of HEK293-FT cells with a 
combination of pLKO.1, ps-PAX2 and VSV-G using Lipofectamine 2000 (Invitrogen. After 
48 hours, viral supernatant was harvested, filtered, concentrated and leukemia cell lines 
were transduced in the presence of 1μg/mL polybrene via spin inoculation and 24 hours 
after transduction selected with 1μg/mL puromycin. The guide RNA (gRNA) for IKZF1 
in exon 3 was cloned into the lentiviral vector pLKO.1 containing CAS9. CRISPR/Cas9-
mediated genome editing was confirmed via Surveyor® Mutation Detection in cell pools. 
Subsequently, IKZF1-gRNA and NT-gRNA transduced cells were subcloned and screened 
for IKZF1 expression via western blotting and sequencing. For shRNA experiments, cells 
were generated as described previously [14].
Cell viability assays
To measure therapy response in the model cell lines, a number of different cell viability 
assays was used. BCP-ALL cell lines were cultured for 48 hours in the absence or 
presence of the chemotherapeutic agents. Amine staining with the LIVE/DEAD™ Fixable 
Dead Cell Stain Sampler Kit (Thermo-Fischer, L34960) was performed according to the 
manufacturers protocol (For representative analysis, see supplemental Figure 1). For 
MTS assays, cells were seeded at a density of 1.0*105 in a flat bottom 96-wells plate. 
Cell were treated with a broad variety of single agent chemotherapies in an increasing 
concentration and incubated for 72 hours. After incubation, 20 μL Cell Titer Aqueous ONE 
Solution (Promega) was added to each well and incubated for 3 hours and cell viability was 
determined via measuring the absorbance at 492 nm. Absorbance data was normalized to 
the untreated sample for each cell type.
Mouse experiments and generation of patient-derived xenografts
Generation of C57BL/6J Ikzf1+/- mice and experimental procedure to obtain B cells has 
been previously described [14,23]. For patient-derived xenograft (PDX) models, NOD.Cg-
PrkdcscidIl2rgtm1Wjl/SzJ mice (NSG-mice) were used. Mice were maintained under specific 
pathogen-free conditions at our Central Animal Laboratory facility. All animal experiments 
were approved by the Animal Experimental Committee of the Radboud university 
medical center and were performed in accordance with institutional and national 
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guidelines. For the expansion of primary leukemic cells, non-conditioned NSG mice were 
injected intrafemurally with 0.5-1x106 viable cells. After 2-4 months, most of these mice 
developed leukemia with an immunophenotype and genetic composition similar to the 
original sample at the time of injection. Leukemic cells were harvested by flushing femurs 
with RPMI medium (Gibco//Life technologies Europe BV, Bleiswijk, The Netherlands) 
containing 10% FBS (Greiner Bio-One BV, Alphen a/d Rijn, The Netherlands) and 50μM 
β-mercaptoethanol (Gibco). Leukemic blasts from spleen were isolated through a 70μM 
filter using RPMI medium containing 10% FBS and 50μM β-mercaptoethanol. Leukemic 
cells were cryopreserved as viable cell suspension in FBS supplemented with 10% DMSO. 
Quantitative RT-PCR
RNA was extracted using a RNeasy minikit (Qiagen) according to the manufacturer´s 
protocol. This was followed by Superscript cDNA synthesis (Bio-Rad, Hercules, CA), 
according to manufacturer´s instructions. mRNA expression levels in NALM6, RS4;11 and 
murine B cells were determined by quantitative PCR reactions using Power SYBR® Green 
PCR master mix (Applied Biosystems, Carlsbad, CA) in combination with mouse specific or 
human specific primers in the CFX96 TouchTM Real-Time PCR detection system (Bio-Rad, 
Hercules, CA, USA). Mouse and human mRNA expression levels were normalized to mouse 
and human HPRT respectively. HPRT mRNA expression was used as a reference to obtain 
the relative fold expression of target genes using the comparative cycle threshold 2(-ΔΔCt) 
method.  A complete list of primers can be found in Supplemental Table 1.
Western blot analysis 
Leukemic cells as well as murine splenocytes were lysed in 2xLaemmli protein sample 
buffer and treated with benzonuclease for 30 minutes, prior to boiling.  Protein lysates 
were separated by SDS-PAGE and transferred to PVDF membranes (Amersham 
Biosciences). After protein transfer, membranes were blocked according to the specific 
antibody and stained with primary antibodies (See Supplemental Table 2), washed in PBS-
0.02% Tween, followed by a horseradish peroxidase (HRP) conjugated secondary antibody. 
Proteins were visualized with ECL reagent (GE Healthcare) and expression was detected 
with Fluorchem (Cell biosciences, Santa Clara, USA). Quantification was performed with 
AlphaView software version 3.3.10 (Cell biosciences, Santa Clara, USA). For cellular 
fractioning, LPS-activated B cells isolated from wild-type and Ikzf1+/- mice were incubated 
in the presence of 1µM prednisolone for 4 hours. Subsequently, cytoplasmic and nuclear 
extracts were prepared using a nuclear extraction kit (Abcam, ab113474) according to the 
manufacturer’s protocol.
Ex Vivo Co-culture of Patient-derived Xenograft Leukemic Cells
The ex vivo co-culture model has been described previously [24]. In short, hTERT 
immortalized human mesenchymal stromal cells (MSCs) [25,26] were seeded in a 96-wells 
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format and allowed to settle for 24 hours prior to the addition of ALL xenografts. ALL cells 
were allowed to settle for 24 hours before prednisolone with or without MK2206 was 
added in increasing concentrations. After 3 days of incubation, cell death was analyzed by 
Amine staining using flow cytometry (for details see Flow Cytometry).
AKT kinase Inhibition
Cells were treated with prednisolone or dexamethasone in continuous presence of 0.5 µM 
MK2206 and analyzed by MTS and Amine assays (48h) or used for RNA isolation (16h).
Flow Cytometry
Leukemic cells were analyzed by Fluorescence Activated Cell Sorting (FACS) using an 
LSRII flow cytometer (BD Biosciences, Breda, The Netherlands). Cells were stained with 
LIVE/DEAD™ Fixable Dead Cell Stain Sampler Kit (Thermo-Fischer, L34960) according to 
manufacturer’s instructions. For co-culture experiments, MSCs were gated out via FSC/
SSC gating. A representative gating strategy can be found in supplemental Figure 2. The 
data were collected and analyzed by FlowJo V10 software (FlowJo, Ashland, Oregon).
Statistical analyses
Statistical analyses for the cell viability assays and quantitative real-time polymerase 
chain reaction (qRT-PCR) were performed using PRISM6 (GraphPad Software, La Jolla, 
CA), and for the MTT data of patient samples, the SPSS program (IBM, Amsterdam, 
Netherlands) was used. For MTS assays, two-sided ANOVA was performed to assess 
differences between the best-fit curves. For the Amine staining and qRT-PCR, student’s t 
tests were performed. For the patient data (MTT assay), the statistical significance in the 
IKZF1-deleted group versus IKZF1-WT group was calculated using the best fit under the 
curve method. All statistical tests were two-sided and P values < 0.05 were considered 
statistically significant.
Results
IKZF1 regulates PTEN expression and AKT signaling in normal and 
leukemic B cells
We and others have shown that IKZF1 alterations confer therapy resistance to leukemic 
cells via distinct mechanisms, including enhanced cell adhesion and modulation of the 
glucocorticoid response [14,27]. However, the molecular mechanisms underlying these 
effects are poorly understood. Here, we investigated whether IKZF1-mediated GC 
resistance in BCP-ALL may involve deregulation of the PTEN/AKT route.
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IKZF1-mediated regulation of the PTEN/AKT pathway was investigated in BCP-ALL cell 
line Nalm6, where IKZF1 expression was knocked out by CRISPR/CAS9-medated gene 
targeting of IKZF1 Exon 3. Subsequently, IKZF1-gRNA (IKZF1KO) and non-targeting gRNA 
(IKZF1 NT Control) transduced cells were subcloned and screened for IKZF1 expression 
by western blotting. Indeed, IKZF1KO cells showed a significant reduction in IKZF1 protein 
levels, which was accompanied by diminished expression of PTEN both at the mRNA 
and protein level (Figure 1A-B). Consistent with a loss in PTEN expression, we observed 
activation of AKT and increased levels of GR-Ser134 phosphorylation as compared NT-
control cells (Figure 1B). In T-ALL, activation of AKT leads to hyperphosphorylation of 
the GR on serine 134, which leads to suppression of GR function and GC resistance [8]. 
Increased phosphorylation of the GR, as observed in the IKZF1KO cells was associated with 
a diminished response to glucocorticoids (Figure 1C). The same effects, i.e. loss of PTEN 
expression, increased phosphorylation of AKT and GC resistance, were seen in response 
to short hairpin RNA (shRNA)-mediated IKZF1 gene knockdown in Nalm6 and RS4;11 
cells, which we generated previously [14] (Supplemental Figure 3A-B).
To demonstrate that the effects on PTEN expression were a direct consequence of IKZF1 
loss, and independent of leukemic context, we generated LPS-activated B cells from Ikzf1+/- 
mice. We have shown earlier that these cells are about 100-fold more resistant to synthetic 
GCs, relative to B cells derived from Ikzf1 wild-type mice [14]. Indeed, similar to Nalm6 
cells, Pten mRNA and protein expression levels were strongly reduced in Ikzf1+/- B cells 
compared to wild-type (wt) control B cells (Figure 2 A-B).  Consistent with the notion that 
PTEN is a negative regulator of the AKT pathway, Ikzf1-haploinsufficiency led to increased 
levels of AKT phosphorylation on Ser473 (Figure 2B). Western blot analysis revealed that, 
similar to T-ALL cases, AKT-mediated phosphorylation of GR was strongly increased in 
Ikzf1+/- B cells (Figure 2B). In T-ALL, phosphorylation of GR on Ser134 appears to interfere 
with its nuclear translocation [8, 28]. Similarly, we observed that nuclear translocation after 
GC treatment was significantly impaired in Ikzf1+/- cells relative to wild-type cells (Figure 
2C). We conclude from these experiments that loss of IKZF1 is associated with diminished 
PTEN expression, leading to activation of AKT and subsequent hyperphosphorylation of 
the GR on Serine 134 both in healthy and leukemic B cells. 
CHAPTER 4
94
 
Figure 1 IKZF1 silencing reduces PTEN expression and activates AKT pathway in NALM6 cells. 
IKZF1 expression was silenced in Nalm6 cells by CRISPR/CAS9-mediated genome editing and 
two independent subclones of IKZF1KO cells (IKZF1KO 1 and IKZF1KO l 2) were compared to non-
targeting-gRNA (NT Control). (A) mRNA transcript levels of PTEN were measured in Nalm6 
IKZF1KO cells in comparison to non-targeting controls by quantitative reverse transcription PCR 
(qRT-PCR) and normalized to Hprt expression. (B) IKZF1, PTEN, AKT, pAKT(Ser473), pGR(Ser134) 
and GR protein expression levels of Nalm6 IKZF1KO cell lysates were analyzed by western blot. 
Non-targeting controls were used as control and actin was used as a loading control (B) NALM6 NT 
controls or IKZF1KO cells were treated for 48 hours with increasing concentrations of prednisolone 
or dexamethasone and analyzed using an MTT based viability assay. All values were normalized 
to untreated Nalm6 cells. Error bars represent ± standard error of the mean (SEM). (C) Data 
represent means, and error bars represent SEM. P values (two-sided t test) are indicated. *P<0.05, 
**P<0.01, and ***P<0.001.  
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Figure 2 Ikzf1-haploinsufficiency downregulates PTEN expression and activates AKT signaling 
in B cells. (A) mRNA transcript levels of PTEN were measured in LPS-activated B cells from wild-
type and Ikzf1+/− mice by quantitative reverse transcription PCR (qRT-PCR) and normalized to Hprt 
expression. (B) PTEN, AKT, p-AKT, p-GR and GR protein expression levels of LPS-activated B cells 
obtained from 4 mice (2 wild-type versus 2 Ikzf1+/- mice) were analyzed by western blot analysis. 
Actin was used a loading control (C) Cellular localization analysis of GR via nuclear and cytoplasmic 
cell fractionation in LPS-activated B cells from wild-type versus Ikzf1+/- mice. Tubulin was used 
as loading control for the cytoplasmic fraction, whereas Histone H3 functions as nuclear loading 
control. (D) Quantification of the relative nuclear GR fraction in wild-type versus Ikzf1+/− murine 
splenocytes after 4-hour induction with 2µM prednisolone.  Data represent means, and error bars 
represent SEM. P values (two-sided t test) are indicated. *P<0.05, **P<0.01, and ***P<0.001.  
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Inhibition of AKT signaling restores GC-sensitivity in IKZF1KO cells
Hyperphosphorylation of AKT leads to GC resistance in T-ALL [8]. To test whether AKT 
functions as a mediator of GC resistance in IKZF1-deleted BCP-ALL cell lines as well, 
the pharmacological AKT inhibitor MK2206 was used. Western blot analysis showed 
that incubation with 0.5µM MK2206 reduced phospho-AKT (Ser473) and phospho-GR 
(Ser134) levels in Nalm6 IKZF1KO cells to about 5-10%, and effectively interfered with AKT 
activation in IKZF1KO cells. (Figure 3B). Moreover, MK2206 treatment of IKZF1KO cells 
restored GC sensitivity to levels observed in IKZF1WT cells.  (Figure 3C-3D). The effects of 
MK2206 on reversing GC therapy resistance were further confirmed in Nalm6 and RS4;11 
transduced with IKZF1-shRNA (Supplemental Figure 3C).
To further explore the effects of AKT inhibition on GC-dependent target gene regulation, 
quantitative reverse transcription PCR (qRT-PCR) was performed for GR target genes 
DUSP1, TSC22D3 and ZFP36L2, which we have shown previously to be attenuated by loss 
of IKZF1 [14]. Incubation of control cells with MK2206 enhanced activation of all three GC-
target genes in Nalm6. Moreover, we observed that the attenuated response of GC target 
genes in Nalm6 IKZF1KO cells was restored by AKT inhibition (Figure 3F). Importantly, 
NR3C1 mRNA levels were not affected by loss of IKZF1, showing that the effects of IKZF1 
on GR mediated gene expression involve regulation of GR activity rather than regulation 
of its expression.
 
Figure 3 Inhibition of AKT restores GC-resistance in IKZF1 KO cells (A) p-AKT protein levels after 
incubation with increasing concentrations of M2206 for 24 hours analyzed by western blot. Actin 
was used as a loading control. (B) AKT, p-AKT, p-GR and GR protein expression levels of Nalm6 
IKZF1KO cell lysates after incubation with or without 0.5µM MK2206 for 24 hours were analyzed 
by western blot. As controls, parental NALM6 and non-targeting Nalm6 were used as control. 
Actin was used as loading control. (C)  Nalm6 parental, non-targeting controls or IKZF1KO cells 
were treated for 48 hours with increasing concentrations of prednisolone with or without 0.5µM 
MK2206 and analyzed using an MTT based viability assay. All values were normalized to untreated 
Nalm6 cells. Error bars represent ± standard error of the mean (SEM).  (D) Quantification of Amine 
stainings measured in Nalm6 IKZF1KO cells in comparison to non-targeting controls treated with 
2µM Prednisolone with or without 0.5uM MK2206. All experiments were repeated three times. 
(E) mRNA transcript levels of GC-target genes were measured in Nalm6 IKZF1KO cells in 
comparison to non-targeting controls after 24-hour incubation with 2µM Prednisolone with or 
without 0.5µM MK2206 by quantitative reverse transcription PCR (qRT-PCR) and normalized to 
Hprt expression. Data represent means, and error bars represent SEM. P values (two-sided t test) 
are indicated. *P<0.05, **P<0.01, and ***P<0.001.
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Silencing of PTEN induces GC resistance in BCP-ALL   
To confirm the pivotal role of PTEN in mediating GC resistance in BCP-ALL, we performed 
shRNA-mediated knockdown of PTEN in BCP-ALL cell line Nalm6. Lentiviral transduction 
with two independent PTEN-shRNAs resulted in a significant decreased PTEN expression, 
both at RNA (Figure 4A) and protein (Figure 4B) level. Western blot analysis revealed 
that knockdown of PTEN led to a significant increase in phospho-AKT (Ser473) levels and 
subsequent phosphorylation of GR on the AKT-specific substrate site Ser134, as compared 
to the control lysates (Figure 4B). In addition, both PTEN-shRNAs conferred resistance 
to prednisolone in comparison to non-targeting controls as measured by amine staining 
(Figure 4C) and by by MTS assays (Figure 4D).  In addition, treatment of PTEN-knockdown 
cells with MK2206 restored the sensitivity to GCs, indicating that the observed GC 
resistance is due to PTEN-mediated AKT regulation (Figure 4D). These results indicate that 
loss of PTEN can contribute to GC resistance in BCP-ALL.
But how does IKZF1 affect PTEN expression in BCP-ALL? To tackle this question, we 
compared protein expression of the transcriptional factor HES1 (hairy enhancer of split 
1) in Nalm6 IKZF1KO cells relative to control cells. HES1 is a known regulator of PTEN 
expression [20]  and was shown to be critically involved in the regulation of  GR-dependent 
gene expression [29]. Moreover, IKZF1 is known to directly repress HES1 expression 
[30]. Indeed, we observed that loss of IKZF1 leads to a strong increase of HES1 protein 
expression both in Nalm6 IKZF1KO cells as well as Nalm6 and RS4;11 IKZF1 knockdown cells 
(Figure 5). In T-ALL, HES1 is controlled via activating mutations in NOTCH1 [20] and IKZF1 
has been shown to repress NOTCH signaling in T cells [31] and to shape the repertoire of 
NOTCH target genes such as HES1 in T cells [32]. Thus, similar to the regulation of HES1 
via NOTCH1 in T cells, we speculate that loss of IKZF1 leads to overexpression of HES1 in 
BCP-ALL.  
Figure 4 Silencing of PTEN induces GC resistance in BCP-ALL cell line NALM6 (A) mRNA 
transcript levels of PTEN were measured in Nalm6 transduced with 2 independent PTEN shRNAs 
in comparison to non-targeting shRNA by quantitative reverse transcription PCR (qRT-PCR) and 
normalized to Hprt expression. (B) PTEN, AKT, p-AKT (Ser473), p-GR (Ser134) and GR protein 
expression levels of protein lysates from Nalm6 transduced with 2 independent PTEN shRNAs in 
comparison to non-targeting shRNA were analyzed by western blot. Tubulin was used as a loading 
control (C) Quantification of amine stainings measured in Nalm6 transduced with 2 independent 
PTEN shRNAs in comparison to non-targeting controls treated with 2µM Prednisolone for 
48 hours. (D) Nalm6 transduced with 2 different PTEN shRNAs were treated for 48 hours with 
increasing concentrations of prednisolone in comparison to non-targeting shRNA with or without 
0.5µM MK2206 and analyzed using an MTS based viability assay. All values were normalized to 
untreated Nalm6 cells. Error bars represent ± standard error of the mean (SEM). All experiments 
were repeated three times.
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Figure 5 Loss of IKZF1 leads to increase in HES1 expression. HES1 protein expression of lysates 
from Nalm6 IKZF1KO cells as well as Nalm6 and RS4,11 transduced with IKZF1-shRNA were 
analyzed by western blot. Respective non-targeting controls were used as control and actin was 
used as a loading control.
 
Figure 6 Patient-derived xenograft samples of primary BCP-ALL are resensitized towards GCs 
after Mk2206 treatment. hTERT immortalized MSCs were seeded in a 96 wells format and allowed 
to settle for 24 hours prior to the addition of BCP-ALL patient –derived xenografts (PDX). Cells 
were allowed to settle for 24 hours before prednisone was added in increasing concentrations 
with or without increasing concentrations of MK2206. (A) Prednisone sensitivity of 10 primary 
patient samples (5 wild-type vs. 5 IKZF1-deleted patient samples) after incubation with increasing 
concentrations of MK2206 and Prednisiolone after 3 days was analyzed by amine staining using 
flow cytometry. (B) Expression levels of PTEN, pGR(Ser134) and GR  were analyzed in total protein 
lysates of three IKZF1–WT  and three IKZF1-deleted PDX samples. Tubulin was used as a loading 
control. 
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AKT inhibition resensitized patient-derived xenografts to GC therapy 
We next assessed the effect of AKT inhibition on GC resistance in primary BCP-ALL 
samples. For this, patient-derived xenografts (PDX) either with or without IKZF1 deletion 
were co-cultured on MSCs and analyzed for GC response in the absence or presence of 
increasing concentrations MK2206. We performed a pilot screen with ten PDX samples 
in total (Five IKZF1 WT samples versus five IKZF1-deleted samples). Out of ten samples, 
we found an effect of MK2206 treatment on GC sensitivity in four PDX samples. In detail, 
one out of five wild-type samples (WT#5) and one out of five IKZF1-deleted PDX samples 
(IKZF1-del #3) displayed a response to MK2206 treatment. Next to this, IKZF1-deleted 
samples #1 and #2 showed increased sensitivity to GCs but only under physiological very 
high concentrations of GCs (Figure 6A). 
To test whether PTEN expression is affected in the PDX-samples, we performed Western 
blotting analysis comparing three available IKZF1-WT vs. three IKZF1-deleted PDX 
samples. We established that PTEN protein expression was reduced by 95% in IKZF1-
deleted compared to IKZF1-WT PDX samples (Figure 6B). Because we detected high 
pGR Ser134 levels in GC resistant cells in our previous experiments, we also opted to 
correlate pGR Ser134 expression levels with PTEN protein expression and sensitivity to 
AKT inhibitors in this selection of PDX models. Indeed, loss of PTEN protein expression 
correlated with increased pGR (Ser134) levels (Figure 6B) in IKZF1-deleted PDX samples 
(2. fold to 4. fold increase in protein expression). Interestingly, the sample with the highest 
expression of pGR Ser134 (4. fold increase) was also effectively resensitized to GCs by AKT 
inhibition (IKZF1-del #3).
These data indicate that PDX samples with IKZF1 deletions showed a decrease in PTEN 
protein expression and hyperactivation of pGR134, but the reversal of GC resistance by 
an AKT inhibitor was only observed in part of the IKZF1-deleted PDX samples.  Whether 
pGR134 expression levels could be an indicator for the success of AKT inhibition to break 
GC resistance in BCP-ALL needs to be studied in more detail in a larger patient cohort. 
Discussion
IKZF1 aberrations can be found in approximately 15% of BCP-ALL [33,34] and have been 
identified as poor prognostic marker in BCP-ALL [15-18]. Moreover, loss of IKZF1 affects 
therapy response in BCP-ALL. For instance, in BCR-ABL1 positive ALL loss of IKZF1 
appears to promote integrin-dependent survival signaling through activation of focal 
adhesion kinase [27]. Indeed, FAK inhibition potentiated the responsiveness to ABL 
inhibitor dasatinib in a xenograft model [35]. Following our initial finding that IKZF1 
confers resistance to GCs [14], several studies have observed resistance to GCs in IKZF1-
deleted ALL [36,37]. However, the molecular mechanism underlying this GC resistance 
has remained largely unknown. In this study, we identified inactivation of PTEN by the 
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transcriptional repressor HES1, a member of the basic helix-loop-helix transcription 
factor family and known target of IKZF1 [30] as a possible mechanism responsible for GC 
resistance in IKZF1-deleted BCP-ALL. Consistent with a loss of PTEN activity, we observed 
that deletion of IKZF1 leads to activation of AKT and phosphorylation of the GR at Ser134, 
resulting in repression of GR mediated gene expression. Importantly, we observed that 
inhibition of AKT re-sensitized both IKZF1-deleted leukemia cell lines and, to a limited 
extend, also primary BCP-ALL cells to GC-induced apoptosis, by reducing GRSer134 
phosphorylation to baseline levels. 
Previous studies have demonstrated that phosphorylation of the GR on Serine 134 impairs 
translocation of the GR to the nucleus, thereby inhibiting the GR response [8].We were 
able to observe the same effect in murine B cells isolated from Ikzf1+/- mice compared 
to wild-type mice. However, diminished nuclear transport of the GR is probably not the 
only explanation for decreased GR activity. Other studies indicate that phosphorylation 
of Ser134 of the GR acts as general stress signal in BCP-ALL. This direct effect on the GR 
activity makes it arguable whether only shuttling of the GR, or also other stress routes may 
contribute to GC resistance [28]. It has been suggested that loss of IKZF1 has a direct effect 
on GR expression levels [38], however neither previously [14] or in the current study did we 
observe changes in GR mRNA or protein expression of the GR as a result of IKZF1 deletion. 
Genetic aberrations leading to loss of PTEN function are common to many solid tumors 
[39], and can be detected in about 10% of T-ALL cases, but not in BCP-ALL. In T-ALL and 
solid tumors, inactivation of PTEN has been reported to lead to hyperactivation of the 
AKT pathway, leading to increased survival of PTEN-deleted cells [40]. Because of these 
observations, PTEN is generally considered a tumor suppressor. In contrast, PTEN has 
been suggested to have oncogenic effects in BCP-ALL [41]. However, shRNA-mediated 
knockdown of PTEN performed in our study did not negatively affect viability of BCP-ALL 
cell line NALM6 and protected cells from GC-induced apoptosis. This ambiguous role of 
PTEN in BCP-ALL should encourage further studies into the role of PTEN and the AKT 
route in BCP-ALL. Consistent with our findings, another study found that loss of PTEN has 
a potential protective role against GCs in BCP-ALL cells [42].
Our observations related to HES1 upregulation in response to loss of IKZF1 are in line 
with previous findings in T-ALL, where aberrated NOTCH1 signaling leads to upregulation 
of HES1 and suppression of PTEN [20,30]. We propose a similar model for BCP-ALL, in 
which HES1 is upregulated as a consequence of loss of IKZF1, a known repressor of HES1. 
It needs to be determined whether IKZF1 directly affects HES1 expression and whether 
we can link HES1-mediated regulation of GR to GC resistance in IKZF1-deleted BCP-ALL. 
Future chromatin immunoprecipitation experiments will help to shed light on question 
whether IKZF1 directly regulates PTEN, or through HES1, or whether other unknown 
factors are involved.  For example, we cannot exclude that expression of NOTCH is 
deregulated in BCP-ALL due to loss of IKZF1, as loss of IKZF1 has been reported to lead to 
lineage infidelity in BCP-ALL [43]. 
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Because of our limited collection of PDX samples and primary patient material available 
for cell viability assays and western blotting, this precludes any firm conclusions on the 
importance of this resistance mechanism in the patient.  It is important to note that in 
this study as well as in previously reports from our group [14] not all patient samples with 
IKZF1 deletions showed a similar poor response to GC-induced apoptosis. These findings 
suggest that threshold levels of IKZF1 expression itself, the type of IKZF1 gene lesions 
as well as specific cell-intrinsic and genetic factors may contribute to the resistance 
phenotype in leukemic cells. 
However, as GC sensitivity could be restored by AKT inhibition in all IKZF1-deleted BCP-
ALL cell lines and in at least part of the PDX samples, this approach could potentially 
represent a new therapeutic option to break GC resistance in IKZF1-deleted BCP-ALL. In 
IKZF1-deleted patients showing resistance to GC therapy, phosphorylation status of the 
GR may be used as a biomarker to identify patients in which AKT inhibition could improve 
GC therapy response. However, for a better understanding of the relationship between 
genetic aberrations targeting IKZF1, phosphorylation of the GR, and the correlation with 
GC sensitivity, a larger cohort of PDX and primary patients will have to be studied. It 
would be valuable to perform phospho- flowcytometric analysis of pGR(Ser134) in a larger 
cohort of IKZF1-deleted leukemia to confirm the value of pGR(Ser134) as biomarker for 
combination of MK2206 and GCs.  In the last years, 2nd and 3rd generation AKT inhibitors 
are entering clinical trials, which would be interesting to test in our PDX model systems to 
assess whether these novel inhibitors would be beneficial for the patient [44]. 
Taken together, our data indicate that IKZF1-mediated regulation of HES1 and PTEN 
represents a novel GC resistance route in BCP-ALL, while inhibition of AKT signaling may 
be effectively used to overcome GC resistance in part of the IKZF1-deleted ALLs. 
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Supplemental Information Chapter 4
Supplementary Table 1 Primer sequences for quantitative reverse transcription PCR, IKZF1 guide 
RNAS and shRNA-vectors
Supplementary Table 2 Antibodies used in this studie
qPCR Targets Forward (5’ -> 3’) Reverse (3’ -> 5’)
 PTEN AAGGGACGAACTGGTGTAATG GCCTCTGACTGGGAATAGTTAC
 IKZF1 ATGGATGCTGACGAGGGTCAAGAC CTCTTGGAGCTTTGCTGTCCTCCC
 ZFP36L2 CACACTTCTGTCCGCCTTCTA GCATGTTGTTCAGGTTGAGGT
Human TSC22D3 CCAGCGTGGTGGCCATAGAC GGATCTGCTCCTTCAGGATCTCCA
 NR3C1 CTGGGGACTCTGAACTTCCCTG CTGTTGTTGCTGTTGAGGAGCTGG
 HPRT GGTCCTTTTCACCAGCAAGCT TGACACTGGCAAAACAATGCA
qPCR Targets Forward (5’ -> 3’) Reverse (3’ -> 5’)
Mouse Pten  ACACCGCCAAATTTAACTGC GATTGTCATCTTCACTTAGCCATTG
 Hprt GGGGGCTATAAGTTCTTTGCTGACC TCCAACACTTCGAGAGGTCCTTTTCAC
shRNA Targets Forward (5’ -> 3’) Reverse (3’ -> 5’)
Human IKZF1 GAAGAATGTGCGGAGGATTT AAATCCTCCGCACATTCTTC
 PTEN #1 AGGCGCTATGTGTATTATTAT ATAATAATACACATAGCGCCT
 PTEN #2 CCACAGCTAGAACTTATCAAA TTTGATAAGTTCTAGCTGTGG
 Control CGTACGCGGAATACTTCGA TCGAAGTATTCCGCGTACG
CRISPR gRNA Targets Forward (5’ -> 3’) Reverse (3’ -> 5’)
Human Control CACCGGTAGCGAACGTGTCCGGCGT AAACACGCCGGACACGTTCGCTACC
 IKZF1 CACCGCTCCAAGAGTGACAGAGTCGT AAACACGACTCTGTCACTCTTGGAGC
Primary Antibody Dilution Buffer Reference Provider Secondary antibody
AKT 1:1000 BSA 9272 Cell Signaling Anti-Rabbit HRP 
p-AKT 1:1000 BSA 9271 Cell Signaling Anti-Rabbit HRP 
GR 1:1000 BSA 12041S Cell Signaling Anti-Rabbit HRP 
p-GR (Ser134) 1:1000 BSA ABS1008 Merck Millipore Anti-Rabbit HRP 
PTEN 1:1000 ELK 9188 Cell Signaling Anti-Rabbit HRP 
IKZF1 1:1000 ELK AF4984 R&D systems Anti-Goat HRP 
Histone H3 1:2000 ELK 2650S Cell Signaling Anti-Rabbit HRP 
HES1 1:1000 BSA 11988S Cell Signaling Anti-Rabbit HRP 
Actin 1:10000 ELK A5441 Sigma Anti-Mouse HRP 
Tubulin 1:10000 ELK T6557 Sigma Anti-Mouse HRP 
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Supplemental Figure 1 Representative gating strategy of primary xenografted patient samples 
on an MSC co-culture. After gating out debris from the viable cell population and the exclusion of 
doublets, population was further analyzed by amine staining.
Supplemental Figure 2 Representative analysis of Nalm6 IKZF1KO cells after amine staining. 
Nalm6 non-targeting controls or IKZF1KO cells treated with 2µM Prednisolone with or without 
0.5µM MK2206 were analyzed by flow cytometry after amine staining
Nalm6 Parental
Nalm6 NT Control 
Nalm6 IKZF1KO 1
Nalm6 IKZF1KO 2
UT PRED MK2206
PRED +
MK2206
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Supplemental Figure 3 shRNA mediated-IKZF1 knockdown cell lines show diminished PTEN 
mRNA expression and their GC sensitivity can be restored by AKT inhibtion. (A) mRNA 
transcript levels of PTEN were measured in Nalm6 transduced with IKZF1-shRNA and RS4,11 
transduced with IKZF1-shRNA in comparison to non-targeting controls by quantitative reverse 
transcription PCR (qRT-PCR) and normalized to Hprt expression. (B) PTEN, AKT and p-AKT (Ser473) 
protein expression levels of protein lysates from Nalm6 and RS4;11 transduced IKZF1-shRNA in 
comparison to non-targeting shRNA were analysed by western blot. Actin was used as a loading 
control (C) Quantification of Amine stainings measured in Nalm6 transduced with IKZF1-shRNA 
(left panel) and RS4;11 transduced with IKZF1-shRNA (right panel) in comparison to non-targeting 
controls treated with 2µM Prednisolone with or without 0.5uM MK2206. All experiments were 
repeated three times.
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Abstract 
Deletions and mutations affecting lymphoid transcription factor IKZF1 (IKAROS) are 
associated with an increased relapse risk and poor outcome in B cell precursor acute 
lymphoblastic leukemia. However, additional genetic events may either enhance or 
negate the effects of IKZF1 deletions on prognosis. In a large discovery cohort of 533 
childhood B cell precursor acute lymphoblastic leukemia patients, we observed that 
single copy losses of BTG1 were significantly enriched in IKZF1-deleted B cell precursor 
acute lymphoblastic leukemia (P=0.007). While BTG1 deletions alone had no impact on 
prognosis, the combined presence of BTG1 and IKZF1 deletions was associated with a 
significantly lower 5-year event-free survival (P=0.0003) and higher 5-year cumulative 
incidence of relapse (P=0.005) when compared with IKZF1-deleted cases without BTG1 
aberrations. In contrast, other copy number losses commonly observed in B cell precursor 
acute lymphoblastic leukemia, such as CDKN2A/B, PAX5, EBF1 or RB1, did not affect 
outcome of IKZF1-deleted acute lymphoblastic leukemia patients. To establish whether 
the combined loss of IKZF1 and BTG1 function cooperate in leukemogenesis, Btg1-
deficient mice were crossed onto an Ikzf1 heterozygous background. We observed that 
loss of Btg1 increased the tumor incidence of Ikzf1+/- mice in a dose-dependent manner. 
Moreover, murine B cells deficient for Btg1 and Ikzf1+/-- displayed increased resistance 
against glucocorticoids, but not to other chemotherapeutic drugs. Together, our results 
identify BTG1 as a tumor suppressor in leukemia that, when deleted, strongly enhances 
relapse risk in IKZF1-deleted B cell precursor acute lymphoblastic leukemia and augments 
the glucocorticoid resistance phenotype mediated by loss of IKZF1 function.
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Introduction 
Acute lymphoblastic leukemia (ALL) is the most common form of cancer in children 
and is characterized by recurrent genetic aberrations and chromosomal abnormalities, 
which represent distinct genetic subtypes that are used for risk stratification. [1] In the 
past, we and others have demonstrated that genomic alterations affecting the lymphoid 
transcription factor gene IKZF1 represent a strong prognostic factor associated with 
relapse in childhood B cell precursor ALL (BCP-ALL). [2-5] Recently, we established that loss 
of IKZF1 affects glucocorticoid (GC)-mediated gene regulation and confers GC resistance 
in BCP-ALL. [6] Deletion of IKZF1 is a hallmark of BCR-ABL1-positive BCP-ALL, [7] and 
within this high-risk cytogenetic subtype, IKZF1 loss is associated with an even worse 
outcome. [8] IKZF1 gene lesions are also frequently present in high-risk leukemias with 
a Philadelphia- or BCR-ABL1-like expression signature, [2,5,9] which often carry activated 
tyrosine kinases (i.e. ABL1, PDGFRB, JAK2, FLT3) or mutations targeting the RAS pathway. 
[10-12] Mouse studies have confirmed that two of these genomic alterations, namely BCR-
ABL1 and mutant RAS, cooperate with loss of IKZF1 during leukemic transformation. 
[13,14] On the other hand, ERG gene deletions constitute a specific subtype of BCP-ALL 
with favorable outcome, despite the frequent co-occurrence of IKZF1 deletions. [15,16] 
Thus, specific genetic interactions may modulate the tumor suppressive functions of 
IKZF1 during leukemia development at initial diagnosis and at relapse after chemotherapy 
treatment. 
Besides IKZF1, many other recurrent genetic aberrations have been observed in BCP-ALL, 
which include deletions affecting BTG1, CDKN2A/B, EBF1, ETV6, PAX5, RAG1, RB1 and 
TCF3. [17-19] For some of these co-occurring genetic lesions, synergistic effects have been 
reported on leukemia development. For example, loss of Rag1 was shown to accelerate 
the onset of B cell lymphoblastic leukemia in Cdkn2a/p19Arf-deficient mice, [20] while 
increasing the incidence of T cell lymphomas in Tcf3-/- mice. [21] Furthermore, combined 
heterozygosity for Ebf1 and Pax5 results in a strong increase in the frequency of pro-B cell 
leukemia in mice. [22]
Here we describe the impact of deletions affecting the transcriptional coregulator B cell 
translocation gene 1 (BTG1), in co-occurrence with IKZF1 loss on both leukemogenesis 
as well as outcome. We demonstrate that BTG1 deletions are enriched in IKZF1-deleted 
pediatric BCP-ALL cases, and correlate with increased relapse risk in this patient group. 
Using mouse knockout models, we further demonstrate that loss of Btg1 cooperates 
with Ikzf1+/- in the onset of ALL. Finally, our data indicate that both BTG1 and IKZF1 are 
important determinants of the GC therapy response and that combined loss of these 
tumor suppressors enhances GC resistance. 
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Methods 
Clinical samples
The discovery cohort comprised of 533 pediatric patients with newly diagnosed BCP-
ALL from three consecutive Dutch Childhood Oncology Group trials (DCOG ALL-8, ALL-
9 and ALL-10) and two German Cooperative ALL trials (COALL 06-97 and 07-03). The 
validation cohort consisted of 515 pediatric patients enrolled in the Australian and New 
Zealand Children’s Oncology Group (ANZCHOG) ALL8 protocol. In accordance with the 
Declaration of Helsinki, written informed consent was obtained from parents or legal 
guardians, and institutional review boards approved the use of excess diagnostic material 
for research purposes. Details on the patient cohorts, treatment regimens and outcomes, 
were described previously. [5,23,24] 
Statistics patient data 
Cumulative incidence of relapse (CIR) was estimated using a competing risks model, 
equality of CIRs was tested with Gray’s test. Relapse and non-response to induction 
chemotherapy were considered as events, with death and secondary malignancy as 
competing events. Event-free survival (EFS) was calculated with non-response, relapse, 
secondary malignancy and death considered as events. EFS probabilities were estimated 
using the actuarial Kaplan-Meier method and survival data between groups were compared 
using univariate and multivariate Cox regression. The proportions of patients with IKZF1 
and other B cell development gene deletions as well as other categorical variables were 
compared using the Fisher’s exact test. All P-values are two-sided, and a significance level 
of 0.05 or less was considered to be significant. Analyses were performed in R 3.0.1 (2013-
05-16), using the packages cmprsk version 2.2-7, mstate version 0.2.7, and survival version 
2.37-4. [25-27]
Mice
Btg1 and Ikzf1 (IkNeo) knockout lines have been described previously, [28,29] and were 
intercrossed on a C57Bl/6J background. Mice were maintained under specific pathogen-
free conditions at our Central Animal Laboratory facility. Genotyping of the offspring was 
performed by PCR (primer sequences are listed in Online Supplementary Table S1). Animal 
experiments were approved by the Animal Experimental Committee of the Radboud 
university medical center and were performed in accordance with institutional and 
national guidelines. 
Functional characterization murine lymphocytes
Detailed information on functional characterization of normal and leukemic lymphocytes 
by flow cytometry, immunohistochemistry, IG/TR PCR and cell viability assays can be 
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found in the Online Supplementary Methods section. For analyzing the glucocorticoid 
response in B-lymphocytes, mononuclear splenocytes were isolated from wild-type and 
the different knockout mice and stimulated in vitro with 5 µg/mL lipopolysaccharide (LPS) 
for 48 hours. The obtained activated B-lymphocytes (≥ 80% B220+) were isolated by ficoll 
gradient and cultured for another 48 hours in the absence or presence of the synthetic 
glucocorticoids prednisolone or dexamethasone. Thereafter, relative cell viability was 
assessed by MTS assay and AnnexinV/7-AAD staining.  
Results 
BTG1 deletions are enriched in IKZF1-deleted pediatric BCP-ALL
Gene deletion of the tumor suppressor IKZF1, creating either dominant-negative IKZF1 
isoforms or haploinsufficiency, is an important predictor of poor outcome in BCP-ALL, [2-5] 
but to what extent other additional common single gene deletions, such as CDKN2A/B, 
PAX5, BTG1, ETV6, EBF1 or RB1 impact the prognostic value of IKZF1 has not been clearly 
established. To address this question, we studied a previously described childhood 
BCP-ALL cohort of 533 cases enrolled in consecutive DCOG and COALL trials. [5] The 
representation of the different BCP-ALL subtypes was similar between the DCOG and 
COALL cohorts, and comparable to that described in literature (Online Supplemental Table 
S2). We identified 105 BCP-ALL patient samples containing an IKZF1 deletion. Within the 
IKZF1-deleted group, we observed a significant enrichment for BTG1 deletions (P=0.007), 
where 17 of the 105 IKZF1-deleted cases (16%) harbored BTG1 deletions as compared to 31 
Table 1 Co-occurrence of IKZF1 deletion with other common gene deletions in BCP-ALL
IKZF1 no deletion IKZF1 deletion Fisher Test
n % n % P-value Odds ratio
BTG1 no deletion 397 0.93 88 0.84 0.0071 2.5
BTG1 deletion 31 0.07 17 0.16
PAX5 no deletion 330 0.77 55 0.52 1.40E-06 3.1
7 deletion 98 0.23 50 0.48
CDKN2A/B no deletion 298 0.70 53 0.50 3.40E-04 2.2
CDKN2A/B deletion 130 0.30 52 0.50
EBF1 no deletion 405 0.95 96 0.91 0.25 1.6
EBF1 deletion 23 0.05 9 0.09
RB1 no deletion 400 0.93 91 0.87 0.026 2.2
RB1 deletion 28 0.07 14 0.13
ETV6 no deletion 296 0.69 80 0.76 0.19 0.7
ETV6 deletion 132 0.31 25 0.24
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of the 397 IKZF1-wild type cases (7%) (Table 1). These focal BTG1 deletions mainly covered 
the second exon of BTG1 and downstream adjacent sequences as described previously. [30] 
Similarly, deletions affecting PAX5 (P<0.0001), CDKN2A/B (P=0.0003) and RB1 (P=0.026) 
were present at higher frequencies in IKZF1-deleted cases, while this was not observed 
for EBF1 or ETV6 deletions (Table 1). To the converse, in the BTG1-deleted group we 
observed significant enrichment for IKZF1 (P=0.007), EBF1 (P=0.0011), RB1 (P=0.042), and 
ETV6 (P=0.0046) deletions (Online Supplemental Table S3), which is in agreement with our 
previous findings. [30] Previously, it has been shown that both IKZF1 and BTG1 deletions 
are strongly enriched in the cytogenetic BCR-ABL1 subtype. [7,31] Consistent with this 
notion, we observed that of 24 BCR-ABL1-positive cases 7 (29%) harbored deletions in 
both IKZF1 and BTG1 (Table 2), which represents 47% of IKZF1-deleted and 100% of the 
BTG1-deleted cases found in the BCR-ABL1-positive group (Table 2).
Table 2 Pediatric BCP-ALL patient characteristics in the BTG1- and IKZF1-single and  BTG1;IKZF1–
double deleted groups 
 
del, deletion; WBC, white blood cell count; NCI-Rome HR, high risk defined by age at diagnosis ≥ 10 years and/
or WBC ≥ 50 cells/nl; HeH, high hyperdiploid (51-65 chromosomes); P-value, Fisher exact test across the four 
deletions groups; WBC for 2 cases missing, NCI Risk for 1 case missing, both in the BTG1-wt ;IKZF1-wt group.
Patients’ 
characteristics
BTG1-del; 
IKZF1-wt
BTG1-wt;
IKZF1-del
BTG1-del; 
IKZF1-wt
BTG1-wt; 
IKZF1-wt
Total Fisher 
P-value
n=17 (3%) n=88 (20%) n=31 (6%) n=397 (74%) n=533 (100%)
n % n % n % n % n %
Gender 0.3
 Female 5 29% 44 50% 11 35% 183 46% 243 46%
 Male 11 71% 44 50% 20 65% 214 54% 290 54%
Age (years) 0.0054
 < 10 11 65% 60 68% 26 84% 330 83% 427 80%
 ≥ 10 6 35% 28 32% 5 16% 67 17% 106 20%
WBC (cells/nl) 0.066
 < 50 11 65% 55 62.5% 23 74% 299 76% 388 73%
 ≥ 50 6 35% 33 37.5% 8 26% 96 24% 143 27%
NCI-Rome 0.016
 SR 8 47% 39 44% 19 61% 245 62% 311 58%
 HR 9 53% 49 56% 12 39% 151 38% 221 42%
Protocol 0.54
 DCOG 14 82% 63 72% 25 81% 311 78% 413 77%
 COALL 3 18% 25 28% 6 19% 86 22% 120 23%
Subtype
 ETV6-RUNX1 2 12% 2 2% 24 77% 126 32% 154 29% <0.0001
 HeH 1 6% 16 18% 2 7% 107 27% 126 24% 0.0055
 B-other 4 24% 23 26% 5 16% 75 19% 107 20% 0.41
 BCR-ABL1-like 3 18% 38 43% 0 0% 51 13% 92 17% <0.0001
 TCF3r 0 0% 0 0% 0 0% 19 5% 19 4% 0.093
 BCR-ABL1 7 41% 8 9% 0 0% 9 2% 24 5% <0.0001
 MLLr 0 0% 1 1% 0 0% 10 3% 11 2% 0.89
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Combined deletions of BTG1 and IKZF1 predict inferior outcome in BCP-ALL
We next compared clinical characteristics of BTG1;IKZF1 double-deleted cases, IKZF1 
and BTG1 only-deleted cases, and cases without IKZF1 or BTG1 deletion in our complete 
childhood BCP-ALL cohort. The characteristics of these four groups were similar to the 
total cohort with respect to gender and treatment protocol (Table 2). The double-deleted 
and IKZF1 only-deleted groups contained more patients older than 10 years of age and 
increased white blood cell counts, and hence more NCI-Rome high-risk cases [32] (Table 
2). We compared the event-free survival (EFS) and cumulative incidence of relapse (CIR) 
between cases with both IKZF1 and BTG1 deletions (BTG1-del;IKZF1-del, n=17) with IKZF1-
only deleted cases (BTG1-wt;IKZF1-del, n=88) (Figure 1A-B). The 5-year CIR in IKZF1 plus 
BTG1-deleted cases was 53% ± 13% compared with 28% ± 5% in IKZF1 only-deleted cases 
(P=0.005; Table 3A). Similarly, the 5-year EFS was lower in double-deleted cases compared 
with IKZF1 only-deleted cases (HR 3.5, P=0.0003; Table 3A). In contrast, the BTG1 only-
deleted cases (BTG1-del;IKZF1-wt, n=31) showed a similar outcome (5-year CIR:10% ± 6%) 
as the reference cases without IKZF1 or BTG1 deletions (n=397; 5-year CIR:13% ± 2%). 
The synergistic effect of loss of BTG1 and IKZF1 on outcome remained after correction for 
subtype in the Cox model (Table 3A) and after leaving out the BCR-ABL1-positive cases 
(Figure 1C-D; Table 3B). For the BCR-ABL1-positive cases, BTG1 deletions did not further 
impact the poor treatment outcome as observed for the IKZF1 only-deleted cases (Figure 
1E-F; Table 3C). 
As deletions of PAX5, CDKN2A/B and RB1 were similarly enriched in IKZF1-deleted BCP-
ALL, we examined the impact of these deletions on the outcome of IKZF1-deleted cases. 
In contrast to IKZF1;BTG1 double-deleted patients, the outcome of patients with co-
occurring PAX5, CDKN2A/B or RB1 deletions did not differ from IKZF1 only-deleted cases 
(Figure 2; Online Supplementary Table S4). Similarly, co-occurrences of IKZF1 deletions 
with either EBF1 or ETV6 deletions did not affect outcome compared with IKZF1 only-
deleted. To validate our findings, we analyzed the Australian ANZCHOG ALL8 cohort 
(n=515) [23,24] to assess the prognostic value of BTG1;IKZF1-double deletions. In this 
cohort, 6 out of 11 BTG1-del;IKZF1-del patients developed a relapse (Online Supplementary 
Figure S1). The 5-year CIR in the BTG1;IKZF1-double deleted group was 61% ± 19% versus 
35% ± 6% in the IKZF1-only deleted group (P=0.19; Table 3D). Hence, the same trend 
was observed in this independent validation cohort, albeit statistically non-significant. 
Together, these data indicate that BTG1 deletions in an unselected leukemia population 
have no prognostic value, but BTG1 copy number losses specifically exacerbate the effects 
of IKZF1 deletion on inferior outcome in BCP-ALL.
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Figure 1 Cumulative incidence of relapse (CIR) and event-free survival (EFS) curves for pediatric 
BCP-ALL cases with or without IKZF1 and BTG1 deletions. (A) CIR and (B) EFS curves for total BCP-
ALL cohort (n=533), IKZF1 plus BTG1 deletion, (C) CIR and (D) EFS curves for BCP-ALL without 
BCR-ABL1-positive cases (n=509), IKZF1 plus BTG1 deletion, (E) CIR (F) EFS curves for BCR-ABL1-
positive cases (n=24), IKZF1 plus BTG1 deletion. Colors: black, IKZF1 and BTG1-wildtype; green, 
IKZF1-wildtype, BTG1-deleted; red, IKZF1-deleted, BTG1-wildtype; blue, both BTG1 and IKZF1-
deleted. Abbreviations: wt, wildtype; del, deletion; n, total number. For CIR graphs (A,C,E) the Gray 
P-value and for the EFS graphs (B,D,F) the Cox P-value is indicated comparing BTG1-del;IKZF1-del 
with BTG1-wt;IKZF1-del.
A B
C D
0 2 4 6 8 10
0
20
40
60
80
100
Time from initial diagnosis (years)
C
um
ul
at
iv
e 
in
ci
de
nc
e 
of
 re
la
ps
e 
(%
)
BTG1-wt;IKZF1-wt (n=397) 
BTG1-wt;IKZF1-del (n=88)
BTG1-del;IKZF1-wt (n=31)
BTG1-del;IKZF1-del (n=17)
0 2 4 6 8 10
0
20
40
60
80
100
Time from initial diagnosis (years)
E
ve
nt
−f
re
e 
su
rv
iv
al
 (%
)
0 2 4 6 8 10
0
20
40
60
80
100
Time from initial diagnosis (years)
C
um
ul
at
iv
e 
in
ci
de
nc
e 
of
 re
la
ps
e 
(%
)
0 2 4 6 8 10
0
20
40
60
80
100
Time from initial diagnosis (years)
E
ve
nt
−f
re
e 
su
rv
iv
al
 (%
)
E F
0 2 4 6 8 10
0
20
40
60
80
100
Time from initial diagnosis (years)
C
um
ul
at
iv
e 
in
ci
de
nc
e 
of
 re
la
ps
e 
(%
)
0 2 4 6 8 10
0
20
40
60
80
100
Time from initial diagnosis (years)
E
ve
nt
−f
re
e 
su
rv
iv
al
 (%
)
BCP-ALL
BTG1-wt;IKZF1-wt (n=397) 
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P=0.005
P=0.0003
P=0.011
P=0.00003
P=0.7
P=0.7
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Table 3 CIR and EFS analysis of BTG1;IKZF1-double deleted pediatric BCP-ALL cases compared 
with IKZF1-only deleted cases
1Discovery cohort: pediatric patients from consecutive DCOG/COALL trials; 2Validation cohort: pediatric 
patients from ANZCHOG ALL8 trial;  CIR, cumulative incidence of relapse; SE, standard error; EFS, event-free 
survival; HR, hazard ratio; CI, confidence interval; multivariate, corrected for BCP-ALL subtype and stratified for 
study cohort (DCOG, COALL). None: neither BTG1 nor IKZF1 deletion. * Report of 1 secondary malignancy in 
these groups; ** Report of 6 independent secondary malignancies in this group.
A
BCP-ALL1  (n=533) Univariate Multivariate
Deletion Total Relapse Death 5-yr CIR
(SE)
Gray
P
EFS HR
(95% CI)
Cox
P
EFS HR
(95% CI)
Cox P
BTG1;IKZF1 17 10 2 53% (13%) 0.005 3.5
(1.8-6.8)
0.0003 2.5
(1.0-5.9)
0.043
IKZF1 88 25 5 28% (5%)
BTG1 31 3 0 10% (6%)
none 397 52 12 13% (2%)
B
BCP-ALL1 without BCR-ABL1 (n=509) Univariate Multivariate
Deletion Total Relapse Death 5-yr CIR
(SE)
Gray
P
EFS HR
(95% CI)
Cox
P
EFS HR
(95% CI)
Cox
P
BTG1;IKZF1 10 6 1 50% (17%) 0.011 4.4
(1.9-10.3)
0.0007 6.7
(2.7-16)
0.00003
IKZF1 80 21 2 26% (5%)
BTG1 31 3 0 10% (6%)
none 388 52 10 13% (2%)
C
BCP-ALL1 BCR-ABL1 only (n=24) Univariate Multivariate
Deletion Total Relapse Death 5-yr CIR
(SE)
Gray
P
EFS HR
(95% CI)
Cox
P
EFS HR
(95% CI)
Cox
P
BTG1;IKZF1 7 4 1 57% (22%) 0.7 0.8
(0.3-2.5)
0.7 ND ND
IKZF1 8 4 3 50% (21%)
BTG1 0 0 0
none 9 0 2 0% (0%)
D
BCP-ALL2 validation cohort (n=515) Univariate Multivariate
Deletion Total Relapse Death 5-yr CIR
(SE)
Gray
P
EFS HR
(95% CI)
Cox
P
EFS HR
(95% CI)
Cox
P
BTG1;IKZF1* 11 6 0 61% (19%) 0.19 01.83
(0.8-4.2)
0.16 ND ND
IKZF1 69 23 4 35%  (6%)
BTG1* 45 13 0 27%  (7%)
none** 390 55 4 13%  (2%)
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Figure 2 Cumulative incidence of relapse (CIR) curves for pediatric BCP-ALL cases with or without 
IKZF1 deletions in combination with other single common gene deletions. (A) IKZF1 plus PAX5, 
(B) IKZF1 plus CDKN2A/B, (C) IKZF1 plus RB1, (D) IKZF1 plus EBF1, (E) IKZF1 plus ETV6 (n=533). 
Colors: black, none of the indicated deletions; green, IKZF1-wildtype, indicated gene deleted; 
red, IKZF1-deleted, indicated gene wildtype; blue, both IKZF1 and indicated gene deleted. 
Abbreviations: wt, wildtype; del, deletion; n, total number. 
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Leukemia predisposition in Btg1 knockout mice
Although deletions affecting the BTG1 gene are a frequent event in BCP-ALL, a direct role 
for BTG1 in leukemia development has not been reported. Therefore, we first examined 
the tumor suppressive function of BTG1 using a constitutive Btg1 knockout line harboring 
a Neo-cassette into the first coding exon. [28] We previously reported that these Btg1 
knockout mice display defective B cell development with a 25% reduction in the amount 
of progenitor B cells within the bone marrow compartment, mainly affecting the pre-B 
and immature B cell stage. [33] Furthermore, Btg1 is required for optimal proliferative 
expansion of early progenitor B cells in methylcellulose in response to interleukin-7. At 
the same time, there was no obvious defect in the development of myeloid and T-lymphoid 
cells in these Btg1-deficient animals. [33] In this study, mice that carried either one or 
two copies of the Btg1-knockout allele were followed over a period of 18 months, along 
with control litter mates. About 6% (n=3/49) of the wild-type C57BL6/J mice developed 
B cell lymphomas between the age of 14 and 18 months (Table 4), which is consistent 
with previous observations. [34] Within the same time period 6% of the Btg1+/- (n=2/34) 
and 18% of the Btg1-/- (n=6/33) mice developed exclusively T cell leukemia (Table 4), 
characterized by enlarged primary lymphoid organs, such as spleen and lymph nodes, and 
focal infiltration of leukemic T cells into peripheral organs, such as lung and liver. These 
Btg1-deficient T cell leukemias expressed the T cell surface marker CD3, and displayed 
clonal T cell receptor (TR) rearrangements (Figure 3B). In addition, these CD3+ T cell 
leukemias showed increased expression of the T cell activation marker CD44, but also 
large numbers of B220+ cells within the infiltrated areas of tissues, such as liver or lung, 
and affected lymph nodes (Online Supplementary Figure S2). There was no evidence for 
clonal immunoglobulin gene rearrangements in these Btg1-/- T cell leukemias (Online 
Supplementary Figure S2), suggesting the presence of a substantial number of non-
malignant B-lymphocytes in the proximity of these leukemic T cells. These data show that, 
although somatic BTG1 deletions predominantly occur in BCP-ALL, Btg1-deficiency in 
the mouse germline predisposes exclusively to T cell malignancies. This predilection for 
T-lineage leukemias is also observed for other knockout mouse models targeting genes 
commonly deleted in BCP-ALL, such as  Ikzf1 mutant mice. [35,36] 
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Figure 3 Leukemia incidence and phenotype of Btg1 knockout mice intercrossed with 
haplodeficient Ikzf1 animals. (A) Kaplan-Meier survival curve indicates the leukemia event 
free survival in wild-type, Ikzf1+/-, Btg1+/-, Btg1+/-;Ikzf1+/-, Btg1-/-, and Btg1-/-;Ikzf1+/- mice over a 
time period of 17 months. Leukemia incidence is significantly increased in Btg1-/-;Ikzf1+/- mice 
as compared to Ikzf1+/- mice (P=0.011). (B) Peripheral blood smear stained with Giemsa and 
immunohistochemistry for CD3 on lung and liver tissues of diseased Ikzf1+/-, Btg1-/-,  Btg1+/-
;Ikzf1+/-, and Btg1-/-;Ikzf1+/- mice. (C) Quantification of blast counts in peripheral blood smear 
stained with Giemsa of diseased wild-type, Ikzf1+/-, Btg1-/-,  Btg1+/-;Ikzf1+/- and Btg1-/-;Ikzf1+/- mice 
(n=3). The percentage of leukemic blasts is indicated. (D) Quantification of T cell (CD3) infiltration 
into liver and lung of diseased wild-type, Ikzf1+/-, Btg1-/-, Btg1+/-;Ikzf1+/- and Btg1-/-;Ikzf1+/- mice (n=3) 
using FIJI software. Data are represented as the positively stained area divided by the total area 
measured, with standard errors of the mean P-values (two-sided t test). *P<0.05, **P<0.01, and 
***P<0.001. (E) T cell receptor beta 2 (Trb2) gene rearrangement analysis by PCR on control tissue, 
B cell lymphoma derived from wild-type mice (#3863), and T cell leukemias derived from Ikzf1+/- 
(#13135, #350), Btg1-/- (#160), Btg1+/-;Ikzf1+/- (#5103 and #5102) and Btg1-/-;Ikzf1+/- mice (#9073, 
#7169, #7173). (F) Flow cytometry analyzing CD4 and CD8 expression on T cell leukemia samples 
of two Ikzf1+/-, Btg1-/-,  Btg1+/-;Ikzf1+/- and Btg1-/-;Ikzf1+/- mice.
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Table 4 Characteristics of lymphoid tumors derived from single and intercrossed Btg1 and Ikzf1 
knockout lines 
a Chi-square analysis comparing incidence of T cell leukemia to indicated genotype at 18 months
 
Loss of Btg1 increases leukemia incidence in Ikzf1+/- mice
To investigate cooperation between BTG1 and IKZF1 during leukemogenesis, we 
intercrossed Btg1-deficient mice with haplodeficient Ikzf1 mice using the IkNeo mouse line, 
[29] which harbors a Neo-floxed knock-in allele combined with a Pax5-IRES-GFP cDNA at 
the first coding exon of Ikzf1, thereby creating an Ikzf1-null allele. [29] These mice are only 
viable as a heterozygous knockout line (Ikzf1+/-). First, we analyzed the phenotype of young 
animals (age 6-12 weeks) to assess the effect of Ikzf1+/--allele on Btg1-deficiency in B- and 
T-lymphoid development. Ikzf1+/- mice, like Btg1-/- mice, displayed a moderate reduction 
in the fraction of B220+-cells in bone marrow (BM) and spleen (Online Supplementary 
Figure S3). This correlated with a partial block at the pre-pro B cell stage (Hardy fraction 
A) and the pre-B cell stage (Hardy fraction D) in Ikzf1+/- mice (Online Supplementary Figure 
S3). Btg1-/-;Ikzf1+/- mice showed an even stronger reduction in B220+-cells, with additive 
effects at both B220+CD43+ and B220+CD43- differentiation stages in BM (Hardy fractions 
A to E) (Online Supplementary Figure S3). In contrast, Btg1-/-;Ikzf1+/- mice, similar to Btg1-
/- and Ikzf1+/- single knockout animals, showed no major defects in post-natal thymic T cell 
development (Online Supplementary Figure S4). 
Next, we followed Ikzf1+/-, Btg1+/-;Ikzf1+/- and Btg1-/-Ikzf1+/- mice for a period of 18 months. 
In our cohort, 14% (n=5/36) of the Ikzf1+/- mice developed T cell leukemia between 3 and 
18 months of age, with a median age of 12 months (Figure 3A; Table 4). Similar to Btg1-
deficient leukemia, the Ikzf1+/- T cell leukemias showed infiltration of CD3+ leukemic blasts 
into distant organs and clonal TR rearrangements (Figure 3). Interestingly, we observed 
an increased leukemia incidence upon combined loss of Btg1 and Ikzf1 (Figure 3A), which 
is consistent with our hypothesis that BTG1 deletions cooperate with IKZF1 aberration 
to induce human BCP-ALL. We found that 26% of the Btg1+/-;Ikzf1+/- mice (n=10/35) and 
40% of the Btg1-/-;Ikzf1+/- (n=12/30) animals developed T cell leukemia, while leukemias 
in Btg1-/-;Ikzf1+/- appeared with a slightly shorter latency (9.4 months) relative to Ikzf1+/-
mice (12.4 months) (P=0.011) (Table 4). Tumors in the Btg1-/-;Ikzf1+/- compound mice were 
Genotype Tumor incidence
(% mice)
Mean age  
(months)
Tumor 
phenotype
  Ikzf1+/-     P-value a 
Btg1+/-      
Btg1-/-
Wild-type 3/49    (6%)     16.4 B cell lymphoma   -    -   -
Ikzf1+/- 5/36    (14%) 12.4 T cell leukemia   - 0.271 0.703
Btg1+/- 2/34    (6%) 15.8 T cell leukemia 0.271   - 0.143
Btg1+/-;Ikzf1+/- 10/35  (29%) 13.6 T cell leukemia 0.134 0.013 0.231
Btg1-/- 6/33    (18%) 17.4 T cell leukemia 0.703 0.143   -
Btg1-/-;Ikzf1+/- 12/30  (40%) 9.4 T cell leukemia 0.011 0.001 0.026
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characterized by significantly higher leukocyte counts in peripheral blood compared 
to single knockout animals (Figure 3B and 3C), and strong infiltration of leukemic cells 
into liver and lungs (Figure 3B and 3D), as well as clonal TR rearrangements (Figure 3E). 
Flow cytometric analysis of the different T cell leukemias revealed that most of the Btg1-
/-;Ikzf1+/- leukemias were CD4+CD8+ double positive T cells with ongoing differentiation 
towards CD4 or CD8 single positive stage (Figure 3F, Online Supplementary Table S5). 
Moreover, isolated leukemic T cells, derived from all the different genetic backgrounds 
included in our studies (Ikzf1+/-, Btg1-/- and Btg1-/-;Ikzf1+/-), could be serially transplanted 
into syngeneic C57BL6/J mice giving rise to similar (oligo)clonal T cell leukemias (Online 
Supplementary Figure S5). Taken together, our data demonstrate that loss of Btg1 
cooperates with haplodeficiency for Ikzf1 during mouse leukemia development in a dose-
dependent manner.
BTG1 modifies glucocorticoid resistance mediated by loss of IKZF1
While these experiments confirm the genetic interaction between BTG1 deletions and 
IKZF1 aberrations during leukemogenesis, they do not explain the poor outcome observed 
in patients showing combined loss of BTG1 and IKZF1. Recently, we established that 
inferior outcome related to IKZF1 deletions in BCP-ALL is correlated with an attenuated 
in vivo day 8 prednisolone response and increased GC resistance in IKZF1-deleted 
primary leukemic cells, as determined by in vitro MTT assays. [6] These results could be 
recapitulated using primary splenic B cells isolated from IIkzf1+/- mice, which revealed 
that also non-leukemic Ikzf1+/- B cells are less sensitive towards GC-induced apoptosis. [6] 
Based on our previous findings that BTG1 regulates glucocorticoid receptor activation, [37] 
we investigated whether loss of BTG1 would impact the GC response in primary murine 
B cells. To this end, B cells isolated from WT, Btg1-/-, Ikzf1-/- and Btg1-/-;Ikzf1+/- mice and 
obtained after lipopolysaccharide activation, were stimulated for 48 hours with increasing 
concentrations of prednisolone or dexamethasone and subjected to MTS assays to assess 
relative cell survival. While Btg1-deficiency alone had no effect on GC-induced apoptosis, 
Ikzf1-haplodeficient B cells showed enhanced cell survival as compared to WT (Figure 
4A), similar to our previous findings. [6] Importantly, Btg1-/-;Ikzf1+/- B cells showed an even 
stronger resistance to GC-induced apoptosis when compared to Ikzf1+/- B cell (P<0.001). 
These findings were confirmed by Annexin V staining, demonstrating a significantly smaller 
apoptotic fraction in Btg1-/-;Ikzf1+/- B cells relative to Ikzf1+/- B cells (P<0.001) (Figure 4B). 
Analyses of primary Btg1-/-, Ikzf1+/- and Btg1-/-;Ikzf1+/- thymocytes revealed no differential 
sensitivity to GC-induced apoptosis as compared to WT (Online Supplementary Figure S6A). 
Next, we assessed whether loss Btg1 and Ikzf1 would promote resistance in B cells to other 
chemotherapeutic drugs commonly used in the treatment of BCP-ALL patients, including 
6-mercaptopurine, doxorubicin, vincristine and asparaginase. However, Btg1-/-, Ikzf1+/- and 
Btg1-/-;Ikzf1+/- B cells showed similar cell survival in comparison to control cells (Online 
Supplementary Figure S6B). Together, these data argue that loss of tumor suppressor BTG1 
enhances GC resistance in the context of IKZF1-deletions, which may explain the inferior 
treatment outcome observed in patients showing combined loss of BTG1 and IKZF1.
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Figure 4 Glucocorticoid resistance of B cells isolated from Btg1 knockout mice intercrossed with 
haplodeficient Ikzf1 animals. (A) Splenic B cells isolated from wild-type (WT), Ikzf1+/- , Btg1-/- and 
Btg1-/-;Ikzf1+/-  mice were activated by lipopolysaccharide (LPS) for 48hrs and subsequently treated 
in vitro for 48 hours with increasing concentrations of prednisolone (left panel) or dexamethasone 
(right panel) and analyzed by MTS assay (n=6). All values were normalized to untreated (UT) B 
cells. Error bars represent ± standard error of the mean (SEM). P values were calculated based on 
the differences of the best-fit curve using two-sided ANOVA. (B) AnnexinV/7-AAD staining of WT, 
Ikzf1+/-, Btg1-/- and Btg1-/-;Ikzf1+/- B-lymphocytes after 2 µM prednisolone or 5 µM dexamethasone 
treatment for 48 hours (n=4). The fraction of AnnexinV-positive cells was determined. Data 
represent means, and error bars represent SEM. P values (two-sided t test) are indicated. *P<0.05, 
**P<0.01, and ***P<0.001.  
 
Discussion
BCP-ALL is a heterogeneous disease characterized by recurrent deletions enriched 
in specific genetic subtypes.1 For instance, it is known that deletions affecting the 
transcriptional co-regulator BTG1 are unevenly distributed among cytogenetic subgroups 
as we and others have shown that BTG1 deletions are strongly enriched in ETV6-RUNX1-
positive leukemia as well as BCR-ABL1-positive ALL. [30,31,38] The presence of these 
lesions in such distinct BCP-ALL subgroups may relate to the fact that deletions of IKZF1 
and BTG1 appear to be the result of illegitimate RAG recombination, [30] as is the case 
for several of the other commonly deleted genes, such as EBF1 and PAX5. In addition 
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to these earlier observations, we find a specific co-occurrence of BTG1 and IKZF1 gene 
deletions across cytogenetic subtypes, suggesting that the combined loss of BTG1 and 
IKZF1 may actively contribute to leukemogenesis. Previous studies, mostly carried out in 
mouse models, revealed that Ikzf1 and Arf alterations in BCR-ABL1-positive ALL synergize 
to promote the development of leukemia by conferring stem cell like properties. [39] This 
leads us to hypothesize that the preponderance of BTG1;IKZF1 double-deletions in this 
particular subgroup may have similar consequences, although this remains to be assessed 
in well-established BCR-ABL1-positive mouse models. As BTG1 and IKZF1 deletions also 
(co)occur in lymphoid blast crises of CML, [7,31] it will be interesting to study if and how 
combined loss of BTG1 and IKZF1 drive the progression of this disease. Of all common copy 
number losses analyzed in our study, including CDKN2A/B, PAX5, EBF1, and RB1, only loss 
of BTG1 appears to worsen outcome of IKZF1-deleted ALL. Our data are consistent with 
the findings of Moorman et al. showing that specific combinations of different deletions 
impact outcome in BCP-ALL. [40] 
A number of different knockout mouse models have provided insight into the role of 
commonly deleted transcription factors in early hematopoiesis and spontaneous tumor 
incidence. It is evident that several of these transcriptional regulators play an important 
role as lymphoid specification factors and are essential for normal lymphopoiesis. [41-44] 
However, in the mouse, loss of these early B cell transcription factors affected in BCP-ALL, 
such as E2A [45] and IKZF1, [46] gives rise to T cell malignancies. E2a-deficient tumors are 
characterized by a strong increase in c-Myc mRNA expression, [45] an oncogene known 
to promote the development of T cell lymphomas. [47] Similarly, while IKZF1 deletions 
predominantly occur in human BCP-ALL, heterozygous Ikzf1 knockout and dominant-
negative Ikzf1 mice exclusively develop T cell malignancies, which has been attributed to 
activation of the Notch pathway. [36,48] In our studies we observed a lower incidence of 
T cell leukemia in Ikzf1+/- mice as compared to what has been reported for some other 
genetically engineered Ikzf1 mouse models, where expression of dominant-negative 
isoforms or hypomorphic knockout alleles of Ikzf1 yielded a higher susceptibility to T cell 
malignancies. [35,36,48] Similar to mice heterozygous knockout for Ikzf1, Btg1 knockout 
mice develop T cell leukemia, while BTG1 deletions are almost exclusively found in human 
BCP-ALL. [30] However, consistent with our finding that mono-allelic BTG1 deletions are 
enriched in human BCP-ALL cases with IKZF1 aberrations, Btg1+/-;Ikzf1+/- mice are more 
prone to develop leukemia relative to Btg1+/- single-knockout mice (P=0.013). In addition, 
we observed a significant acceleration in the onset of disease in Btg1-/-;Ikzf1+/- mice as 
compared to Btg1-/- (P=0.026) or Ikzf1+/- mice (P=0.011), indicating that loss of these tumor 
suppressor genes cooperates during leukemogenesis. Genomic DNA analyses further 
indicate that both the wild-type Btg1 allele and Ikzf1 allele are maintained in the Btg1+/-
;Ikzf1+/- leukemias (data not shown), arguing that Btg1 and Ikzf1 dosage contribute to 
leukemia development. These data confirm that BTG1 acts as a tumor suppressor gene 
that cooperates with IKZF1 loss during leukemia development.
COMBINED LOSS OF BTG1 AND IKZF1 INCREASES RELAPSE RISK IN BCP-ALL PATIENTS
127
Another important finding in this study is that BTG1 deletions define a high-risk group 
within the IKZF1-deleted subtype. Our finding that loss of BTG1 specifically enhances GC 
resistance mediated by Ikzf1-haplodeficiency implies that the prognostic value of BTG1 
and IKZF1 deletions could be dependent on the upfront treatment and dose of synthetic 
glucocorticoids used. However, this remains to be established in future studies. The 
relation between BTG1 deletions and inferior outcome was recently confirmed with the 
analyses of a relapsed BCP-ALL cohort, showing that BTG1 and NR3C1 deletions were 
associated with higher risk of disease progression. [49] Collectively, our data demonstrate 
that BTG1 is a prognostic factor and regulator of the GC response, particularly in the 
context of IKZF1-deletions. 
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Supplementary Material Chapter 5
Supplementary methods
Cytogenetic and molecular analysis of patient samples
Cases were screened for high hyperdiploidy (51-65 chromosomes), ETV6-RUNX1 and 
BCR-ABL1 fusion products and rearrangements of TCF3 and MLL by routine diagnostic 
procedures. Cases in the discovery cohort were identified as BCR-ABL1-like, based on a 
previously described expression signature of 110 probe sets. [1,2] The multiplex ligation-
dependent probe amplification assay SALSA MLPA P335 ALL-IKZF1 (MRC-Holland, 
Amsterdam, the Netherlands) was performed according to the manufacturer’s protocol 
and analyzed as previously described.1 A ratio lower than 0.75 for the exon intensity in 
patients versus the healthy control reference was considered to represent a deletion. For 
scoring CDKN2A/B deletion, it was sufficient to have either CDKN2A or CDKN2B deleted. 
Mutation status for IKZF1 was neither assessed in discovery (n=533) nor validation 
(n=515) cohort. 
Flow cytometric analysis
Murine bone marrow (BM) cells were harvested by flushing femurs with RPMI medium 
(Gibco//Life technologies Europe BV, Bleiswijk, The Netherlands) containing 10% FBS 
(Greiner Bio-One BV, Alphen a/d Rijn, The Netherlands) and 50μM ↑-Mercaptoethanol 
(Gibco). Cells from spleen and thymus were isolated through a 70μM filter using RPMI 
medium containing 10% FBS and 50μM ↑-Mercaptoethanol. Leukemic blasts isolated 
from either lymph nodes, spleen or thymus were analyzed by FACS using the LSRII flow 
cytometer (BD Biosciences, Breda, The Netherlands). Single cell suspensions were 
treated with red blood cell lysis buffer (Sigma-Aldrich, Zwijndrecht, The Netherlands) and 
pre-incubated with unlabeled anti–Fc III/II receptor (2.4G2) (BD Biosciences) to inhibit 
unspecific antibody binding. Cells were stained with the following antibodies purchased 
from BD Biosciences (Franklin Lakes, New Jersey) and eBiosciences (Vienna, Austria): 
anti-B220/CD45R (RA3-6B2); BP1 (6C3); CD4 (RM4-5); CD8 (53-6.7); CD11b/Mac1 
(M1/70); CD24/HSA (M1/69); CD25 (PC61.5); CD43 (S7); CD44 (IM7); IgM (II/41); IgD 
(11-26c). The data were collected and analyzed by FlowJo V10 software (FlowJo, Ashland, 
Oregon). 
Immunohistochemistry
Tissues isolated from diseased mice were fixed in 4% formalin for 24 hours. Specimens 
were embedded in paraffin, 4 µM serial sections were prepared and stained with 
hematoxylin and eosin (HE). For immunohistochemistry, slides were dewaxed and 
rehydrated prior to heat-induced antigen retrieval using sodium citrate buffer. After 
blocking with 2% goat serum and 2% BSA in 0.05% Tween-PBS, the slides were incubated 
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overnight with B220/CD45R (RM2600) (Invitrogen, Amsterdam, The Netherlands) and 
CD3 (A0452) (DAKO Netherlands BV, Heverlee, Belgium) antibodies.  Biotinylated anti-rat 
IgG (BA9401) (Vector Laboratories, Peterborough, United Kingdom) and anti-rabbit IgG 
(BA1000) (Vector Laboratories) were used as secondary antibody and subsequently the 
slides were incubated with metal-enhanced diaminobenzidine in stable peroxide substrate 
buffer (Thermo Fisher Scientific Inc., Amsterdam, The Netherlands), counterstained with 
hematoxylin, and after dehydration coverslipped with Entellan. Four selected regions per 
murine liver or lung histological slide were used for the quantification of CD3+ positively 
stained areas. The analysis was performed with FIJI software. [3] For the quantification 
of the blood smears, 10 visual fields with a 40x objective were scored for the number of 
blasts. In total, 10 visual fields per blood smear were averaged and for each genotype the 
percentage of blasts was determined for three independent mice.
VDJ rearrangement analysis
DNA was extracted from enlarged spleen or lymph nodes using the Gentra Puregene 
Mouse Tail kit (Qiagen, Venlo, The Netherlands). PCR analysis was performed with primers 
specific for the DB1-JB region of Trb1, Dβ2.1-Jβ2.7 region of Trb2, and 5’VH2-3’Cµ and 
5’VH2-3’Cκ primers for the Igh and Igk genes, respectively (Supplementary Table S1).
Viability assays on murine splenic B cells 
Spleens from healthy young (6-12 weeks of age) wild-type, Ikzf1+/-, Btg1-/- and Btg1-/-
;Ikzf1+/- mice were isolated and single mononuclear cells were harvested through a 70 µM 
cell strainer. Erythrocytes within the cell suspensions were removed by Red blood cell lysis 
buffer (Sigma-Aldrich, Zwijndrecht, The Netherlands). Next, splenocytes were cultured for 
48 hours in RPMI 1640 medium (Life technologies, Carlsbad, CA) supplemented with 10% 
heat-inactivated fetal calf serum (FCS), 1% penicillin/streptomycin (Invitrogen), and 50 µM 
↑-Mercaptoethanol in the presence of 5 µg/mL lipopolysaccharide (LPS). Subsequently, 
splenic B-lymphocytes obtained after ficoll gradient were cultured in a 96-well plate at 
a density of 1x 105 cells/well in the presence of 5 µg/mL LPS. Splenic B cells were treated 
with increasing concentrations of prednisolone or dexamethasone (both Centrafarm, 
Etten-Leur, the Netherlands). After 48 hours, relative cell viability was assessed using the 
CellTiter 2 96® AQueous One Solution Cell Proliferation (MTS) Assay (Promega, Madison, 
WI). Absorbance was acquired using a plate reader (Infinite F50; TECAN, Männedorf, 
Switzerland). For AnnexinV analyses, splenic B-lymphocytes obtained from young (6-12 
weeks of age) wild-type, Ikzf1+/-, Btg1-/- and Btg1-/-;Ikzf1+/- mice were treated for 48 hours 
with prednisolone or dexamethasone and stained with the AnnexinV-PE/7-AAD Viability 
Kit (BD Biosciences) according to manufacturer’s instructions and analyzed by FACS. 
AnnexinV-positive cell fractions were determined by FlowJo software Version 10 (Treestar, 
Ashland, OR).
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Supplementary Tables
Supplementary Table S1 Oligonucleotide primers used for genotyping and IG/TR clonality 
analysis.
Supplementary Table S2 Representation of pediatric ALL subtypes in DCOG and COALL cohorts
* Pui et al, Journal of Clinical Oncology 2011
Gene locus Forward primer (5’-3’) Reverse primer (5’-3’)
Wild-type Btg1 CCATGCATCCCTTCTACACCC TGCAGGCTCTGGCTGAAAGT
Knockout Btg1 CCATGCATCCCTTCTACACCC CGGAGAACCTGCGTGCAATC
Wild-type Ikzf1 ATGGATGTCGATGAGGGTCAAGAC AGTTCTCTGAACACAGACACACGT
Knockout Ikzf1 GCGGAGCTCCTCAGGTGCAGGCTGCCTATC GACGCGTCGACGCTAACATCCTGAGGGACTGT
Trb1 (DJ) CAGCCCCTTCAGCAAAGAT CCTAAGTTCCTTTCCAAGACCAT
Trb2 (DJ) GTAGGCACCTGTGGGGAAGAAACT TGAGAGCTGTCTCCTACTATCCATT
Igh CCCGAATTCCAGGTCCAGTTGCAGCAGWCWGG CCCGAATTCGCTCTCGCAGGAGAC
Igk CCCGAATTCCAGGTCCAGTTGCAGCAGWCWGG CCCGAATTCTAACTGCTCACTGGA
ALL subtypes DCOG (N=470) COALL (N=128) Total (N=598) Literature*
N Perc N Perc N Perc Perc
ETV6-RUNX1 120 26% 34 27% 154 26% 25%
High hyperdiploid (51-65 chr) 95 20% 31 24% 126 21% 25%
Non-BCR-ABL1-like B-other 80 17% 27 21% 107 18% 10-15%
BCR-ABL1-like B-other 69 15% 23 18% 92 15% 10-15%
TCF3-rearranged 17 4% 2 2% 19 3% 5%
BCR-ABL1 22 5% 2 2% 24 4% 3%
MLL-rearranged 10 2% 1 1% 11 2% 2%
T-ALL 57 12% 8 6% 65 11% 15%
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Supplementary Table S3 Co-occurrence of BTG1 deletion with other common gene deletions in 
BCP-ALL
BTG1 no deletion BTG1 deletion Fisher Test
N Perc N Perc P-value Odds ratio
IKZF1 no deletion 397 0.82 31 0.65 0.0071 2.5
IKZF1 deletion 88 0.18 17 0.35
PAX5 no deletion 352 0.73 33 0.69 0.61 1.2
PAX5 deletion 133 0.27 15 0.31
CDKN2A/B no deletion 323 0.67 28 0.58 0.27 1.4
CDKN2A/B deletion 162 0.33 20 0.42
EBF1 no deletion 462 0.95 39 0.81 0.0011 4.6
EBF1 deletion 23 0.05 9 0.19
RB1 no deletion 451 0.93 40 0.83 0.042 2.6
RB1 deletion 34 0.07 8 0.17
ETV6 no deletion 351 0.72 25 0.52 0.0046 2.4
ETV6 deletion 134 0.28 23 0.48
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Supplementary Table S4 Outcome analysis in BCP-ALL cases double-deleted for common gene 
deletions and IKZF1 versus IKZF1-only deleted cases.
CIR, cumulative incidence of relapse; SE, standard error; EFS, event-free survival; HR, hazard ratio; CI, 
confidence interval; multivariate, corrected for BCP-ALL subtype and stratified for study cohort (DCOG, 
COALL)
 
Supplementary Table S5 Excel data sheet with leukemia phenotype mouse tumors. See online 
version at Hematologica website.
PAX5 Univariate multivariate
Deletion Total Relapse Death 5-yr CIR
(SE)
Gray
P
EFS HR 
(95% CI)
Cox
P
EFS HR 
(95% CI)
Cox P
PAX5;IKZF1 50 17 3 32% (7%) 0.8 1.0 
(0.6-1.9)
0.9 0.7 0.2
IKZF1 55 18 4 33% (7%) (0.3-1.3)
PAX5 98 19 1 19% (4%)
none 330 36 11 11% (2%)
CDKN2A/B Univariate multivariate
Deletion Total Relapse Death 5-yr CIR
(SE)
Gray
P
EFS HR 
(95% CI)
Cox
P
EFS HR 
(95% CI)
Cox P
CDKN2A/B; IKZF1 52 20 3 39% (7%) 0.2 1.4
(0.8-2.5)
0.3 0.9 0.7
IKZF1 53 15 4 26% (6%) (0.4-1.8)
CDKN2A/B 130 23 5 18% (4%)  
 none 298 32 7 10% (2%)
EBF1 Univariate multivariate
Deletion Total Relapse Death 5-yr CIR
(SE)
Gray
P
EFS HR 
(95% CI)
Cox
P
EFS HR 
(95% CI)
Cox P
EBF1;IKZF1 9 3 1 22% (15%) 0.9 1.2
(0.4-3.3)
0.7 2.1 0.2
IKZF1 96 32 6 33% (5%) (0.7-6.9)
EBF1 23 3 0 15% (8%)  
 none 405 52 12 13% (2%)
RB1 Univariate multivariate
Deletion Total Relapse Death 5-yr CIR
(SE)
Gray
P
EFS HR 
(95% CI)
Cox
P
EFS HR 
(95% CI)
Cox P
RB1;IKZF1 14 5 1 37% (14%) 0.7 1.2
(0.5-2.9)
0.6 0.6 0.3
IKZF1 91 30 6 31% (5%) (0.2-1.6)
RB1 28 5 1 18% (8%)  
 none 400 50 11 12% (2%)
ETV6 Univariate multivariate
Deletion Total Relapse Death 5-yr CIR
(SE)
Gray
P
EFS HR 
(95% CI)
Cox
P
EFS HR 
(95% CI)
Cox P
ETV6;IKZF1 25 10 0 40% (10%) 0.4 1.0
(0.5-2.0)
0.9 1.5 0.3
IKZF1 80 25 7 30% (5%) (0.7-3.4)
ETV6 132 11 1 8% (3%)  
 none 296 44 11 15% (2%)
CHAPTER 5
136
Supplementary Figures
 
Supplementary Figure S1 Cumulative incidence of relapse (CIR) and event-free survival (EFS) 
curves for pediatric BCP-ALL cases from the Australian and New Zealand Children’s Oncology 
Group (ANZCHOG) ALL8 trial with or without IKZF1 and BTG1 deletions. (A) CIR and (B) EFS 
curves for total BCP-ALL cohort (n=515). Colors: black, IKZF1 and BTG1-wildtype; green, IKZF1-
wildtype, BTG1-deleted; red, IKZF1-deleted, BTG1-wildtype; blue, both BTG1 and IKZF1-deleted. 
Abbreviations: wt, wildtype; del, deletion; n, total number.
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Supplementary Figure S2 Characteristics of Btg1-deficient T cell leukemias. (A-B) T cell 
leukemias in Btg1-deficient mice are characterized by a significant proportion of B220+ 
B-lymphocytes within the tumor area, which can be demonstrated by B220-positive staining 
as determined by immunohistochemistry of infiltrated liver (A) and flow cytometry of the 
primary leukemia (B). (B) T cell leukemias in Btg1 knockout mice are characterized by relative 
high expression of CD44, which is evident in both CD3+CD4-CD8- fraction (red line), CD3+CD4- 
CD8+ fraction (black curve) and CD3+CD4+CD8- fraction (gray curve). (C) Immunoglobulin gene 
rearrangements for heavy chain (Igh) and kappa light chain (Igk) show clonal rearrangement in B 
cell malignancies derived from wild-type C57Bl/6J mice, but not in leukemias derived from  Btg1-/- 
mice, indicating that B220+ cells in leukemic infiltrates of Btg1-/- mice represent non-leukemic B 
cells.
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Supplementary Figure S3 Analysis of B cell development in Ikzf1+/-, Btg1-/- and Btg1-/-;Ikzf1+/- 
mice in bone marrow and spleen. Bone marrow (BM) and splenic cells from WT, Ikzf1+/-, Btg1-/- 
and Btg1-/-;Ikzf1+/-  mice were stained with an antibody cocktail against B220, CD43, BP-1, IgD and 
IgM. (A-B) Flow cytometric analysis on the fraction of B220+-cells in bone marrow (A) and spleen 
(B) of the different genotypes (n=4). (C) Representative gating strategy of the early B-lymphoid 
populations in the bone marrow compartment. After gating on the viable cell population and 
according to B220 and CD43 expression levels, the B220+CD43+ population was further analyzed 
for their BP-1 and CD24 expression to identify Hardy Fraction A (B220+CD43+BP-1-CD24-) and BC 
(B220+CD43+BP-1-CD24+). Hardy fraction D, E and F were identified by gating for the B220+CD43- 
population. Subsequently IgD and IgM expression levels in the B220+CD43- gate were used to 
distinguish Hardy fraction D (B220+CD43-IgM-IgD-) Hardy fraction E (B220+CD43-IgM+IgDlow) 
and F (B220+CD43-IgM+IgDhigh). (D) The relative percentages of different Hardy fractions within 
the bone marrow compartment is indicated for BM of WT, Ikzf1+/-, Btg1-/- and Btg1-/-;Ikzf1+/- mice 
(n=4). Data for all experiments are means, and error bars represent SEM. P values (two-sided t test) 
are indicated. *P<0.05, **P<0.01, and ***P<0.001.
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Supplementary Figure S4 Analysis of T-lymphopoiesis in Ikzf1+/-, Btg1-/- and Btg1-/-;Ikzf1+/-  mice. 
(A-B) Flow cytometric analysis was performed on the lymphoid cells isolated from thymus of wild-
type (WT), Ikzf1+/-, Btg1-/- and Btg1-/-;Ikzf1+/- mice (n=3). Cells were stained with an antibody cocktail 
against CD3, CD4, CD8, CD44 and CD25 to identify the different stages of T cell development. 
(A) Thymocytes were analyzed for expression of CD4 and CD8. (B) Early T cell development can 
be identified in the CD4-CD8- double negative (DN) T cell fraction. To further distinguish the DN 
stages of T cell development, the CD4-CD8- cells were gated for CD25 and CD44 expression. DN1 
is defined as CD44+CD25- fraction, DN2 as CD44+CD25+ fraction, DN3 as CD44-CD25+ fraction 
and DN4 as CD44-CD25- fraction in the thymus. Each value represents the mean of three mice. 
Data are means, and error bars represent SEM.
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Supplementary Figure S5 Leukemias arising in Btg1 and Ikzf1 knockout animals are (oligo)
clonal and transplantable into syngeneic mice. (A) Schematic overview of the transplantation 
experiments. Leukemias (L) derived from either Ikzf1+/-, Btg1-/-, and  Ikzf1+/-;Btg1-/- mice were 
transplanted intravenously into syngeneic mice at a concentration of 2x105 cells (transplant-1; T1) 
or 5x105 cells (transplant-2; T2). T cell leukemias were observed 4 weeks after transplantation. (B) 
T cell receptor beta 2 (Trb2) gene rearrangements were determined by PCR on DNA isolated from 
non-lymphoid tissue (earclip) as control for germline configuration, and DNA derived from L, T1 
and T2 tumor tissues of  kzf1+/-, Btg1-/-, and  Ikzf1+/-;Btg1-/- mice. (C) Flow cytometry was performed 
on the original leukemia (L) and two independent serial transplantations (T1 and T2). The upper 
panel shows the side scatter (SSC) and CD3 profile. The CD3-positive fraction was subsequent 
analyzed for CD4 and CD8 staining (second panel) and gated for the CD4-CD8- fraction to analyze 
CD44 and CD25 expression (third panel) as well as on the complete CD3+ fraction (fourth panel).
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Supplementary Figure S6 Chemotherapy response in primary lymphoid cells isolated from 
Ikzf1+/-, Btg1-/- and Btg1-/-;Ikzf1+/- mice. (A) AnnexinV/7-AAD staining of WT, Ikzf1+/-, Btg1-/- and 
Btg1-/-;Ikzf1+/- murine thymocytes after treatment with increasing concentrations of prednisolone 
(left panel) or dexamethasone (right panel) for 12 hours (n=4) or left untreated (UT). The fraction 
of AnnexinV-positive cells was determined. Data are means, and error bars represent SEM. 
Differences were statistically non-significant (ns) as assessed by two-sided t-test. (B) Splenocytes 
isolated from wild-type (WT), Ikzf1+/-, Btg1-/- and Btg1-/-;Ikzf1+/- mice were stimulated with 
lipopolysaccharide (LPS) for 48 hrs. Ficoll-purified splenic B cells were treated with increasing 
concentrations of common single chemotherapeutic agents used in ALL treatment. Cells were 
treated with 6-mercaptopurine, daunorubicine, vincristine or doxorubicine for 48 hours, or for 
72 hours with asparaginase, and analyzed by MTS assay. All values were normalized to untreated 
B cells. Error bars represent ± standard error of the mean(SEM) and a two-sided ANOVA was 
performed for statistical analysis (n=2).
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Abstract
Deletions and mutations affecting lymphoid transcription factor IKZF1 occur in about 10-
15% of patients with B cell precursor acute lymphoblastic leukemia (BCP-ALL) and predict 
a poor outcome. We have recently shown that loss of IKZF1 function compromises the 
therapeutic efficacy of glucocorticoids (GCs) in the treatment of IKZF1-deleted BCP-ALL. 
Here, we investigated whether loss of IKZF1 function also affects therapy resistance to 
other chemotherapeutic agents used in the treatment of ALL. We observed that CRISPR/
CAS9-mediated knock-out of IKZF1 (IKZF1KO) in Nalm6 pre-B ALL was sufficient to make 
these cells highly resistant to the pyrimidine analogs gemcitabine and cytarabine (AraC) 
relative to IKZF1 wild type cells. The same drug resistance profile was observed upon 
short hairpin RNA (shRNA)-mediated knockdown of IKZF1 as well as in B cells isolated 
from Ikzf1+/- mice. We confirmed these findings by ex vivo profiling of patient-derived 
xenografts, where we observed that IKZF1-deleted cases were significantly (10logIC50 3.2 
nM) more resistant to AraC and gemcitabine than those wild type for IKZF1 (10logIC50 1.8 
nM) Previous studies have identified the metabolic enzyme cytidine deaminase (CDA) as 
a determinant of AraC therapy response, both in ALL and acute myeloid leukemia (AML). 
Consistent with these findings, we observed that loss of IKZF1 increases the expression 
of CDA in BCP-ALL cell lines as well as mouse primary B cells. In addition, treatment of 
IKZF1KO cells using pharmacological inhibitors of CDA, restored pyrimidine analog 
sensitivity to control levels. Together, these results demonstrate that loss of IKZF1 confers 
resistance to AraC and gemcitabine, both in experimental models and in patient derived 
leukemic cells. Moreover, we postulate that replacing AraC with alternative nucleoside 
analogs may enhance treatment efficacy in this high-risk patient group. 
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Introduction
Over the last decades, the treatment outcome of children with pediatric B cell precursor 
acute lymphoblastic leukemia (BCP-ALL) has drastically improved due to improvements in 
ALL risk stratification and treatment regimens [1]. Despite this, still 15% of these patients 
develop a relapse, which strongly reduces the chance of cure. Therefore, better upfront 
therapies are necessary for children who are at risk of developing a relapse, while more 
effective and less toxic treatments for relapsed patients are urgently needed. In the last 
decades, the immunophenotype of the disease (B or T cell leukemia) [2], age at initial 
diagnosis [3] and response on treatment defined by day 8 prednisone response [4] and 
minimal residual disease (MRD) status [5-7] have been established as important parameters 
for risk stratification of ALL patients receiving current, multi-agent chemotherapy [8].
In addition, treatment response is partly determined by the (cyto)genetic context of the 
leukemia, which has led to the implementation of risk-adapted therapies based on specific 
genetic abnormalities [9,10]. By focusing on the molecular mechanisms that contribute 
to therapy resistance in distinct high-risk ALL subtypes, more personalized treatment 
strategies, aimed at preventing relapse, can be developed.
Detailed characterization of the ALL genome by SNP array profiling and next-generation 
sequencing (NGS) has identified novel genetic aberrations that affect response to anti-
cancer agents. Deletions or mutations affecting the lymphoid transcription factor IKZF1 
can be detected in approximately 10-15% of pediatric BCP-ALL patients [11,12] and several 
studies have identified loss of IKZF1 as an independent poor prognostic factor in BCP-ALL 
[13-15]. Therefore, deletion of IKZF1 is now considered a high-risk feature that requires an 
intensified treatment, but it remains to be established whether treatment intensification 
improves overall survival in this patient group. Over the past few years, much has been 
learned about the tumor suppressive role of IKZF1 during leukemia development and 
the molecular pathways that relate to its impact on treatment outcome. For instance, it 
was shown in BCR-ABL1 positive ALL that loss of IKZF1 promotes integrin-dependent 
survival signaling through activation of focal adhesion kinase (FAK) [16]. Moreover, FAK 
inhibition potentiated the responsiveness to ABL inhibitor dasatinib in a xenograft 
model [17]. In addition, we recently established that single copy loss of IKZF1 contributes 
to a poor response to synthetic glucocorticoids, both in genetic models and in patients 
[18]. However, to what extent loss of IKZF1 function affects cellular responses to other 
leukemia drugs has not been explored. 
It is well known that loss of p53 function, activation of c-MYC, BCR-ABL1 or mutation of 
RAS, profoundly affect cancer metabolism, and, as a consequence, the way tumor cells 
respond to treatment [19,20]. A similar principle may apply to loss of IKZF1 function in 
ALL, as it was recently shown that B cell transcription factors, including IKZF1, function 
as metabolic gate-keepers, controlling glucose and energy metabolism during pre-B cell 
expansion [21]. We therefore investigated whether the metabolic changes associated with 
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loss of IKZF1 function impact the cellular responses to specific antimetabolites, such as 
nucleoside analogs, used in the treatment of children with ALL. Nucleoside analogs play 
a prominent role in the treatment of children with hematological malignancies, affecting 
both mitotic and quiescent cells. Once modified into nucleotides, they are incorporated 
into the DNA/RNA to inhibit DNA/RNA synthesis, leading to DNA fragmentation or 
transcriptional arrest, resulting in cell death [22]. Resistance to nucleoside analogs can 
be a consequence of ineffective cellular uptake, for instance due to reduced expression 
of nucleoside transporters, or changes in metabolic handling of these drugs [22]. For 
example, previous studies have identified the metabolic enzymes cytidine deaminase 
(CDA) and deoxycytidine kinases as key determinants of cytarabine (AraC) therapy 
response both in ALL and acute myeloid leukemia (AML) [22,23], while activating mutations 
in the 5’ nucleotidase NT5C2 lead to resistance to thiopurines such as 6-mercaptopurine 
(6MP) and 6-thioguanine (6TG) [24,25]. In this study, we found that loss of IKZF1 function 
drives resistance to pyrimidine analogs, both in our experimental cell model-based drug 
screens as well as in patient-derived xenografts. Moreover, we established that this effect 
is a consequence of increased expression of metabolic enzyme CDA in response to IKZF1 
loss of function.
Methods 
Cell culture and cell lines
HEK293-FT cells and BCP-ALL cell lines, RS4;11 and Nalm6, were cultured in DMEM 
GlutaMAX medium (Life Technologies) or RPMI 1640 GlutaMAX medium (Life 
Technologies), respectively. Culture media were supplemented with 10% heat inactivated 
fetal calf serum (HI-FCS) and 1% Penicillin/Streptomycin (P/S) (Invitrogen). Cells were 
maintained in a humidified incubator at 37 °C with 5% CO2.  
Lentiviral production and transduction 
Virus particles were produced by transient transfection of HEK293-FT cells with a 
combination of pLKO.1, ps-PAX2 and VSV-G using Lipofectamine 2000 (Invitrogen). 
After 48 hours, viral supernatant was harvested, filtered, concentrated and leukemia 
cell lines were transduced in the presence of 1μg/mL polybrene via spin inoculation 
and 24 hours after transduction selected with 1μg/mL puromycin. The guide RNA 
(gRNA) for IKZF1 exon 3 (Forward: CACCGCTCCAAGAGTGACAGAGTCGT,Reverse: 
AAACACGACTCTGTCACTCTTGGAGC) was cloned into the lenti-viral vector pLKO.1 
containing CAS9. CRISPR activity was confirmed via Surveyor® Mutation Detection in 
cell pools. Subsequently, IKZF1-gRNA and control non-targeting (NT)-gRNA (Forward: 
CACCGGTAGCGAACGTGTCCGGCGT, Reverse: AAACACGCCGGACACGTTCGCTACC) 
transfected cells were single cell cloned and screened for IKZF1 expression via western 
blotting and sequencing. The generation of IKZF1-shRNA and control non-targeting NT-
shRNA cell lines has been described previously [18].
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Primary patient samples 
Bone marrow patient samples were obtained from the Dutch Childhood Oncology group 
(DCOG). In accordance with the Declaration of Helsinki, written informed consent was 
obtained from parents or legal guardians, and institutional review boards approved the 
use of excess diagnostic material for research purposes. 
Automated drug screen
In an automated drug screen approach, we challenged IKZF1KO cells and Nalm6 Non-
targeting (NT) controls for 72 hours with a library of drugs containing 88 different 
compounds that are already used, or under evaluation for the treatment of pediatric 
cancers. Viability was assessed using CCK-8 colorimetric cell viability assay. Details of the 
automated drug screen procedure were described previously [26,27].
Cell viabilty assays
AraC, Gemcytabine, Cladribine, Clofarabine, Fludarabine, Methotrexate, 6-MP, 6-TG 
(all Centrafarm, Etten-Leur, the Netherlands) Tetrahydrouridine (THU, Abcam) and 
Zebularine (ZEB, Sigma) were dissolved according to the manufacturer´s guidelines. To 
measure therapy response in the model cell lines, a number of different apoptotic assays 
was used. BCP-ALL cell lines were cultured for 72 hours in the absence or presence of the 
chemotherapeutic agents. After this, viability was measured by amine staining, MTS and 
PARP Cleavage. Leukemic cells were analyzed by Fluorescence Activated Cell Sorting 
(FACS) using an LSRII flow cytometer (BD Biosciences, Breda, The Netherlands). Cell 
membrane integrity as a measure of cell death following exposure to antimetabolites was 
measured by amine staining with the LIVE/DEAD™ Fixable Dead Cell Stain Sampler Kit 
(Thermo-Fischer, L34960). This was performed according to the manufacturers protocol 
and assayed by flowcytometry.  For co-culture experiments, MSCs were gated out via FSC/
SSC gating. A representative gating strategy can be found in the supplement. The data 
were collected and analyzed by FlowJo V10 software (FlowJo, Ashland, Oregon).
Mitochondrial activity as a measure for viability was determined using an MTS assay. 
For this, cells were seeded at a density of 1.0*105 in a flat bottom 96-wells plate. Cell 
were treated with a broad variety of single agent chemotherapies in an increasing 
concentration and incubated for 72 hours. After incubation, 20 μL Cell Titer Aqueous ONE 
Solution (Promega) was added to each well and incubated for 3 hours and cell viability was 
determined via measuring the absorbance at 492 nm. Absorbance data was normalized to 
the untreated sample for each cell type.
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Mouse studies and generation of patient-derived xenografts
Generation of C57BL/6J Ikzf1+/- mice and experimental procedure to obtain B cells has 
been previously described [18,28]. For patient-derived xenograft (PDX) models, NOD.
Cg-PrkdcscidIl2rgtm1Wjl/SzJ mice (NSG-mice) were used. Mice were maintained under 
specific pathogen-free conditions at our Central Animal Laboratory facility. All animal 
experiments were approved by the Animal Experimental Committee of the Radboud 
university medical center and were performed in accordance with institutional and 
national guidelines. For the expansion of primary patient cells, non-conditioned NSG 
mice were injected intrafemurally with 0.5-1x106 viable cells. After 2-4 months these mice 
developed leukemia with an immunophenotype and genetic composition that in the large 
majority of cases is identical to the original material at the time of injection. Leukemic 
cells were harvested by flushing femurs with RPMI medium containing 10% FBS and 50μM 
β-Mercaptoethanol (Gibco). Leukemic blasts from spleen were isolated through a 70μM 
filter using RPMI medium containing 10% FBS and 50μM β-Mercaptoethanol. The ex vivo 
co-culture has been described previously [26]. In short, hTERT immortalized mesenchymal 
stem cells (MSCs) [29,30] were seeded in a 96-wells format and allowed to settle for 24 
hours prior to the addition of ALL xenografts. ALL cells were allowed to settle for 24 
hours before chemotherapeutic agents were added in increasing concentrations. After 
3 days of incubation, cell death was analyzed by Amine staining using flow cytometry 
(Supplemental Figure 1).
Quantitative RT-PCR
RNA was extracted using a RNeasy minikit (Qiagen) according to the manufacturer´s 
protocol. This was followed by Superscript cDNA synthesis (Bio-Rad, Hercules, 
CA), according to manufacturer´s protocols. CDA mRNA expression levels in 
NALM6, RS4;11 and murine splenocytes were determined by quantitative PCR 
reactions using Power SYBR® Green PCR master mix (Applied Biosystems, Carlsbad, 
CA) in combination with mouse specific (Forward:ATGGCACATTCGTAGTCAGG 
Reverse: CTTCCAAGAGCCGTTCCTTAG) or human specific (Forward: 
CCGGATGGTACGTATATTGTCATG, Reverse: TTATGAAGTTCTCCAGGTGGC) CDA primers 
in the CFX96 TouchTM Real-Time PCR detection system (Bio-Rad, Hercules, CA, USA). Mouse 
and human CDA mRNA expression levels were normalized to mouse HPRT (Forward: 
TCGGTCGGAGATGATCTCTCAAC, Reverse: AGAGGTCCTTTTCACCAGCA) and human 
HPRT (Forward: GGTCCTTTTCACCAGCAAGCT, Reverse: TGACACTGGCAAAACAATGCA) 
respectively. HPRT mRNA expression was used as a reference to obtain the relative fold 
expression of target genes using the comparative cycle threshold 2(-ΔΔCt) method. 
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Western blot analysis
Leukemic cells were lysed in laemmli protein sample buffer and treated with 
benzonuclease for 30 minutes, prior to boiling. Proteins were isolated to determine the 
extent of PARP cleavage as a measure of apoptosis and for expression levels of relevant 
proteins. Purified proteins were separated by SDS-PAGE and then transferred to PVDF 
membranes (Amersham Biosciences). After protein transfer, membranes were blocked 
according to the specific antibody and stained with primary antibodies for PARP (9542, 
Cell signaling), IKZF1 (AF4984, R&D systems) and ↑-Tubulin (T6557, Sigma). After 
incubation, membranes were washed in PBS-0.02% Tween, followed by horseradish 
peroxidase (HRP) conjugated secondary antibody. Proteins were visualized with ECL 
reagent (GE Healthcare) and expression was detected with Fluorchem (Cell biosciences, 
Santa Clara, USA). Quantification was performed with AlphaView software version 3.3.10 
(Cell biosciences, Santa Clara, USA).
CDA activity measurements
CDA activity in cell lysates was determined by photometric detection of the ammonia 
release after reaction with Nessler reagent (Sigma-Aldrich). In brief, 50x106 viable cells 
were lysed by shear stress in buffer consisting of 0.07 M potassium dihydrogenphosphate 
and 0.07 M disodium hydrogenphosphate (adjusted to pH 7.5) [31]. Lysates were 
centrifuged for 5 min at maximum speed (14.000 rpm). Subsequently 20 μL supernatant 
was incubated with 80 μL 4 μM cytidine with or without 100 μM Tetrahydrouridine 
(THU, Abcam) at 37°C for 16 hours. The reaction was stopped by the addition of 62,5 μL 
of trichloroacetic acid (24.5% [w/v]; Sigma-Aldrich). After centrifugation, 15 μL of the 
supernatant was added to 120 μL of Nessler solution diluted with deionized water (1:8). 
The optical density of the solution was measured at 450 nm using the Multiskan Ascent 
plate reader (MTX Lab Systems).
Statistical analyses
Statistical analyses for cell viability assays and quantitative real-time polymerase chain 
reaction (qRT-PCR) were performed using PRISM6 (GraphPad Software, La Jolla, CA). 
For MTS assays, two-sided ANOVA was performed to assess differences between the 
best-fit curves. For the Nessler Reaction, Amine staining, PARP cleavage and qRT-PCR, a 
student’s t test was performed. For the ex vivo patient-derived xenograft data (Live/dead 
staining), the statistical significance in the IKZF1–deleted group versus IKZF1-WT group 
was calculated using the best fit area under the curve method using PRISM6 (GraphPad 
Software, La Jolla, CA). All statistical tests were performed two-sided and P values of less 
than 0.05 were considered statistically significant.
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Results 
Loss of IKZF1 drives resistance to pyrimidine analogs cytarabine and 
gemcitabine in BCP-ALL cell lines
We and others have recently shown that IKZF1 alterations contribute to therapy resistance 
to leukemic cells via distinct mechanisms, including enhanced cell adhesion and 
modulation of glucocorticoid response [16,18]. However, the effect of IKZF1 aberrations 
on the response to other drugs normally used in ALL treatment has not been investigated. 
Recent studies suggest that B cell developmental genes such as IKZF1 are capable of 
altering the metabolic state of expanding leukemic cells [21], which in principle, could 
affect response to antimetabolites. While antimetabolites are closely resembling the 
chemical structure of their natural counterparts, these chemical analogs incorporate into 
the DNA during DNA repair and replication to induce apoptosis. Here, we investigated 
whether loss of IKZF1 function affects sensitivity to specific chemotherapeutic drugs 
using Nalm6 pre-B ALL cells that were either wild type for IKZF1 or carried a heterozygous 
loss of function allele (IKZF1KO), obtained by CRISPR/CAS9-mediated targeting of the 
IKZF1 locus. Western blot analysis confirmed successful reduced expression of the target 
protein (Figure 1A). In an automated drug screen, we challenged IKZF1KO cells and NT 
control cells with a library of drugs containing 88 different compounds that are already 
used, or under evaluation for the treatment of pediatric cancers and measured viability 
via an CCK-8 colorimetric cell viability assay [26] (Supplementary Table 1). We observed 
that for the pyrimidine analogs gemcitabine and cytarabine (AraC) the IC50 concentration 
of IKZF1KO cells was about 1000-fold increased, compared to control cells (Figure 1B). 
To confirm the observed resistance phenotype by independent cell viability assays, 
we determined accessible amine as indicator of cell membrane integrity (Figure 1C) or 
assessed sub-G1-phase with a cell cycle profile (Figure 1D) as direct measurement of 
apoptosis with flow cytometry. Both assays confirmed that IKZF1 KO cells were significantly 
more resistant to AraC and gemcitabine treatment. In line with these observations, we 
found that shRNA-mediated knockdown of IKZF1 in Nalm6 and RS4;11 led to pyrimidine 
analog resistance (Supplemental Figure 2), while a similar phenotype was observed in 
mouse Ikzf1-haplodeficient B cells (Supplemental Figure 3).
To validate the observed resistance to pyrimidine analogs in a model more closely 
resembling ALL in the patient, we exposed primary leukemic cells expanded as patient-
derived xenograft (PDX) models to AraC using an ex vivo MSC co-culture system [26,32] 
(Figure 1E). Consistent with our previous findings in BCP-ALL cell lines, samples obtained 
from IKZF1-deleted tumors (n=5) were significantly more resistant to AraC (10logIC50 3.2 
nM), relative to xenografts wild type for IKZF1 (IKZF1-WT; n=5) (10logIC50 1.8 nM) (Figure 
1E/F/G). Intriguingly, while the overall response to AraC was attenuated in all IKZF1-
deleted samples, in four out of five cases, a sub-population of leukemic cells was observed 
that was completely refractory to AraC (Figure 1F). 
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Figure 1 Loss of IKZF1 induces resistance to pyrimidine analogs in BCP-ALL cell lines and patient 
derived xenografts (A) A single allele of the IKZF1 gene was disrupted by CRISPR/Cas9-mediated 
genome editing introducing a frame shift mutation in Nalm6 cells. Cells were subcloned and were 
evaluated for IKZF1 expression using Western blot. (B) Nalm6 control or IKZF1KO cells were treated 
for 72 hours with increasing concentrations of AraC (left panel) or gemcitabine (right panel) and 
analyzed using an MTT based viability assay. All values were normalized to untreated Nalm6 cells. 
Error bars represent ± standard error of the mean (SEM). (C) Nalm6 control and IKZF1KO cells were 
either treated with 500 or 1000nM AraC or left untreated for 72 hours before the presence of 
apoptotic cells was measured by flow cytometry using amine staining based on cell membrane 
integrity. (D) DNA fragmentation was assayed in the same cells by flow cytometry using Hoechst 
dye to detect the sub-G1 (apoptotic) fraction. (E) Schematic overview representing the workflow 
used to test drug sensitivity in PDX samples. Briefly, hTERT immortalized MSCs were seeded in a 
96 wells format and allowed to settle for 24 hours prior to the addition of ALL xenografts. Cells 
were allowed to settle for 24 hours before AraC was added in increasing concentrations. (F) After 
3 days of incubation, cell death was analyzed by 7AAD staining using flow cytometry. (G) AraC log 
IC50 of the graphs in F were calculated. Asterisks indicate a significant difference: ** p<0.01
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Figure 2 Inhibition of Cytidine Deaminase (CDA) in IKZF1KO cells reverses their resistance 
phenotype against AraC (A) Schematic overview of of AraC and gemcitabine metabolism. (B) 
Relative mRNA expression of CDA in Nalm6 and IKZF1KO cells as measured by real time quantitative 
PCR. Data are normalized for HPRT expression and shown as mean ± SD of n = 3. Statistical 
significance was determined by unpaired 2-sided t test. **P < 0.01. (C) Nalm6 NT controls and 
IKZF1KO cells were treated for 72 hours with increasing concentrations of AraC (left panel) or 
gemcitabine (right panel) in the presence or absence of the CDA inhibitor zebularine (ZEB; 100 
ng) or tetrahyrouridine (THU, 100uM) and analyzed using an MTT based viability assay. (D) Nalm6 
control and IKZF1KO cells were either treated with 500 or 1000nM AraC in the presence or absence 
of ZEB or THU for 72 hours before the presence of apoptotic cells was measured by flow cytometry 
using amine staining (n=3) (E) The same cells were analyzed for caspase activity as measured by 
PARP cleavage using Western blot. A representative example of multiple experiments (n = 3) is 
shown.
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Pyrimidine resistance induced by IKZF1 loss is a result of increased 
cytidine deaminase activity
Previous studies have identified the metabolic enzyme cytidine deaminase (CDA) as a key 
determinant of AraC therapy response both in ALL and AML [22,23]. CDA catalyzes the 
deamination of cytosine to uracil as part of the nucleotide salvage pathway [22], but it also 
catalyzes the conversion of AraC into AraU, leading to inactivation of the drug (Figure 2A). 
Using quantitative RT-PCR, we observed a 3 to 4-fold increase in CDA mRNA expression 
in our model cell line Nalm6 (Figure 2B). Consistent with this observation, B cells isolated 
from 8 to 14 weeks-old Ikzf1+/-- mice showed a significant increase in CDA mRNA levels 
(Supplemental Figure 4).
To further investigate the relation between CDA activity in IKZF1KO cells and AraC 
resistance in BCP-ALL, we exposed Nalm6 IKZF1KO cells and controls to two independent 
pharmacological inhibitors of CDA, Zebularine (Zeb) or tetrahydroyuridine (THU) in the 
presence of AraC. For both inhibitors, concentrations were chosen that do not affect cell 
viability as a single agent (Supplemental Figure 5). However, in combination with AraC, 
both Zeb and THU restored pyrimidine analog sensitivity of IKZF1KO cells to control levels 
in MTS assays (Figure 2C). We were able to validate the inhibitor-mediated reversal of AraC 
sensitivity by amine staining (Figure 2D). Additionally, determination of PARP cleavage 
indicated that pharmacological inhibition of CDA effectively re-sensitizes IKZF1KO cells to 
pyrimidine analogs (Figure 2E). 
To test whether CDA activity is indeed elevated in IKZF1KO cells, we assayed enzyme 
activity in cells lysates from WT and IKZF1KO Nalm6. For this, we measured the release of 
ammonia following the deamination of cytidine using a Nessler reaction. Compared to 
control lysates, those obtained from IKZF1KO cells showed a strong increase in CDA activity 
as measured by the formation of amines during the Nessler reaction. In line with previous 
observations, treatment of IKZF1KO lysates with the CDA inhibitor THU was sufficient to 
restore CDA activity to levels comparable to that of the control lysates (Figure 3). We 
conclude from these experiments that increased activity of CDA contributes greatly to 
AraC resistance in IKZF1-deleted BCP-ALL. 
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Figure 3 Loss of IKZF1 function leads to increased CDA activity. Lysates from Nalm6 NT control 
C1 and C2 and IKZF1KO cells were incubated with a cytidine containing buffer for 16 hours. 
Ammonia release was analyzed by absorbance measurements after a Nessler reaction. The CDA 
inhibitor tetrahyrouridine (THU) was added to confirm contribution of CDA in this reaction. 
Results represent the mean and standard deviation from two independent experiments performed 
in duplicate.
 
 
Figure 4 IKZF1KO cells show differential sensitivity to adenine-containing antimetabolites
(A) Structural formula of three different adenine-containing antimetabolites. (B) Nalm6 NT 
controls or IKZF1KO cells were treated for 72 hours with increasing concentrations of fludarabine, 
cladribine and clofarabine and analyzed using a MTT based viability assay. All values were 
normalized to untreated Nalm6 cells. Error bars represent ± standard error of the mean (SEM) 
from 3 independent experiments. 
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Loss of IKZF1 function affects the cellular response to other 
antimetabolites 
In addition to pyrimidine analogs, we determined the response to three adenine-containing 
nucleosides, clofarabine, cladribine and fludarabine (Figure 5) in IKZF1KO knockout cells. 
While no difference in cellular sensitivity was found to clofarabine between control and 
IKZF1KO cells, we observed high resistance to cladribine in IKZF1KO cells. Surprisingly, the 
IC50 to fludarabine was significantly lower for IKZF1KO cells in comparison to control cells, 
where IKZF1KO cells appeared to be about five-fold more sensitive to fludarabine. In view 
of these findings, it will be important to investigate whether antimetabolites other than 
AraC, such as fludarabine or clofarabine, may be used to enhance cellular response to 
therapy in IKZF1-deleted ALL.
Discussion 
Pyrimidine analogs, such as AraC and gemcitabine, are common components of leukemia 
treatment regimens. Resistance to these drugs remains a problem in the effective 
treatment of hematopoietic malignancies, and methods to predict resistance in patients 
are needed. In this study, we demonstrate that loss of IKZF1 confers resistance to 
pyrimidine analogs both in BCP-ALL cell line model system as well as in ex vivo PDX of 
primary BCP-ALL. In addition, we show that an increase in CDA expression and activity 
drives this resistance in IKZF1-deleted BCP-ALL. 
Exposing IKZF1KO cells to two independent specific inhibitors of CDA, ZEB and THU, re-
sensitized these cells to AraC and Gemcitabine. However, to further support the relation 
between increased CDA expression and AraC resistance in IKZF1KO cells, shRNA-mediated 
knockdown of CDA in IKZF1KO cells should be performed. In addition, CRISPR-CAS9 
mediated knockout of CDA in BCP-ALL cell lines will further shed light on the direct 
effect of CDA in drug sensitivity in BCP-ALL independent of IKZF1 aberrations. To further 
support the observation that loss of IKZF1 function enhances the activity of CDA, lysates 
from wild-type and IKZF1-deleted primary patient samples should also be measured in a 
deamination assay to further demonstrate that AraC resistance is a direct consequence of 
enhanced CDA activity
Although our results would suggest that pharmacological inhibition of CDA could be of 
potential use in vivo, CDA activity in the liver or other organs protects these cells from 
AraC induced toxicities during treatment. Thus, strategies aimed at systemically reducing 
CDA activity will likely result in severe toxicities. Therefore, identification and targeting 
of hematopoietic-cell specific regulators of CDA may be used to selectively enhance 
sensitivity to AraC in leukemic cells in the future. In contrast to the findings in our model 
cell lines, we did not observe an effect of the pharmacological inhibitors Zeb and THU on 
AraC sensitivity in our ex vivo co-culture experiments (data not shown). We attribute this 
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phenomenon to the MSC feeding layer, which is described to function as a “sink” for certain 
drugs and inhibitors, in which the MSC feeding layer metabolizes drugs before they can 
affect the supported leukemic cells [33]. In addition, the impact of deoxycytidine kinase as 
functional opponent of CDA should be studied to fully understand how AraC is metabolized 
in IKZF1KO cells [34]. The differential sensitivity to AraC, but not other antimetabolites, 
argues that not a generic apoptotic pathway, but rather a specific metabolic pathway is 
responsible for the observed resistance phenotype. CRISPR/CAS9 based reverse genetics 
screens could identify pathway components that enhance response to AraC, for instance 
by regulating the expression of CDA. Most ALL treatment protocols rely on combinations 
of nucleoside analogs including Cytarabine (AraC), 6-mercaptopurine (6MP) and other 
antimetabolites, such as the antifolate methotrexate (MTX) during consolidation phase 
[35]. This makes it difficult to assess the leukemia response to individual components of 
the treatment
The finding that IKZF1KO cells show a differential response to adenine-containing 
nucleosides clofarabine, cladribine and fludarabine was unexpected. While no difference 
in cellular sensitivity was found to clofarabine between wild type or IKZF1KO cells, IKZF1-
deleted cells were highly resistant to cladribine. In contrast, IKZF1KO cells were highly 
sensitive to fludarabine. These findings suggest that treatment of IKZF1-deleted tumors 
may benefit from a switch from cladribine to clofarabine or the addition of fludarabine 
to the protocol. We found that IKZF1-deleted PDX samples from our collection were 
significantly resistant to AraC, but we need to evaluate historical data and confirm the 
phenotype in a broader cohort to fully capture the genetic complexity of IKZF1 deletions. 
Several studies indicate that the genetic context of IKZF1 deletions is important because 
co-occurring genetic events in this so-called IKZF1Plus patient group can alter the 
prognostic value of IKZF1 deletions [36]. For example, we have recently established that 
combined loss of BTG1 and IKZF1 represents a patient group with poor outcome in ALL 
and is characterized by a strong GC- resistance phenotype [37]. In contrast, the presence 
of ERG deletions has been shown to negate the negative effect of IKZF1-deletions on 
outcome [38]. Future efforts should therefore include these more complex genetic cases 
to understand whether IKZF1Plus cases differ in their response to pyrimidine analogs. 
Remarkably, our PDX models revealed that 4 out of 5 IKZF1 deleted cases contained a 
completely resistant fraction even under high concentrations of AraC. We speculate 
that clonal differences within these PDX contribute to this phenomenon and it would 
be interesting to fully genetically characterize those subclonal populations selected by 
chemotherapy to identify drivers of resistance in those IKZF1-deleted PDX models. In this 
context, poor responses to pyrimidine analogs have been observed to be enriched in a 
cohort of BCR-ABL-like leukemias [39]. These “B-others” show and increased incidence of 
relapse, while deletions of IKZF1 are prevalent. Therefore, it would be interesting to see 
whether IKZF1 deletions can also be linked to AraC resistance in this leukemia subgroup. 
Although IKZF1 is primarily a regulator of lymphoid development, there is evidence 
supporting a role for this transcriptional regulator in myeloid differentiation. For 
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instance, IKZF1 is implicated in megakaryopoiesis, which involves cooperation with 
transcriptional regulators such as RUNX1 and GATA1 [40]. Moreover, deletions in IKZF1 
were found to occur during progression from myeloid proliferative neoplasms to AML 
[41]. Indeed, deletion of chromosome seven, which harbors the IKZF1 gene, is associated 
with poor outcome in AML [42], although response to AraC in this AML subgroup has not 
been determined. We therefore hypothesize that loss of IKZF1 may contribute to AraC 
resistance not only in ALL but also in AML. Given the fact that AraC is a cornerstone of 
AML treatment and CDA activity is a key determinant of AraC responsiveness in AML, 
future efforts should therefore explore the relation between IKZF1 and AraC resistance 
and the underlying regulatory network in ALL and AML.
Conclusion
Taken together, this study highlights a role for loss of IKZF1 in resistance to pyrimidine 
analogs. Currently, treatment protocols are already adjusted based on IKZF1 status, in 
which patients with IKZF1-deleted leukemia receive a higher dose of methotrexate and an 
extra year of consolidation therapy. Based on our findings, replacing AraC with alternative 
antimetabolites  may be considered for this ALL subgroup. For instance, the introduction 
clofarabine or fludarabine in upfront protocols may prevent the outgrowth of resistant 
clones and consequently reduce the number of relapses in IKZF1-deleted ALL.
CHAPTER 6
158
References 
1 Pui, C.H., et al., Biology, risk stratification, and therapy of pediatric acute leukemias: an 
update. J Clin Oncol, 2011. 29(5): p. 551-65.
2 Sobol, R.E., C.D. Bloomfield, and I. Royston, Immunophenotyping in the diagnosis and 
classification of acute lymphoblastic leukemia. Clin Lab Med, 1988. 8(1): p. 151-62.
3 Moricke, A., et al., Prognostic impact of age in children and adolescents with acute 
lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95. Klin Padiatr, 2005. 
217(6): p. 310-20.
4 Dordelmann, M., et al., Prednisone response is the strongest predictor of treatment 
outcome in infant acute lymphoblastic leukemia. Blood 1999 Aug 15; 94(4): p.1209-1217.
5 Yamada, M., et al., Minimal residual disease in childhood B-lineage lymphoblastic leukemia. 
Persistence of leukemic cells during the first 18 months of treatment. N Engl J Med, 1990. 
323(7): p. 448-55.
6 van Dongen, J.J., et al., Prognostic value of minimal residual disease in acute lymphoblastic 
leukaemia in childhood. Lancet, 1998. 352(9142): p. 1731-8.
7 Brisco, M.J., et al., Outcome prediction in childhood acute lymphoblastic leukaemia 
by molecular quantification of residual disease at the end of induction. Lancet, 1994. 
343(8891): p. 196-200.
8 Pieters, R., et al., Relation of cellular drug resistance to long-term clinical outcome in 
childhood acute lymphoblastic leukaemia. Lancet, 1991. 338(8764): p. 399-403.
9 Iacobucci, I. and C.G. Mullighan, Genetic Basis of Acute Lymphoblastic Leukemia. J Clin 
Oncol, 2017. 35(9): p. 975-983.
10 Pui, C.H., et al., Clinical impact of minimal residual disease in children with different 
subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy. 
Leukemia, 2017. 31(2): p. 333-339.
11 Kuiper, R.P., et al., High-resolution genomic profiling of childhood ALL reveals novel 
recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell 
cycle progression. Leukemia, 2007. 21(6): p. 1258-66.
12 Mullighan, C.G., et al., Genome-wide analysis of genetic alterations in acute lymphoblastic 
leukaemia. Nature, 2007. 446(7137): p. 758-64.
13 Iacobucci, I., et al., IKZF1 (IKAROS) deletions as a prognostic marker in BCR-ABL1 positive 
acute lymphoblastic leukemia patients: A GIMEMA ALL WP Report. J Clin Oncol, 2009. 
27(15_suppl): p. 11005.
14 Kuiper, R.P., et al., IKZF1 deletions predict relapse in uniformly treated pediatric precursor 
B-ALL. Leukemia, 2010. 24(7): p. 1258-64.
15 Mullighan, C.G., et al., Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N 
Engl J Med, 2009. 360(5): p. 470-80.
16 Churchman, M.L., et al., Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute 
Lymphoblastic Leukemia. Cancer Cell, 2015. 28(3): p. 343-56.
17 Churchman, M.L., et al., Synergism of FAK and tyrosine kinase inhibition in Ph(+) B-ALL. JCI 
Insight, 2016. 1(4).
18 Marke, R., et al., Tumor suppressor IKZF1 mediates glucocorticoid resistance in B cell 
precursor acute lymphoblastic leukemia. Leukemia, 2016. 30(7): p. 1599-603.
19 Boroughs, L.K. and R.J. DeBerardinis, Metabolic pathways promoting cancer cell survival and 
growth. Nat Cell Biol, 2015. 17(4): p. 351-9.
20 Palm, W. and C.B. Thompson, Nutrient acquisition strategies of mammalian cells. Nature, 
2017. 546(7657): p. 234-242.
21 Chan, L.N., et al., Metabolic gatekeeper function of B-lymphoid transcription factors. 
Nature, 2017. 542(7642): p. 479-483.
LOSS OF IKZF1 CONFERS RESISTANCE TO PYRIMIDINE ANALOGS IN BCP-ALL
159
22 Galmarini, C.M., J.R. Mackey, and C. Dumontet, Nucleoside analogues: mechanisms of drug 
resistance and reversal strategies. Leukemia, 2001. 15(6): p. 875-90.
23 Ge, Y., et al., The role of cytidine deaminase and GATA1 mutations in the increased cytosine 
arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Cancer Res, 
2004. 64(2): p. 728-35.
24 Meyer, J.A., et al., Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic 
leukemia. Nat Genet, 2013. 45(3): p. 290-4.
25 Tzoneva, G., et al., Activating mutations in the NT5C2 nucleotidase gene drive 
chemotherapy resistance in relapsed ALL. Nat Med, 2013. 19(3): p. 368-71.
26 Frismantas, V., et al., Ex vivo drug response profiling detects recurrent sensitivity patterns in 
drug-resistant acute lymphoblastic leukemia. Blood, 2017. 129(11): p. e26-e37.
27 Fischer, U., et al., Genomics and drug profiling of fatal TCF3-HLF-positive acute 
lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat 
Genet, 2015. 47(9): p. 1020-1029.
28 Souabni, A., et al., Pax5 promotes B lymphopoiesis and blocks T cell development by 
repressing Notch1. Immunity, 2002. 17(6): p. 781-93.
29 Manabe, A., et al., Bone marrow-derived stromal cells prevent apoptotic cell death in 
B-lineage acute lymphoblastic leukemia. Blood, 1992. 79(9): p. 2370-7.
30 Iwamoto, S., et al., Mesenchymal cells regulate the response of acute lymphoblastic 
leukemia cells to asparaginase. J Clin Invest, 2007. 117(4): p. 1049-57.
31 Okamura, T., et al., Cytidine deaminase activity in abnormal pregnancy. Int J Gynaecol 
Obstet, 1993. 41(1): p. 53-60.
32 Bonapace, L., et al., Induction of autophagy-dependent necroptosis is required for childhood 
acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest, 
2010. 120(4): p. 1310-23.
33 Kucerova, L., et al., Altered features and increased chemosensitivity of human breast cancer 
cells mediated by adipose tissue-derived mesenchymal stromal cells. BMC Cancer, 2013. 13: 
p. 535.
34 Veuger, M.J., et al., Deoxycytidine kinase expression and activity in patients with resistant 
versus sensitive acute myeloid leukemia. Eur J Haematol, 2002. 69(3): p. 171-8.
35 Cooper, S.L. and P.A. Brown, Treatment of pediatric acute lymphoblastic leukemia. Pediatr 
Clin North Am, 2015. 62(1): p. 61-73.
36 Stanulla, M., et al., IKZF1(plus) Defines a New Minimal Residual Disease-Dependent Very-
Poor Prognostic Profile in Pediatric B cell Precursor Acute Lymphoblastic Leukemia. J Clin 
Oncol, 2018. 36(12): p. 1240-1249.
37 Scheijen, B., et al., Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia 
development and increase relapse risk in B cell precursor acute lymphoblastic leukemia 
patients. Haematologica, 2017. 102(3): p. 541-551.
38 Zaliova, M., et al., ERG deletion is associated with CD2 and attenuates the negative impact 
of IKZF1 deletion in childhood acute lymphoblastic leukemia. Leukemia, 2014. 28(1): p. 
182-5.
39 Den Boer, M.L., et al., A subtype of childhood acute lymphoblastic leukaemia with poor 
treatment outcome: a genome-wide classification study. Lancet Oncol, 2009. 10(2): p. 125-
34.
40 Malinge, S., et al., Ikaros inhibits megakaryopoiesis through functional interaction with 
GATA-1 and NOTCH signaling. Blood, 2013. 121(13): p. 2440-51.
41 Jager, R., et al., Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. 
Leukemia, 2010. 24(7): p. 1290-8.
42 Hasle, H., et al., Monosomy 7 and deletion 7q in children and adolescents with acute 
myeloid leukemia: an international retrospective study. Blood, 2007. 109(11): p. 4641-7.
CHAPTER 6
160
Supplemental Information Chapter 6
Supplementary Table 1 An automated drug screen was used to compare the efficacy of 88 
different compounds in Nalm6 leukemic cells, either wild type for IKZF1 or carrying a deletion 
affecting IKZF1 expression or function.  Indicated in this table are those drugs that elicit reduced 
cellular responses in IKZF1-deleted cells relative to controls. + indicates degree of resistance,  the 
more +, the more resistant the IKZF1-deleted cells.
Drug Working mechanism Reduced cellular response in IKZF1 
deleted ALL
Nutlin Inhibition of MDM2,p53 upregulation +
Methotrexate Inhibits de novo DNA synthesis +
6-MP inhibits purine nucleotide synthesis -+
Obatoclax Bcl-2 inhibitor -+
ZM-447439 ATP-competitive inhibitor for Aurora 
A and Aurora B
++
XL228 inhibitor targeting IGF1R, the Aurora kinases, 
FGFR1-3, ABL and SRC family kinases
++
Dexamethasone Synthetic Glucocorticoid +
I3 Notch +
AZD1152-HQPA Aurora Inhibitor -+
Velcade proteasome inhibitor ++
AT9283 Aurora Inhibitor +
Mitoxantrone type II topoisomerase inhibitor, it dis-
rupts DNA synthesis and DNA repair
++
Gemcitabine nucleoside analog family of medication. It 
works by blocking the creation of new DNA
+++
Cytarabine Interferes with DNA synthesis in S phase ++
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Supplementary Figure 1 Representative gating strategy of primary xenografted patient samples 
on an MSC co-culture. After gating out debris from the viable cell population and the exclusion of 
doublets, population was further analyzed by amine staining.
Supplemental Figure 2 Nalm6 (Upper panel) and RS4,11(Lower panel) transfected with control 
or IKZF1-shRNA were treated for 72 hours with increasing concentrations of AraC and analyzed 
using an MTT based viability assay. All values were normalized to untreated Nalm6 cells. Error bars 
represent ± standard error of the mean (SEM).
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Supplemental Figure 3 LPS-activated B cells isolated from wild-type and Ikzf1+/-  mice were 
incubated for 72 hours with increasing concentrations of AraC and analyzed using an MTT based 
viability assay. All values were normalized to untreated B cells. Error bars represent ± standard 
error of the mean (SEM).
Supplemental Figure 4 Relative mRNA expression of Cda in B cells isolated from wild-type and 
Ikzf1+/-  mice as measured by real time quantitative PCR. Data are normalized for HPRT expression 
and shown as mean ± SD of n = 3. Statistical significance was determined by unpaired 2-sided t 
test. **P < 0.01.
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Supplemental Figure 5 Nalm6 were incubated for 72 hours with increasing concentrations of 
either Zebularine or Tetrahydrouridine and analyzed using an MTT based viability assay. All values 
were normalized to untreated Nalm6 cells. Error bars represent ± standard error of the mean 
(SEM).
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Summary 
B cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most common 
malignancy in children. During the last decades, improvements in risk stratification and 
treatment protocols have led to cure rates of almost 90% in BCP-ALL. However, still 
approximately 10 % of all BCP-ALL patients relapse after initial treatment success, often 
due to chemotherapy resistance. To understand why these leukemic cells are resistant to 
chemotherapy, we have to acknowledge that tumors are characterized by a broad variety 
of cytogenetic aberrations. Many of these are correlated with the survival outcome of 
BCP-ALL patients. Next to this, small genomic aberrations (deletions, mutations) are 
commonly detectable in BCP-ALL. Among the most prominent examples are aberrations 
affecting the IKZF1 gene. In approximately 15-20% of all pediatric BCP-ALL patients IKZF1 
aberrations can be detected, and several studies have shown that loss of IKZF1 represents 
an independent poor prognostic factor in BCP-ALL. However, a direct link between loss of 
IKZF1 and chemotherapy resistance had remained elusive at the start of this thesis work.
Since the start of my PhD project in 2014, much has been learned about the molecular 
mechanisms related to the effects of IKZF1 loss on treatment outcome. Chapter 2 
of my thesis reviews the role of IKZF1 in chemotherapy resistance and summarizes 
recent findings on the potential molecular mechanisms underlying IKZF1-mediated 
chemotherapy resistance. In chapter 3, we established that single copy losses of IKZF1 
contribute to a poor response to synthetic glucocorticoids (GCs), both in genetic models 
as well as in patients. To examine whether loss of the tumor suppressor IKZF1 directly 
causes resistance to chemotherapeutic agents commonly used in the treatment of BCP-
ALL, we studied loss of IKZF1 in a broad variety of model systems. We found that loss of 
IKZF1 conferred a strong resistance to synthetic GCs both in B cells isolated from Ikzf1+/- 
mice and BCP-ALL cell lines displaying loss of IKZF1 function through knockout (CRISPR/
CAS9) and knockdown (short hairpin RNA) approaches. Furthermore, analysis of historical 
ex vivo MTT data obtained from the Dutch Childhood Oncology Group revealed that IKZF1-
deleted leukemic cells were significantly more resistant to GCs than wild type leukemic 
cells. Moreover, IKZF1 deletions were highly enriched in leukemias showing a poor initial 
response to GC therapy (Prednisone day 8 response). Microarray gene expression analysis 
comparing wild-type versus Ikzf1+/- B cells with or without GC treatment revealed that the 
activation of GC-target genes is strongly diminished in Ikzf1+/- B cells. Notably, expression 
of NR3C1 (glucocorticoid receptor, GR) was not altered in any of our model systems. 
These data suggest that resistance to prednisolone in IKZF1-deleted cells is not regulated 
at the level of NR3C1 expression, but rather that mechanisms influencing GR activity or 
downstream signaling are responsible for the observed phenotype. 
In chapter 4 we describe how loss of IKZF1 reduces expression of protein phosphatase 
PTEN, leading to activation of its downstream effector AKT and AKT-specific 
phosphorylation of the GR at Ser134. The AKT inhibitor MK2206 significantly sensitized 
IKZF1-deleted cells to prednisolone. Moreover, primary patient samples carrying 
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aberrations in IKZF1 were also characterized by loss of PTEN protein expression and high 
phospho-GR levels. The GC resistance of these IKZF1-deleted samples could be reversed 
by treatment with the AKT inhibitor MK2206.  Based on these data, we would like to 
further examine the effects of AKT inhibitor treatment on GC therapy response in vivo, 
using patient-derived xenograft models and explore whether high phospho-GR levels are 
a reliable biomarker for response to AKT inhibitors in GC-resistant, IKZF1-deleted ALL.    
Despite the fact that IKZF1 deletions are a poor prognostic marker in BCP-ALL, not all 
IKZF1-deleted leukemias respond poorly to therapy, suggesting that next to IKZF1 
deletions, also other co-occurring events may impact response to therapy. In chapter 5, 
we investigated which other gene deletions co-occurred in IKZF1-deleted BCP-ALL and 
whether these impacted the prognostic value of IKZF1. We demonstrated that single 
copy loss of tumor suppressor BTG1, as well as CDKN2A, PAX5 and RB1 deletions were 
significantly enriched in IKZF1-deleted BCP-ALL. Of these co-occuring lesions, only the 
combined loss of IKZF1 and BTG1 impacted the prognostic value of IKZF1. The combined 
presence of IKZF1 and BTG1 deletions appeared to be associated with a significantly 
lower event-free survival and higher cumulative incidence of relapse in pediatric BCP-
ALL patients. To explore the cooperativity between copy number losses of IKZF1 and 
BTG1 in leukemogenesis, we examined the combined loss of Ikzf1 and Btg1 in a murine 
knockout model and observed that leukemogenesis in Ikzf1+/- mice was accelerated by 
the loss of Btg1 in a Btg1 dose-dependent manner. Moreover, combined loss of Btg1 and 
7 further enhanced GC resistance in murine splenocytes. These data provide compelling 
in vivo evidence that copy number losses in Btg1 and Ikzf1 cooperate during leukemia 
development and affect response to synthetic GCs. 
In Chapter 6 we explored the effects of IKZF1 loss on response to different antimetabolites 
commonly used in the treatment of ALL and AML. We discovered that loss of IKZF1 in 
leukemic cell lines conferred resistance to pyrimidine analogs, synthetic nucleosides 
closely resembling the chemical structure of pyrimidines. Moreover, we found that 
IKZF1-deleted primary patient samples were highly resistant to pyrimidine analogs. We 
hypothesized that upregulation of cytidine deaminase (CDA) is responsible for pyrimidine 
resistance in BCP-ALL. Indeed, we established that CDA expression levels were increased 
in IKZF1 knockout cells, accompanied by an increase in CDA activity in tumor cell lysates. 
Moreover, pharmacological inhibition of CDA restored pyrimidine analogue sensitivity 
in cell lines in which we reduced expression of IKZF1 by shRNA mediated knockdown or 
CRISPR/CAS9 mediated deletion of IKZF1. Together these data point to a pivotal role for 
IKZF1 copy number losses in mediating resistance to pyrimidine analogues. 
Overall, the results in this thesis highlight an important role for IKZF1 in chemotherapy 
resistance. Further investigations should focus on approaches to effectively modify 
pathways acting downstream of IKZF1 in order to enhance response to therapy.  
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General discussion 
This thesis aimed to study the role of IKZF1 aberrations in chemotherapy resistance in 
BCP-ALL by using Ikzf1-knockout mice, human ALL cell models lacking IKZF1 as well as 
primary leukemia patient material. In addition, we investigated if and how IKZF1 deletions 
cooperate with other co-occurring genetic events during leukemic transformation. 
Loss of IKZF1 confers glucocorticoid resistance 
GCs are crucial components in the treatment of ALL, and a poor response to GC therapy, 
is considered a predictor of poor outcome in BCP-ALL [1, 2]. GCs are highly effective drugs 
in the treatment of lymphoid malignancies and major efforts have been undertaken to 
improve their effect and to break therapy resistance.
One of the key findings in this thesis is the observation that loss of IKZF1 contributes to 
glucocorticoid (GC) resistance, both in experimental models and in childhood leukemia 
patients [3] (Chapter 3, 4 and 5). Other studies confirmed that IKZF1 deletions are 
enriched in BCP-ALL leukemia patients showing GC resistance [4]. 
In our experiments aiming to model loss of IKZF1 in leukemic cell lines, short hairpin RNA 
(shRNA)-mediated knockdown of IKZF1 Exon 3 was effective in conferring GC resistance 
in BCP-ALL cell lines Nalm6, RS4;11 and ALL-PO (Chapter 3). In contrast to this, Vitanza 
et al did not observe GC resistance in IKZF1-deleted leukemic BCP-ALL cell lines, which 
could be explained by the choice of intrinsically GC resistant cell lines (REH and SEM) in 
their study [3, 5]. Next to models reproducing loss of IKZF1, we observed that also primary 
IKZF1-deleted leukemic cells showed resistance to GCs ex vivo. Additionally, we found 
that IKZF1-deletions were significantly enriched in day 8 poor prednisone responders. 
However, not all patient samples were resistant to GCs ex vivo, which implies that other 
co-occurring genetic events could shape the resistance of IKZF1-deleted cells (Chapter 
5). For future studies, it is important to note that a broad variety of IKZF1 aberrations 
have been observed in BCP-ALL [6]. For example, it would be interesting to investigate 
the impact of the dominant–negative isoform IK6 as well as of rare IKZF1 deletions on 
GC therapy responses. Previously, loss-of-function but not dominant-negative IKZF1 
deletions have been associated with an adverse prognosis in adult acute lymphoblastic 
leukemia [7].
In our study, we analyzed historical data from ex vivo primary patient material treated 
with L-asparaginase, GCs, vincristine and 6-MP because those drugs are used during 
induction treatment [8]. However, these data historical data were limited to a restricted 
set of chemotherapies and these initial ex vivo drug screens did not contain combinations 
of therapies or novel therapeutic agents. Therefore, it would be interesting to screen more 
primary patient leukemia samples in the future using a larger panel of chemotherapeutic 
agents with state-of-the-art screening devices, in which a broad variety of novel 
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compounds, but also combinations of drugs, could be screened for their efficacy (Similar 
to our approach in chapter 6). 
We further investigated in Chapter 3 how loss of IKZF1 could lead to GC resistance and 
found that IKZF modulates the GC response by regulating Glucocorticoid Receptor (GR)-
mediated gene expression. Still, how IKZF1 functionally regulates the GR remains elusive. 
A recent study has suggested that NR3C1 expression levels are reduced due to loss of 
IKZF1 [9], however in our studies (Chapter 3 and 4) we did not observe any changes in 
NR3C1 expression but rather diminished activation of GC-target genes, potentially due 
to impaired nuclear translocation of the GR after GC stimulation (Chapter 4). Moreover, 
we observed direct regulation of GR-mediated transcription by IKZF1 on glucocorticoid 
responsive elements (GREs) in an GC-responsive luciferase reporter assay (Chapter 3). 
Chromatin immunoprecipitation and coimmunoprecipitation experiments should help 
improve our understanding of the complex interactions between IKZF1 and the GR. 
Our results show that intrinsic mechanisms of resistance affect the cells response to GCs 
in IKZF1-deleted BCP-ALL. However, other studies found that loss of IKZF1 increases 
leukemic cell adhesion to the stromal niche [10], which has led to the suggestion that this 
adhesion phenotype may contribute to chemotherapy resistance in the bone marrow 
[11]. Recently, it was shown that IKZF1 regulates the expression of epithelial membrane 
protein 1 (EMP1), a protein implicated in GC resistance [12]. Knockdown of EMP1 
sensitizes BCP-ALL cells to prednisone while abrogating adhesion of leukemic cells to 
mesenchymal stroma cells (MSCs) [13]. The bone marrow microenvironment may alter 
chemotherapy responses of leukemic cells by secretion of pro-survival chemokines by 
MSCs [14, 15]. Therefore, leukemic cells showing a loss of IKZF1 may interact with the bone 
marrow microenvironment to alter chemotherapy responses. The in vitro assays used in 
chapter 3 did not include an MSC feeding layer that allowed crosstalk between MSCs 
and leukemic cells. Still, even in the absence of these microenvironmental influences, we 
observed GC resistance in IKZF1-deleted patient samples and model systems, arguing that 
microenvironmental influences may contribute to therapy resistance in IKZF1-deleted 
BCP-ALL, but that leukemia cell intrinsic mechanisms are most likely primarily responsible 
for the observed GC resistance phenotype. 
An unexpected role for PTEN in IKZF1-deleted ALL
The PKB/AKT pathway is frequently deregulated in both solid and hematopoietic tumors 
[16]. Consistent with previous findings that suggests a role for AKT in GC resistance [17], 
we demonstrated in Chapter 4 that AKT is activated in IKZF1-deleted leukemic cells, 
which is in agreement with studies of Chan et al [9]. We further observed that activation 
of AKT in IKZF1-deleted cells involves repression of the lipid phosphatase and tumor 
suppressor PTEN, which is a key regulator of AKT [18]. Transcriptional repression of PTEN 
by loss of IKZF1 function, appears to involve, at least in part, upregulation of HES1, a 
known repressor of PTEN function in T-ALL [19] (Figure 1). However, Chapter 4 describes 
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that PTEN protein levels appear to be more strongly affected than PTEN mRNA levels, 
implying that PTEN expression is also regulated at a post transcriptional level. The notion 
that  mutations in PTEN [20, 21], and its upstream regulatory pathway NOTCH [22-24], are 
almost exclusively found in T-ALL [25], suggests therefore that PTEN is rather influenced at 
the transcriptional and/or protein level in BCP-ALL. Our finding in the model systems we 
used point to potential transcriptional regulation of PTEN via HES1 in BCP-ALL similar to 
what is described in T-ALL [26], but interaction studies will be necessary to shed more light 
on this observation and to further understand the parallels between T-ALL and BCP-ALL 
(Figure 1). 
 
Figure 1 Schematic overview of the proposed parallels in the regulation of PTEN during normal 
hematopoiesis and leukemogenesis between T and B cell leukemia. 
We observed that activation of AKT leads to increased levels of GR-Ser134 phosphorylation, 
which is linked to nuclear translocation of GR, in all of our IKZF1 model systems as well as 
in patient-derived xenografts (PDX) (Chapter 4). In line with our results, high GR-Ser134 
phosphorylation has been correlated with GC resistance in T-ALL [17]. This further supports 
the notion that IKZF1 affects the GR-mediated gene expression rather on the activation 
level than on the expression level of the GR. Furthermore, analysis of phospho-GR protein 
expression levels in a larger cohort of BCP-ALL patients may provide more insight into 
the value of GR-Ser134 phosphorylation as potential biomarker for responsiveness to GC 
therapy in BCP-ALL. 
Other studies have shown that inhibition of casein kinase II (CK2) enhances the 
transcriptional repressor function of IKZF1 [27,28]. As CK2 inhibits PTEN activation [29-31], 
it would be potentially interesting to investigate the role of CK2 in IKZF1-mediated loss of 
PTEN and how this impacts downstream AKT signaling.
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We reported in Chapter 4 that pharmacological inhibition of AKT via MK2206 successfully 
restored GC sensitivity both in IKZF1-deleted BCP-ALL cell lines as well as in primary 
leukemic cells. Despite the fact that clinical trials with MK2206 were discontinued due 
to insufficient clinical anti-leukemia activity when given alone at tolerated doses [32], 
monotherapies with novel AKT inhibitors as well as combination therapy of AKT inhibitors 
with additional therapeutic agents are under clinical evaluation [33]. As low dosages of 
MK2206 were sufficient to sensitize IKZF1-deleted cells to GCs in our studies, while not 
affecting overall cell viability, inhibition of AKT may represent a novel way to specifically 
enhance response to therapy in GC resistant IKZF1-deleted BCP-ALL cells. In vivo 
treatment of mice xenotransplanted with IKZF1-deleted leukemic cells may provide more 
insight into the potential beneficial effect of combined treatment with AKT inhibitors and 
GCs. 
A role for BMI-1 in IKZF1-mediated GC resistance?
In addition to the regulation of the PTEN/AKT route via HES1 in IKZF1-deleted BCP-ALL, 
IKZF1 may also exert control over the PTEN/AKT signaling cascade by regulation of the 
B-lymphoma Mo-MLV insertion region 1 homolog gene BMI-1.
BMI-1 is a member of the Polycomb group (PcG) protein family and is critically involved 
in maintaining self-renewal of normal and malignant human stem cells [34]. Over the past 
years, BMI-1 has attracted interest as an oncogene; high expression of BMI-1 is correlated 
with a broad variety malignancies, including solid tumors [35-38] and hematopoietic 
malignancies [39-41]. Moreover, high levels of BMI-1 predict poor prognosis in BCP-ALL [42] 
and diffuse large B-cell lymphomas [43]. 
Preliminary data of our lab revealed that IKZF1KO Nalm6 cells showed increased expression 
of BMI-1 after prednisolone treatment (Figure 2A). Next to this, treatment of IKZF1KO 
Nalm6 cells with the BMI-1 inhibitor PTC209 [44] reversed GC resistance in those cells 
(Figure 2 B, C). Previous studies have already linked BMI-1 overexpression to drug 
resistance in B-cell lymphomas [45] and osteosarcoma [46]. Moreover, AKT-mediated 
phosphorylation of BMI-1 has been reported to alter its oncogenic function [47]. In 
Chapter 4, we report that the transcription factor HES1 protein expression is upregulated 
in IKZF1KO cells. Interestingly, HES1 is known to activate BMI-1 [48] and to repress 
expression of PTEN [49,50]. Based on our finding that loss of IKZF1 leads to upregulation 
of HES1, we hypothesize that IKZF1 mediated regulation of PTEN involves repression by 
HES1. Because BMI-1 is functionally linked to both HES1 and PTEN [48,50], we speculate 
that BMI-1 could somehow be involved in this regulation. Future efforts should therefore 
aim to unravel the connection between BMI-1, HES1 and PTEN in IKZF1-deleted BCP-ALL.
SUMMARY AND GENERAL DISCUSSION
173
Figure 2 IKZF1KO cells overexpress BMI-1 upon glucocorticoid treatment and are sensitive to 
BMI-1 inhibition (A) IKZF1 and BMI-1 protein expression levels of Nalm6 IKZF1 KO cell lysates 
after incubation with or without 2 µM Prednisone for 48 hours were analyzed by western blot. As 
controls, non-targeting Nalm6 cells were used while actin was used to control for loading. (B) BMI-
1 protein levels after incubation with increasing concentrations of PTC209 for 48 hours analyzed 
by western blot. Actin was used as a loading control (C) Nalm6 parental, non-targeting controls 
or IKZF1KO cells were treated for 48 hours with increasing concentrations of prednisolone with or 
without 1uM PTC209 and analyzed using an MTT based viability assay. All values were normalized 
to untreated Nalm6 cells. Error bars represent ± standard error of the mean (SEM).  
Co-occurring genetic events in IKZF1-deleted BCP-ALL
Deletions affecting B-cell developmental genes such as E2A, PAX5 and IKZF1 are common 
events during lymphoid leukemogenesis and contribute to the development of leukemia 
[20,51]. IKZF1 aberrations are among the most prominent reported alterations implicated 
in leukemia development. However, loss of IKZF1 alone does not seem to be sufficient 
to induce leukemogenesis [52,53] and despite the fact that IKZF1 deletions are enriched 
in relapsed ALL, the majority of patients with IKZF1-deleted BCP-ALL will not undergo 
relapse [54,55]. This indicates that next to IKZF1 deletions, additional co-occurring genetic 
events may alter the impact of IKZF1 alterations in BCP-ALL.
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In chapter 5, we observed that single copy losses affecting tumor suppressor BTG1 are 
enriched in patients with IKZF1 deletion. Whereas deletions in BTG1 alone did not have 
a prognostic value in our study cohort, combined loss of BTG1 and IKZF1 correlated with 
lower-event free survival and a higher incidence of relapse. Other common copy number 
losses such as CDKN2A/B, PAX5, EBF1 and RB1 were enriched in IKZF1-deleted BCP-ALL, 
but did not alter the outcome.  
Both deletion of IKZF1 and BTG1 were shown to be a result of illegitimate RAG-mediated 
recombination [56] and activation- induced deaminase (AID) activity [57], which could 
explain that these lesions are prominent in specific BCP-ALL subgroups. Despite the fact 
that BTG1 deletions are frequent event in BCP-ALL [56], there has been limited evidence 
showing that deletions affecting BTG1 impact outcome. Only recently, BTG1 deletions 
were found to be associated with a higher relapse risk in a large relapsed B-cell precursor 
ALL patient cohort treated on the international ALLR3 trial [58]. Furthermore, recent 
studies of the German BMF consortium support our initial findings that combined loss 
of IKZF1 together with other genetic events can alter disease outcome of BCP-ALL [59]. 
However, in contrast to our findings, loss of BTG1 had no significant influence on outcome 
in IKZF1-deleted leukemia in their so called IKZF1plus high risk group. It will be important 
to compare several international study cohorts and also shed more light on effects of 
different national treatment protocols and population genetics to understand these 
cohort-dependent differences in more detail.  
In chapter 5, we provided additional evidence for the tumor suppressive function of Btg1 
and Ikzf1 in a genetic mouse model. Ikzf1+/- mice alone showed only a low incidence of 
lymphoid tumors during the monitoring period of 18 months. In contrast, transgenic Ikzf1 
mouse models expressing dominant negative isoforms of Ikzf1 are highly susceptible for 
T-cell malignancies [60-62]. However, we observed that leukemia development was strongly 
increased by the combined loss Btg1 and Ikzf1 in a Btg1-dose dependent manner, indicating 
that the tumor suppressor genes Btg1 and Ikzf1 cooperate in leukemia development. 
Modeling the loss of B-cell specific tumor suppressor genes in relevant clinical models 
remains a challenge. Despite the fact that murine knockout models led to novel insights 
into the role of tumor suppressor genes in hematopoiesis and leukemogenesis, these 
mouse models do not always resemble the human phenotype. It is a commonly observed 
phenomenon of murine knockout mouse models for B-cell specific tumor suppressor 
genes that these mice develop T cell malignancies rather than expected B cell leukemias 
[63,64]. In Chapter 5, we also observed that loss of the two B-cell genes Btg1 and Ikzf1 in 
murine models exclusively led to T cell leukemias.
Loss of BTG1 enhances IKZF1-mediated GC resistance
Combined loss of Btg1 and Ikzf1 also enhanced the resistance of murine B-cells towards 
GCs, even surpassing the GC-resistance observed in Ikzf1+/- B cells. The underlying 
molecular mechanism remains elusive, as initial RNA sequencing experiments did not 
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reveal common pathways altered in Btg1-/-;Ikzf1+/- cells. However, in earlier work, our 
laboratory has identified BTG1 as a determinant of GC resistance in BCP-ALL [65]. It was 
shown to function as a transcriptional coregulator, as it has no catalytic activity. Instead, 
BTG1 regulates and interacts with the protein arginine methyltransferase PRMT1 [66,67]. 
We established that PRMT1 is able to associate with the promoter regions of both 
BTG1 and the GR in a BTG1-dependent manner, thereby influencing GR-mediated gene 
expression [65]. Preliminary experiments in our laboratory suggest that BTG1 and IKZF1 
may be part of a complex (data not shown). Based on these observations, we postulate 
that BTG1 and IKZF1 interact either directly or via PRMT1 to fulfill their function, but 
further interaction studies will be needed to confirm this theory.
Loss of IKZF1 confers pyrimidine analog resistance 
In chapter 6 of this thesis, we observed that, apart from resistance to GCs, loss of IKZF1 
confers resistance to pyrimidine analogs. Limited numbers of xenografted patient material 
restricted the sample size of this study, and future efforts should focus on validating the 
observed resistance phenotype of IKZF1-deleted leukemic cells to pyrimidine analogs 
in a larger patient cohort. Furthermore, the current ALL-11 treatment protocol states 
treatment with Ara-C in four interval blocks of each 4 days between Day 34 and Day 62 
of the treatment [68]. It would be interesting to study whether patients with a IKZF1-
deleted leukemia depict a poor respond towards AraC during this interval in comparison 
to patients with wild-type IKZF1 leukemias.
Although IKZF1 is primarily a regulator of lymphoid development, there is some evidence 
supporting a role for this transcriptional regulator in myeloid differentiation: For instance, 
IKZF1 has been implicated in megakaryopoiesis, which involves cooperation with 
transcriptional regulators such as RUNX1 and GATA1 [69]. Moreover, deletions in IKZF1 
were found to occur during progression from myeloid proliferative neoplasms to AML 
[70]. More recently, de Rooij et al showed that IKZF1 deletions and point mutations are 
present in pediatric AML, while IKZF1-deleted cases consistently showed upregulation 
of GATA1 target genes [71]. CDA, the enzyme responsible for inactivation of AraC, is such 
an GATA1 target gene. Mutations leading to GATA1 loss of function are frequently found 
in down syndrome children with acute megakaryocytic leukemia (AMkL) and associated 
with strongly increased sensitivity to AraC [72]. This appears to be a direct consequence 
of the lack of CDA expression in these leukemias. Since CDA is subject to regulation by 
GATA1 and IKZF1 is a repressor of GATA1 function, single copy loss of IKZF1 in AML, 
by similarity to ALL, could lead to upregulation of CDA expression and consequently 
a poor response to AraC therapy (Figure 3). Indeed, deletion of chromosome 7, which 
harbors the IKZF1 gene, is associated with poor outcome in AML [73], although this 
particular chromosome harbors other important leukemia genes, such as EZH2, that 
could affect outcome.  We hypothesize, based on these findings and our results describe 
in chapter 6, that loss of IKZF1, both in ALL and AML, may contribute to AraC resistance 
by derepression of GATA1 activity (Figure 3). Given the key role of AraC in the treatment 
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of AML, future efforts should explore the relation between IKZF1, GATA1 and AraC 
resistance both in ALL and AML.
 
 
Figure 3 IKZF1 mediated control of CDA expression. Schematic overview of the proposed 
molecular mechanism that controls CDA expression
 
Overall Conclusion
This thesis provides novel insights into the contribution of lymphoid transcription factor 
IKZF1 to chemotherapy resistance in BCP-ALL. We show that loss of IKZF1 confers 
resistance to synthetic GCs. Subsequently, we provide evidence that GC resistance in IKZF1-
deleted model systems involves alterations in the PTEN/AKT signaling cascade. Moreover, 
we show that loss of IKZF1 contributes to resistance to pyrimidine analogs. Furthermore, 
we observed that combined loss of Ikzf1 and Btg1 enhances murine leukemogenesis in a 
Btg1-dose dependent manner and that combined loss of Ikzf1 and Btg1 enhances GC 
resistance.  We also show that BCP-ALL patients that show a combined loss of IKZF1 and 
BTG1 represent a novel risk group with a very poor survival outcome. From this thesis, it 
becomes evident that we need to specifically identify and target IKZF1-deleted tumors and 
that distinct mechanisms downstream of IKZF1 can affect the response to chemotherapy 
in IKZF1-deleted BCP-ALL. To decipher the most important pathways, screens with gRNA/
CRISPR libraries as well as combinations of RNA-seq and proteomic approaches will be 
necessary to fully shed light on the impact of IKZF1 on (chemo)therapy resistance. Instead 
of targeting only one pathway, combining drugs hold promising potential to target minor 
chemoresistant subpopulations. Finally, this thesis shows that the genetic context in 
which IKZF1 deletions occur is important and that next to the IKZF1 status, also other co-
occurring genetic events should be included to predict disease outcome.  
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Nederlandse samenvatting
Voorloper B-cel leukemie, afgekort BCP-ALL, is de meest voorkomende vorm van kanker bij 
kinderen. In Nederland wordt deze diagnose gemiddeld bij 120 kinderen per jaar gesteld. In 
de laatste jaren hebben verbeteringen in de risico stratificatie en behandelingsprotocollen 
geleid tot een overlevingskans van 85-90% voor kinderen met BCP-ALL. Ondanks deze 
veelbelovende ontwikkelingen, ontstaat er bij 20% van alle patiënten met BCP-ALL 
een recidief. Dit kan direct gebeuren omdat de leukemie resistent is geworden tegen 
de behandeling, maar ook jaren na het bereiken van de remissie kunnen recidieven 
ontstaan omdat een dormante kleine populatie van leukemische cellen op later termijn 
opeens weer begint uit te groien. Om te begrijpen hoe dit recidief ontstaat, is het van 
belang te bergrijpen dat een tumor genetisch heterogeen is en meerdere en verschillende 
genetische afwijkingen bevat. Sommige van deze veranderingen in de genetische 
informatie van de tumor beinvloeden de overlevingskans van BCP-ALL patiënten en 
kunnen een voorspellende waarde hebben over het ziekteverloop. Eén van de voorbeelden 
van zo’n prognostische marker betreft genetische veranderingen (deleties of mutaties) in 
het IKZF1 gen. Veranderingen in dit gen komen in 15-20 % van alle pediatrische BCP-ALL 
patiënten voor en meerdere studies hebben laten zien dat verlies van IKZF1 functie een 
onafhankelijke marker is voor een slechte prognose bij BCP-ALL. Alhoewel voorafgaand 
aan mijn promotieonderzoek IKZF1 genveranderingen als prognostische factor waren 
geïdentificeerd in BCP-ALL, was een directe link tussen verlies van IKZF1 functie en 
(chemo)therapie resistentie nauwelijks onderzocht. Mijn promotieonderzoek richt zich 
op deze resistentie tegen synthetische glucocorticoïden (GC), omdat GC behandelig een 
belangrijke deel is van de BCP-ALL behandeling. Resistentie tegen GCs is gecorreleerd met 
een slechte uitkomst van de behandeling.  De mechanismen verantwoordelijk voor het 
optreden van GC resistentie zijn nog steeds grotendeels onbekend.     
Hoofdstuk 1 omvat een algemene inleiding over de biologie van kinder ALL en hierin 
wordt de vraagstelling van mijn promotieonderzoek uiteen gezet. In hoofdstuk 2 wordt 
een overzicht gegeven over de rol van IKZF1 op de ontwikkeling van leukemie en therapie 
resistentie, waarbij de mogelijke moleculaire mechanismen van IKZF1-gemedieerde 
therapie resistentie worden besproken. In de studie beschreven in hoofdstuk 3 laten wij 
zien dat verlies van IKZF1 functie bijdraagt aan een slechte respons tegen synthetische 
glucocorticoïden, zowel in genetische modellen in het laboratorium als ook in 
patiëntenstudies. Om te kunnen bepalen of genveranderingen van de tumorsuppressor 
IKZF1 leiden tot therapie resistentie, hebben wij het verlies van IKZF1 in verschillende 
modelsystemen nagebootst. Wij vonden dat  verlies van IKZF1 leidt tot reistentie tegen de 
synthetische glucocorticoïden prednison en dexamethason, zowel in B cellen afkomstig 
uit Ikzf1 knockout muizen als in BCP-ALL cellijnen De analyse van laboratorium en 
klinische data verkregen van de Stichting Kinderoncologie Nederland (SKION) laat zien 
dat leukemie cellen van patiënten met verlies van IKZF1 significant ongevoeliger zijn 
tegen corticosteroïden en dat IKZF1 deleties sterk verrijkt zijn in BCP-ALL patiënten 
met een slechte initiële response tegen therapie met glucocorticoïden. Met behulp van 
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genexpressie studies hebben we aangetoond dat in B cellen van Ikzf1 knockout muizen 
genregulatie door glucocorticoïden is onderdrukt, terwijl expressie van de glucocorticoïd 
receptor zelf niet veranderd is.
 Deze data suggereren dat glucocorticoïd resistentie in cellen met IKZF1 genveranderingen 
een gevolg is van verschillen in functionele activiteit van de glucocorticoïd receptor.  Er zijn 
een aantal mechanismen beschreven die de effectiviteit van glucocorticoïd behandeling 
kunnen beïnvloeden. In T cel leukemie is verhoogde activiteit van de AKT signalerings 
route  gerelateerd aan glucocorticoïd resistentie. Op basis van deze observaties hebben 
wij in de studies beschreven in hoofdstuk 4 onderzocht of een verandering in AKT 
signalering verantwoordelijk is voor de glucocorticoïd resistentie van leukemie cellen 
met een IKZF1 deletie. Wij hebben ontdekt dat verlies van IKZF1 leidt tot gereduceerde 
expressie niveaus van het eiwit phosphatase PTEN. Dit resulteert vervolgens in activering 
van het kinase AKT en AKT-afhankelijke fosforylering van de glucocorticoïd receptor. 
Hierdoor is, na  binding van glucocorticoïden, deze minder goed in staat om zich vanuit 
het cytoplasma naar de kern te verplaatsen. Het blijkt dat de AKT remmer MK2206 in staat 
is glucocorticoïd resistentie in IKZF1-gedeleteerde cellen op te heffen. Verder zien wij dat 
leukemiecellen van patiënten met verlies van IKZF1 gekenmerkt worden door lage eiwit 
expressie van PTEN and hoge phospho-glucocorticoid receptor niveaus. De glucocorticoïd 
resistentie in de leukemiecellen van deze patiënten kon in een aantal gevallen opgeheven 
worden door behandeling met MK2206. Op basis van deze resultaten  zal nu het effect 
van AKT remming op glucocorticoïd resistentie in een muis model verder kunnen worden 
onderzocht. Ook kan worden onderzocht of hoge phospho-glucocorticoïd receptor 
expressie een betrouwbare biomarker is voor de effectiviteit van AKT remmers voor de 
behandeling van glucocorticoïd resistentie in patiënten met een IKZF1 deletie.
Ondanks het feit dat IKZF1 deletie een genetische marker is die geassocieerd is met een 
slechte respons op de behandeling, blijkt dat lang niet iedere leukemiepatiënt met een 
IKZF1 deletie slecht reageert op therapie. Dit suggereert dat naast IKZF1 deleties ook 
andere genetische veranderingen de prognose van IKZF1-gedeleteerde patiënten kunnen 
beïnvloeden. In het onderzoek beschreven in hoofdstuk 5 tonen wij aan dat verlies van 
het BTG1 gen, maar ook deleties in CDKN2A, PAX5 en RB1, significant verrijkt zijn in BCP-
ALL met IKZF1 deleties. Daarop hebben wij onderzocht of de prognostische waarde van 
IKZF1 verlies wordt beïnvloed door combinaties met andere gen deleties. Verrassend 
genoeg vonden wij dat alleen het gecombineerde verlies van BTG1 en IKZF1 geassocieerd 
was met een lagere overleving en een hogere kans op een recidief in pediatrische BCP-
ALL patiënten. Om verder de coöperatie tussen verlies van BTG1 en IKZF1 tijdens het 
ontstaan van leukemie beter te begrijpen, hebben wij het gecombineerde verlies van Ikzf1 
en Btg1 in een muizen knockout model verder onderzocht. Wij vonden dat de leukemie 
ontwikkeling in heterozygote Ikzf1 knockout muizen significant wordt versneld door 
verlies van Btg1 functie op een dosis afhankelijke manier. Daarnaast konden wij een 
sterkere glucocorticoïd resistentie in B cellen aantonen bij een gecombineerd verlies van 
Btg1 en Ikzf1 ten opzichte van Ikzf1 verlies alleen. Samengevat betekenen deze resultaten 
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dat effecten van het verlies van Btg1 and Ikzf1 elkaar versterken tijdens de ontwikkeling 
van leukemie en dat deze samen de respons op glucocorticoïden onderdrukken. 
Naast resistentie tegen glucocorticoïden zou IKZF1 ook de cellulaire respons op andere 
(chemo)therapeutica kunnen beïnvloeden. IKZF1 is recent  ook beschreven als een 
‘metabole poortwachter’ van de leukemische B cel. Op basis van deze observaties hebben 
wij in hoofdstuk 6 het effect van IKZF1 verlies op de gevoeligheid van verschillende 
antimetabolieten onderzocht. Onze data laten zien dat verlies van IKZF1 in leukemische 
cellen leidt tot resistentie tegen pyrimidine analogen, synthetische moleculen die lijken 
op de bouwstenen van het DNA en de celdeling verstoren. Verder hebben wij ontdekt dat 
ook  leukemie cellen verkregen uit patienten met een IKZF1 deletie veel minder gevoelig 
zijn voor behandeling met het middel cytarabine, een pyrimidine analoog dat gebruikt 
wordt in de behandeling van patienten met ALL. Ook hebben wij aangetoond dat deze 
verminderde gevoeligheid voor cytarabine verband houdt met verhoogde expressie/
activiteti van het enzym cytidine deaminase (CDA). Dit enzym zorgt er namelijk voor dat 
chemotherapeutische metaboliten zoals cytarabine, worden omgezet naar een vorm die 
niet langer toxisch is voor de leukemiecel. Het blijkt inderdaad het geval dat zowel de 
activiteit als de mRNA expressieniveaus van CDA verhoogd zijn in IKZF1 knockout  cellen. 
Verder herstelde de farmacologische remming van CDA de gevoeligheid van BCP-ALL 
cellen voor cytarabine. Concluderend, wijzen deze resultaten erop dat er een belangrijke rol 
is voor IKZF1 verlies in de relatie tot resistentie tegen pyrimidine analogen, als cytarabine, 
in BCP-ALL patiënten met een IKZF1-deletie. In hoofdstuk 7 worden  de resultaten van dit 
proefschrift in de vorm van een samenvatting en discussie gepresenteerd in relatie tot de 
relevante literatuur.
Samenvattend beschrijft dit proefschrift dat er een belangrijke rol is voor IKZF1 in 
chemotherapie resistentie bij BCP-ALL patiënten. Toekomstig onderzoek zou zich moeten 
richten op signalering routes die aangestuurd worden door IKZF1, zodat selectief de 
gevoeligheid voor therapie in patienten met IKZF1-gedeleteerde BCP-ALL verbeterd kan 
worden. 
CHAPTER 8 
188
Dankwoord
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Fachaustausch in den letzen Jahren immer sehr genossen (2 Hypochonder vereint, 
wuhuu!), und freue mich auf neue Kunst von dir auf meinem Körper!
Im Leben geht es immer weiter, mein nächster Schritt in 2018 war der Weg in die klinische 
Forschung. Ich möchte meinem gesamten KliFo Kurs am mibeg-Institut Medizin danken, 
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Sandra und Mike, danke, dass ich mich bei euch immer zu Hause fühlen durfte und für all 
die Abende, wo man bei einem leckeren Bierchen oder Weinchen oder Grappa oder allem 
zusammen versackt ist. 
Meine liebe Oma, ich will mich von Herzen für deine bedingungslose Liebe bedanken. 
Du hast mich großgezogen und liebst mich wie keine andere, danke. Mein lieber Opa, 
zu deiner großen Enttäuschung bin ich leider doch kein berühmter Fußballer geworden, 
wofür ich mich herzlich entschuldigen möchte. Auch wenn du die letzten 10 Jahre nicht 
mehr bei uns sein konntest, warst du doch jeden Tag bei mir im Herzen, das versprech ich 
dir.
Lieber Opa Dieter, du bist der coolste Schwiegeropa den man sich wünschen kann, und du 
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Meine Schwiegereltern Rita, Iris und Jo und meine Lieblingsschwägerin Valerie, danke das 
ihr meinen Wahnsinn aushaltet und immer an mich glaubt, ich bin unendlich froh euch in 
meiner Familie zu haben und freue mich vor allem auf die kommende Zeit mit euch allen, 
auf brausende Feste und einfach schöne Zeiten.
Liebe Mama, lieber Papa, der Moment ist endlich gekommen in dem ihr dieses Buch in den 
Händen halten könnt, und ich will sagen, dass ich all das, was ich bin und geleistet habe, 
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damit ich mein Ding machen konnte, sondern ich wusste auch immer, egal wie schlimm es 
wird, dass ihr hinter mir steht. Ich werde niemals in der Lage sein, all das zurückzugeben, 
was ihr für mich getan habt, aber glaubt mir, ich bin euch für immer dankbar. Ihr habt 
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Sam, meine Schnippel-Hilfe. Danke, dass du jeden Abend zuhörst, wenn ich begeistert 
über tödliche Krankheiten und tote Mäuse geredet habe. Wenn du mich zur Ruhe 
gebracht hast in all den schlaflosen Nächten, in denen ich nicht wusste, was die Zukunft 
bringt und du mir in diesen Momenten gezeigt hast, dass du meine Zukunft bist. Danke, 
dass du immer an meiner Seite bist und mich auffängst. Wenn ich daran denke, dass 
alle meine Entscheidungen in meinem Leben dazu geführt haben, dass ich dich kennen 
lernen durfte, weiß ich, dass ich alles richtig gemacht habe. Du bist meine beste Freundin, 
meine große Liebe und meine Partnerin. Danke, dass du es mit mir aushältst und dass 
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Rechtschreibfehler hier rausholst). Neben deiner Liebe hast du mir aber auch dieses Jahr 
das allergrößte Geschenk gemacht. Und nein, ich meine nicht nur Dobby („Feiner Hund“). 
Ich meine unsere kleine Bohne. 
Ich liebe euch beide und ihr seid die Welt für mich.
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